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Summary 
Molluscum contagiosum virus (MCV) is a significant human pathogen causing benign 
tumours in the human skin. Molluscum contagiosum (MC) infection is most common in 
children, young adults and immunodeficient individuals. MCV replicates well in the 
human skin in vivo, but conditions that support MCV replication in vitro are unknown. 
The lack of in vitro cell culture system has significantly limited progress in MCV 
research. The aims of this study were, (i) To develop a reporter assay for the sensitive 
detection and quantitation of MCV infections in vitro, (ii) To express suitable MCV 
virion surface antigens to develop a sensitive MCV ELISA assay, and (iii) To raise and 
characterize monoclonal antibodies (mAbs) against these antigens for the detection of 
MCV in infected human skin. All goals were achieved. A reporter assay based on 
simultaneous transfection of luciferase/EGFP reporter plasmids and infection with live 
MCV worked well and was used to test the infectivity of MCV in several human and 
animal cells. A novel C-terminal MC084 ELISA was established and used to determine 
MCV seroprevalence in two European populations. mAbs against MC084 and MC133 
were raised and partially characterized. Interesting findings were that MCV not only 
infects human keratinocytes, but also a wide range of animal and human cells in vitro, 
which, however, do not support replication. Our MCV ELISA gives seroprevalences in 
UK and German general populations comparable with previous Australian and Japanese 
studies (<40 years of age). Surprisingly, in older age groups (vaccinated against 
smallpox), a significantly higher MCV seroprevalence was observed. This was not due 
to crossreactivity with VACV. We propose this increase may be due to childhood MCV 
antibodies being boosted by subsequent vaccination or vice versa. Finally, the mAbs 
raised are unique reagents and will be used in future work to test a hypothesis that MCV 
replicates in human epidermal stem cells. 
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VACV  Vaccinia Virus 
VAR  Variola 
VARV  Variola Virus 
vRNA  Viral RNA 
vDNA  Viral DNA 
V3  Recombinant form of vaccinia virus expressing firefly luciferase with 
an early and late poxvirus promoter 
WHO  World Health Organisation 
vWR RK13 Western reserve preparation of vaccinia virus prepared in RK13 cells 
WR  Western Reserve 
24wp  24 well cell culture plate 
293  Human Kidney Epithelial Cell 
3T3  Swiss Mouse Embryo Fibroblast Cell 
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Chapter 1 - Introduction 
 
1.1 General Introduction 
Molluscum contagiosum virus (MCV) is a significant benign but underreported skin 
pathogen for children and adults.  The typical poxvirus particle morphology and 
genome organisation of MCV led to its classification as a member of the family 
Poxviridae where it is the sole member of the genus Molluscipoxvirus. Compared to 
other human skin viruses it has failed to garner sustained interest from a research 
perspective due to the lack of a conventional cell culture system or animal model as 
well as the benign nature of the clinical disease. The inability to grow the virus in vitro 
has hampered biological studies and rendered the development of specific therapeutics 
difficult.  Also, virions can only be obtained from limited patient material. The resulting 
lack of reagents has proven a major obstacle in further investigation and research.  In 
the absence of reliable clinical data the true prevalence of molluscum contagiosum 
(MC) is unknown. Inspite of the common occurrence of the disease, till now only a very 
limited number of seroprevalence studies have been conducted. No studies have been 
reported on how common MC is in Europe. Age dependent seroprevalence studies can 
help establish burden of disease. My doctoral research project focuses on aspects 
relating to the lifecycle of Molluscum contagiosum virus and the human immune 
response to it. In light of the fact that any research in this field is affected by a complete 
absence of reagents enabling its further investigation, one of aims of this PhD project 
was to develop and design MCV gene specific reagents to enable study of MCV 
lifecycle and immunity.  
 
1.2 Poxviruses 
Poxviruses are large, double-stranded DNA viruses that infect vertebrates and insects 
(Moss, 2007b).  Members of the Poxviridae family replicate exclusively in the 
cytoplasm of vertebrate and invertebrate cells (Fields, 2013). The best known members 
of the family belong to the orthopoxvirus (OPV) genus, namely variola virus (Moratilla 
et al., 1997), the causative agent of smallpox, and the closely related vaccinia virus 
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(VAC) which has successfully served as the smallpox vaccine. Vaccinia virus was also 
the first animal virus to be visualised microscopically, grown in tissue culture, 
accurately tittered, physically purified and chemically analysed (Fields, 2013). The 
complete genome sequences of VAC (192 kbp) and VAR (186 kbp) have been 
determined (Goebel et al., 1990; Shchelkunov et al., 1993). The genome of one other 
poxvirus, molluscum contagiosum virus has also been sequenced (Senkevich et al., 
1996). VAR and MCV are unique among the poxviruses in their specific adaptation to 
humans as and with the eradication of smallpox in 1977 spearheaded by the World 
Health Organisation, MCV is the only member of the family that has a strictly human 
host range. MCV produces small, benign, cutaneous tumours primarily in children and 
young adults that persist for many months with only a weak immune response and 
almost no inflammation (Postlethwaite, 1970; Epstein, 1992; Porter et al., 1992; 
Gottlieb and Myskowski, 1994). In immunodeficient individuals, however, the skin 
lesions can become extensive, and MCV is a common and untreatable opportunistic 
infection of AIDS patients (Cotton et al., 1987; Schwartz and Myskowski, 1992 a and 
b). 
 
Poxviruses are large double-stranded DNA viruses with genomes ranging from 130 to 
380 kbp (Fields, 2013) with a preference for the epidermis. They are highly successful 
pathogens known to infect a wide variety of animals, including insects, reptiles, birds 
and mammals. They can be spread by aerosol, direct contact, and insects. The most 
infamous member of the family Poxviridae is Variola virus, the causative agent of 
smallpox, which caused millions of deaths before its eradication from the natural 
environment (Esposito and Fenner, 2001). The threat from multiple poxviruses to 
humans remains, including the use of smallpox as a bioterrorism weapon in a now 
largely unvaccinated population and infection from other existing animal poxviruses 
such as  including monkeypox virus, tanapoxvirus, Yaba-like disease virus, and cowpox 
virus, which can infect humans and cause morbidity (Downie, 1972; Espana, 1971; 
Espana et al., 1971; McNulty et al., 1968). Monkeypoxvirus is of particular concern 
because it causes high human mortality and can spread from human to human (Hutin et 
al., 2001). There are also reports of an emerging poxvirus infection, cantagalo, in 
Brazil, which has apparently evolved from the locally used smallpox vaccine strain 
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(Damaso et al., 2000). Another member of the poxvirus family, molluscum 
contagiosum virus (MCV) occurs commonly in humans (39% of a population over 50 
year olds tested seropositive) but causes significant disease only in 
immunocompromised individuals and rarely in children (Konya and Thompson, 1999). 
MCV may cause long-standing disfiguring infections, mostly on the skin of the face 
(Xiang and Moss, 2001). The existence of multiple poxviruses that can infect humans 
raises the possibility of the evolution of a new smallpox-like virus through host gene 
acquisitions or intervirus recombination events (Upton et al., 2003). If the new virus 
retained the ability to infect animals, however, then its eradication would be unlikely 
due to the natural animal reservoir of infection. In addition to the importance of 
poxvirus pathogens, multiple attenuated poxviruses are being used as vectors for 
clinical purposes, including cancer treatment, vaccines for human immunodeficiency 
virus, cytomegalovirus, and measles virus, and a successful rabies virus vaccine for 
feral animals (Artois et al., 1990; Hu et al., 2001) 
 
Currently, three poxviruses have been established as human pathogens: variola virus 
(VARV), the etiologic agent of smallpox, monkeypox virus (MPXV), which induces 
morbidity similar to smallpox, and molluscum contagiosum virus, which causes benign 
skin lesions. The best understood poxvirus is vaccinia virus (VACV), which is closely 
related to VARV and was used as a live vaccine for the eradication of smallpox (Goebel 
et al., 1990; Perkus et al., 1990; Lun et al., 2005; McFadden, 2005). 
 
1.2.1 Classification 
The characteristic properties of members of the family Poxviridae include cytoplasmic 
site of replication, a large complex virion containing mRNA synthesizing enzymes and 
genome consisting of a single linear double-stranded DNA molecule of 130-300 
kilobase pairs (kbp) with a hairpin loop at each end (Fields, 2013). Based on vertebrate 
or insect host range, the family Poxviridae is divided into two subfamilies 
Chordopoxvirinae and Entomopoxvirinae. The subfamily Chordopoxvirinae consists of 
eight genera: Orthopoxvirus, Parapoxvirus, Avipoxvirus, Capripoxvirus, 
Leporipoxvirus, Suipoxvirus, Molluscipoxvirus and Yatapoxvirus. The members of a 
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genus are related genetically, morphologically and with respect to host range. 
Orthopoxviruses have been the subject of intense investigation and DNA sequencing 
studies reveal that genes common to VACV, VARV, ectromelia virus, camelpoxvirus 
and cowpoxvirus show greater than 90% identity whereas other poxviruses such as 
racoonpoxvirus and volepoxvirus indicate genetic divergence (Knight et al., 1992). The 
prototypic virus of the orthopoxvirus genera is the vaccinia virus which has been used 
as the smallpox vaccine for over 200 years and may no longer exist in the natural host 
(Slifka and Hanifin, 2004). 
 
Table 1.1. Family Poxviridae 
 
 
1.2.2 Morphology 
The virions of poxviruses (Figure 1.1) are large and barrel shaped particles measuring 
400 × 230 nm. The thickness of the outer layer varies between 5-6 nm which along with 
the density is consistent with the one lipid membrane bilayer (Fields, 2013). The outer 
membrane has irregular protrusions extending 3-5 nm. Inner structure of the virion 
consists of a dumbbell shaped core lateral bodies which are aggregates of heterogenous 
material. The core wall is two layered with an overall thickness of 18-19 nm whereas 
the inner layer is continuous except for a few lipid channels (Fields, 2013).   
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Figure 1.1. Poxvirus virion. Poxvirus virions are enveloped, brick-shaped or ovoid, 220-450 
nm long and 140-260 nm wide. The surface membrane displays surface tubules or surface 
filaments. Two distinct infectious virus particles exist: the intracellular mature virus (IMV) and 
the extracellular enveloped virus (EEV). (Adapted fromviralzone.expasy.org) 
1.2.3 Genome 
The linear double stranded genomes vary from 134 kbp in parapoxviruses to more than 
300 kbp in some avipoxviruses (Garon et al., 1978). All poxviruses have inverted 
terminal repeats (ITRs) which contain identical, but oppositely oriented sequences at the 
two ends of the genome. These are A+T rich, incompletely base paired hair-pin loops 
which connect the two DNA strands (Baroudy and Moss, 1980).  
 
1.2.4 Poxvirus Tropism 
Poxviruses have a narrow animal host range capable of supporting their survival in the 
wild (McFadden, 2005). The successful eradication of smallpox could not have been 
possible if there were a non-human reservoir. Genes responsible for tropism and 
pathogenicity are species specific rather than essential genes which are common to most 
poxviruses (Fields, 2013). Different aspects of host-virus interactions define the three 
levels of tropism specific to poxviruses. The first level of tropism which is cellular 
tropism, refers to the observation that virus replication can be permissive, semi-
permissive or abortive in cultured cells of different lineages or species (McFadden, 
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2005). The second level refers to the frequently observed increased levels of virus 
replication in specific host organs or tissues, which can be influenced by factors that 
mediate cellular tropism as well as by tissue-specific antiviral responses. Finally, the 
third level, manifests with overt pathogenesis and symptoms of disease in the infected 
organism, is influenced by the first two levels of tropism as well as by the overall host 
immune and inflammatory responses (McFadden, 2005). At the cellular level poxvirus 
tropism seems to be regulated by intracellular events downstream of virus binding and 
entry, rather than at the level of specific host receptors.  
 
Entry of enveloped viruses into the host can be divided into six general steps: binding, 
cell surface movement, signalling, internalization, intracellular transport, and membrane 
penetration (Marsh and Helenius, 2006). In many viruses the host tropism is determined 
by the attachment and entry receptors used, however poxvirus tropism is usually 
determined by post entry steps (McFadden, 2005) . Poxviruses produce two types of 
infectious particles namely the mature virions (MVs) and extracellular virions (EVs) 
(Moss, 2007) (Figure 1.1). Both particles differ in the epitopes which they exhibit on 
their surfaces and thus use different attachment factors for entry. Fusion of enveloped 
viruses with cellular membranes can occur either at the plasma membrane or after 
endocytic uptake of viral particles. While fusion at the plasma membrane would depend 
less on cellular machinery, fusion after endocytosis would have several striking 
advantages for both MVs and EVs (Marsh and Helenius, 2006). First, cellular transport 
mechanisms ferry virus particles to the point of fusion, avoiding cytoskeleton barriers 
such as cortical actin. Second, spatially/temporally controlled endosomal cues, 
including acidic pH and proteases, among others, may activate viral fusion at the 
appropriate cellular location. Third, no virus components that could be recognized by 
the immune system are left at the plasma membrane. Fourth, endocytic vesicles may 
protect activated viral fusion proteins, often sensitive to neutralizing antibodies, from 
immune recognition (Shedlock et al., 2010).  
 
VACV MVs consist of the viral core containing the dsDNA genome, two proteinaceous 
lateral bodies, and one lipid bilayer containing at least 25 viral proteins. EVs consist of 
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an MV-like particle surrounded by a second viral membrane containing cellular and at 
least six unique viral proteins. MVs are the more abundantly produced infectious form 
and are thought to mediate host-to-host transmission, while EVs mediate virus spread 
within an infected host (Smith et al., 2003). The majority of EVs remain associated with 
the producer cell. These particles can induce the formation of actin tails that push them 
away from the producer cell mediating local virus dissemination. EVs released into 
body fluids are thought to mediate virus transmission from tissue to tissue. Thus two 
forms of infectious particles, each wrapped with a unique number of membranes of 
varying lipid and protein compositions offer different modes of entry of virus.   
 
MVs use several, partly redundant binding mechanisms that involve glycosaminglycans 
(GAGs) in addition to other surface molecules. The dependence on GAGs for binding 
and infection varies with cell type, virus strain, and experimental conditions (Bengali et 
al., 2009; Carter et al., 2005; Whitbeck et al., 2009). Electron microscopy used to study 
MV entry point towards either fusion or endocytosis as the major infectious entry 
pathway for most poxviruses (Granados, 1973; Chang and Metz, 1976; Townsley and 
Moss, 2007). Both virus particles utilise the host cell machinery of endocytosis for 
internalisation and cell fusion (Schmidt et al., 2012). The size limitations imposed by 
the large size of the particles make endocytosis the only possible strategy for large 
particle uptake by non-phagocytic cells and preventing early immune recognition of 
viral factors at the plasma membrane level especially in the case of MVs.  
 
The mechanisms used by both for macropinocytosis differ (Schmidt et al., 2011). MV 
fusion is facilitated by the inactivation of fusion inhibitory proteins. EVs lack fusion 
inhibitory proteins and have to shed an additional membrane so as to expose the fusion 
complex. VAC MVs employ apoptotic mimicry dependent on phosphatidylserine (PS)-
binding serum protein in the viral membrane and epidermal growth factor receptor 
(Butala et al., 2013) signalling leading to micropinosome formation (Mercer and 
Helenius, 2009). It has been demonstrated that macropinocytosis is a productive route 
of intact EV entry into HeLa cells (Schmidt et al., 2011). Unlike MVs, intact EVs do 
not rely on exposed phosphatidyl serine to trigger macropinocytosis, although both 
share the need for EGFR signaling. Endocytic vesicles provide the virus with a means 
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of cytoplasmic transport and promote virus escape from endocytic organelles by 
membrane fusion. This entry program is typically followed by delivery of incoming 
viral genomes to the site of virus replication. 
 
An important intracellular event that regulates the efficiency of poxvirus replication is 
the lineage and differentiation state of the infected cell (Weedon et al., 2010). For 
example, some poxviruses are dependent on the precise differentiation state of the host 
cell, such as the restriction of productive replication of molluscum contagiosum virus to 
keratinocytes that arise from the basal epidermal layer of the skin. The cellular factors 
that are required for the virus to complete its replication cycle beyond the stage of early 
gene expression are unknown, but it is noteworthy that the molluscum contagiosum 
virus encodes fewer immunomodulatory proteins than any other poxvirus that can infect 
humans (Senkevich et al., 1996). 
 
1.3 Poxvirus Entry Mechanisms 
1.3.1 Mature virions 
The mechanisms by which poxviruses enter cells remain the focus of much research, 
most of which is conducted with the prototypic virus, vaccinia virus (VACV) (Moss, 
2007). The morphogenesis of vaccinia virions is summarised in figure 1.2. VACV exists 
in multiple infectious forms, the most abundant being the mature virion (MV). These 
can enter cells by a low pH endosomal pathway or through direct fusion with the plasma 
membrane (Townsley and Moss, 2007; Bengali et al., 2009) To achieve entry, 
enveloped viruses first bind to the cell, activate surface proteins and then fuse with the 
membrane (Earp et al., 2005; Townsley et al., 2006).  The initial binding to cellular 
attachment factors is aided by certain membrane proteins. It has been found that A27 
and H3L proteins bind to heparan sulphate (Chung et al., 1998; Lin et al., 2000) and D8 
to chondroitin sulphate (Hsiao et al., 1999). Experiments conducted by Senkevich and 
Moss demonstrated that deletion of A27 protein still allowed for entry, illustrating such 
proteins are not essential for fusion (Senkevich and Moss, 2005). An entry and fusion 
complex of at lease nine MV transmembrane proteins has been identified as necessary 
for successful fusion (Roberts and Smith, 2008).  
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H3L is an integral membrane protein predominantly found in the envelope of IMVs of 
vaccinia virus. Soluble H3L binds to cell surface heparan sulphate and blocks the 
adsorption of IMVs thereby indicating that it is a VV receptor involved in target cell 
binding (da Fonseca et al., 2000; Lin et al., 2000). VV H3L deletion mutants exhibited 
a small plaque phenotype and decreased viral yields further substantiated by 
microscopic examination revealing defective virion morphogenesis (da Fonseca et al., 
2000; Lin et al., 2000). The H3L gene is strongly conserved amongst orthopoxviruses 
with the H3L protein from VVWR and variola sharing 96% amino acid identity (Davies 
et al., 2005). 
 
It has been extensively investigated that H3L, the vaccinia intracellular mature virion 
envelope protein, which is a homolog of the molluscum contagiosum virus surface 
protein MC084 (29% identity), is an antigen capable of eliciting a human humoral 
immune response recognised by high titre antibodies in human donors particularly after 
a secondary smallpox vaccination (Davies et al., 2005). Experiments by Davies and co-
workers concluded that anti-H3L antibody responses provided partial protection in vivo 
in mice from lethal challenges with VV.  
 
1.3.2 Extracellular virions 
The MV may become an ‘Intracellular Enveloped Virion’ (Shchelkunov et al., 1993) if 
subjected to additional membrane wrapping by the trans-golgi or endosomal cisternae 
(Tooze et al., 1993). The IEV subsequently moves to the cell surface and is exocytosed. 
If retained on the cell surface the virion is referred to as Cell-Associated Enveloped 
Virus (CEV), but if released it is known as Extracellular Enveloped Virus (Smith et al., 
2002).  CEVs lead to the formation of actin tails which allow propulsion of virions from 
the cell surface, facilitating the infection of neighbouring cells (Smith et al., 2002).  The 
extracellular virion (EV) can be considered an MV surrounded by an additional 
membrane, which contains at least four glycoproteins and one non-glycosylated protein, 
none of which exist on the inner, MV membrane (Moss, 2007). Owing to the location of 
entry proteins on the MV membrane, removal of the additional external membrane is 
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required for spread of VACV infection (Senkevich et al., 2004a; Senkevich et al., 
2004b). 
 
Figure 1.2. Overview of VACV morphogenesis. (A) IMV made in virus factory and relocated 
via microtubules (MT) to wrapping membranes. Here IEV is formed which moves to cell surface 
via MT. At cell surface outermost IEV membrane fuses with plasma membrane to form CEV that 
induce actin tail formation to propel virion from cell. CEV may also be released to form EEV 
(From Janeczko et al., 1987). (B) Transmission electron micrograph of MV. Arrow points to the 
single membrane of MV (Townsley et al., 2006). (C) Transmission micrograph of EV. One 
arrow points to the outer wrapping membrane that has fused with the plasma membrane and the 
others to the MV and remaining EV wrapper (Moss, 2007). 
 
1.3.3 Virus entry 
The number of membranes surrounding a VACV virion is fundamental to virus entry. 
One of the earliest studies used electron microscopy (EM) and demonstrated the 
presence of virions within intracellular cytoplasmic vesicles (Janeczko et al., 1987). 
Later investigators suggested viral core entry was a result of fusion between the plasma 
membrane and virus particle envelopes (Sieczkarski and Whittaker, 2002). Such 
findings, in conjunction with other studies gave rise to the current models of poxvirus 
B A 
C 
a) 
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entry. Direct fusion involves the fusion of the MV membrane to the cellular plasma 
membrane, followed by membrane flattening and release of the naked viral core (Carter 
et al., 2005).  
 
A low-pH endosomal entry pathway was proposed due to evidence of a tenfold increase 
in MV entry following treatment at a pH <6. In addition, inhibitors of endosomal 
acidification (bafilomycin A1, concanamycin A, and monensin) reduced entry by more 
than 70% (Townsley et al, 2006). Clathrin, a mediator of the primary route of 
internalization, is necessary for successful endocytic entry. This forms a clathrin- coated 
pits on the inner surface of the plasma membrane. Interactions of clathrin with other 
molecules, e.g. dynamin GTPase, are essential for vesicle formation (Abazeed et al., 
2005). Recent studies have reported the existence of alternative pathways which do not 
depend on clathrin (Figure 1.3) (Laliberte and Moss, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Summary of the major routes of endocytosis used by viruses. The most 
established is via clathrin-coated pits. Clathrin-coated vesicles (CCVs) progress to early 
endosomes, which is dependent upon Rab5. Endosomes recycle back to cell surface which is 
dependent on Rab4 and/or 11 or progress to late endosome/lysosome, controlled by Rab7. 
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Other pathways include non-coated pits (non-CCV), macropinocytosis or caveolae (Laliberte 
and Moss, 2009). 
 
The model proposed by Laliberte and Moss (Laliberte and Moss, 2009) describes a 
possible apoptotic mimicry entry mechanism whereby phosphatidylserine (PS), located 
on the VACV membrane, flags virions as apoptotic debris. This triggers a common 
cellular uptake pathway to gain cell entry, possibly due to an interaction with a PS-
specific receptor on the eukaryotic cell surface. 
 
1.4 Zoonoses 
Whereas the molecular mechanisms involved in host cell infection, viral replication and 
virulence are better understood after the genome sequence analysis of many poxviruses, 
the understanding of poxvirus maintenance in nature and transmission to humans is still 
less clear. Information on the epidemiology of zoonotic poxviruses is still too poor to 
enable us to clearly understand and estimate the chances of zoonoses in humans. A 
recent review has shed light on aspects of the host range of some poxviruses being 
broader than initially thought (Essbauer et al., 2010). 
 
Poxviruses are some of the oldest known viruses known to mankind with respect to 
infection of humans and are well documented viruses of livestock as well. Only 
members of the subfamily Chordopoxvirinae are capable of infecting vertebrate hosts, 
with four genera containing species that induce disease in humans. Of these, three 
harbour zoonotic potential; namely the genera Orthopoxvirus, Parapoxvirus and 
Yatapoxvirus.  
 
Despite the general consensus that MCV is highly specific to humans in the skin, MCV 
lesions have been reported in various animals. As early as 1967, molluscum lesions 
were reported in chimpanzees by Douglas and colleagues (Douglas et al., 1967). Post 
this observation others were reported in red kangaroos and horses (Bagnall and Wilson, 
1974; Lange et al., 1991). In spite of these observations no in vitro model exists which 
would allow molecular biological analysis of MCV.  
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From published literature it seems that the duration of immunity conferred by the 
smallpox vaccine is uncertain and people vaccinated during the WHO campaign could 
be susceptible to OPV infections (de Souza Trindade et al., 2007) although studies 
propose a half-life of 92 years for variola virus antibodies (Amanna et al., 2007). 
However information on the epidemiology of zoonotic poxviruses is still too poor to 
enable us to clearly understand and estimate the chances of zoonotic infections in 
humans. The end of the vaccination campaign against smallpox in the late seventies to 
early eighties led to the development of a generation unprotected against OPVs and in 
turn created a niche for these infections in humans (Essbauer et al., 2010). Although 
studies indicate that the host range of some poxviruses is broader than previously 
thought (Essbauer et al., 2010), it is understood that most cases of poxviral zoonotic 
infections are the result of occupational risk e.g. for cow workers (PPV) and their 
families, health care workers (VACV), animal traders (MPXV) and animal keepers 
(MPXV, CPXV) (Reynolds et al., 2006; Croft et al., 2007; Trindade et al., 2006; Kurth 
et al., 2008). 
 
1.4.1 Orthopoxvirus zoonoses 
Orthopoxviruses are immunologically cross-reactive and cross-protective, so that after 
infection with any member of this genus a protection against an infection with any other 
member of the genus is obtained. Monkeypox was first described as a rash causing 
illness in captive monkeys in the zoo of Copenhagen in 1957. The following years saw 
reports of several outbreaks in European and American zoos. Based on its distinct 
phenotype monkeypox virus (MPXV) is regarded as a discrete species within the genus 
orthopoxvirus. Human monkeypox was reported for the first time in the 1970s in 
countries of Western and Central Africa (Jezek et al., 1986). Investigations by the WHO 
pointed towards a fatality rate of up to 10–17%. Large human monkeypox outbreaks 
were reported in the Democratic Republic of Congo (DRC) in 1996/1997 and 2001–
2004 (Rimoin et al., 2007). Whereas in 1996/1997 the mortality was low (1.5%), the 
secondary attack rate was high (up to 78%).  
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Monkeypox can be described as an ‘emerging disease’ as cases have not only been 
reported in Africa but also from USA after its accidental introduction through MPXV-
infected rodents imported from Ghana which had been kept with native prairie dogs that 
were later distributed as pets (Croft et al., 2007). Seventy-one human cases were 
reported of which 26% of the patients had to be hospitalized. However, the MPXV from 
the USA had a very low virulence with no fatalities (Chen et al., 2005). Comparison of 
different MPXV strains showed that there were two distinct clades i.e. Western 
Africa/US and a Central Africa clade, the clinical and pathological characteristics of 
which demonstrated that the Western Africa/US strains are less virulent than the Central 
Africa strains (Tesh et al., 2004; Xiao et al., 2005; Sbrana et al., 2007).  
 
Various vaccinia virus strains have historically been used for the vaccination of various 
populations during the worldwide smallpox prevention campaign which eventually led 
to the eradication of the variola virus prior to 1980. Protective function of antibodies 
after smallpox infection in humans is displayed by both by neutralising the initial virus 
inoculums and also by limiting viral particle spread in the host hours after initiation of 
infection (Fenner et al., 1988). Memory B cells contribute to smallpox immunity via 
their response to infection with an anamnestic antibody response and their potential for 
maintenance of long term serum antibody levels by replenishment of long lived plasma 
cells (Crotty et al., 2003). Also various T cell responses including the VV-specific 
memory T-cells are important components of the vaccine mediated protection against 
smallpox virus (Slifka, 2004).  
 
Numerous strains of vaccinia virus (VACV), differing in their biological properties and 
virulence in man and in animal models (Mercer et al., 2007) exist. Vaccine escape has 
been hypothesized to account for some VACV strains isolated from domesticated 
animals and endemic to buffalopox in India. Phylogenetic analysis based on three genes 
also confirmed that buffalopox virus (BPXV) is closely related to VACV (Singh et al., 
2006) and is often seen in milkers, who accidently get pox-like local lesions on their 
hands, forearms and forehead accompanied with fever, axillary lymphadenopathy and 
general malaise (Singh et al., 2007). Reports in 2004–2005 suggested a nosocomial 
  
16 
 
outbreak of BPXV in humans in five major burn units of the city Karachi in Pakistan 
(Zafar et al., 2007).  
 
Starting in 1999 several VACV strains were shown to be responsible for zoonotic 
disease affecting more than 1100 dairy cattle and up to 80% of their handlers in rural 
tropical rainforest and woodland Savanna areas in southeast Brazil (Trindade et al., 
2006, Trindade et al., 2007). Comparable to BPXV infections, milkers presented 
pleiomorphic lesions on their hands (mainly papules and painful ulcers), fever, and 
lymphadenopathy. Initial hypotheses on the reasons for the occurrence of VACV in 
these areas of South America involved a long-term survival of VACV vaccine strains in 
nature. Orthopoxviruses are known to have a high tenacity (Essbauer et al., 2007), 
which indeed could account for such a phenomenon. Studies have shown the presence 
of viral DNA in blood samples of OPV-infected patients. Other works involving 
VACV-vaccinated patients demonstrated viral DNA in blood until 20 days post-
vaccination (Savona et al., 2006). 
 
Cowpox virus (CPXV) is known to naturally infect a very broad range of host species in 
Western Eurasia such as cats, various zoo animals and humans. More than 400 cases of 
CPXV infections have been described for domestic cats (Essbauer et al., 2010; Bennett 
et al., 1986, 1989; Hinrichs et al., 1999; Brown et al., 1989; Baxby, 1994; Pfeffer et al., 
2002), but it is estimated that many infections are not recognized by veterinarians 
and/or owners. The real incidence of CPXV in cats may be reflected by serological data. 
One study gives a variation of 0-16% in cats with antibodies against CPXV (OPV, 
respectively) reported from England, Norway, Austria, Germany and Finland (Juncker-
Voss et al., 2004). The variation is seasonal, with an accumulation of CPXV infections 
in late summer and autumn (Bennett et al., 1986; Pfeffer et al., 2002).  
 
Cats as predators are exposed to CPXV while hunting rodents which serve as a reservoir 
for CPXV (Pfeffer et al., 2002. Human CPXV cases are mainly caused by direct contact 
to ‘‘cuddly’’ cats (Baxby, 1994). Transmission of infection has been described to other 
close contacts (Coras et al., 2005) with reports of systemic involvement and/or fatal 
outcome of immune-compromised individuals with CPXV infections (Czerny et al., 
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1991; Pelkonen et al., 2003). Cowpox virus infections in humans may become more 
numerous due to the lack of an adequate immune status of the population because of the 
abrogated but cross-protective smallpox vaccination in the 1980s (Essbauer et al., 
2010). Nitsche et al. showed the long lasting viremia of the Cowpox virusin humans, 
and the presence of IgG and IgM were not sufficient to resolve infection (Nitsche et al., 
2007). 
 
1.4.2 Parapoxvirus zoonoses 
Parapoxviruses (PPV) form a divergent group of viruses with zoonotic potential.  
Infections are mainly reported in persons with close contact to sheep and cattle. The 
majority of human cases are caused by Orf virus. In the last decade infections of 
different seal species (e.g. Callorhinus ursinus, Phoca virulina, Halichoerus grypus, 
Leptonychotes weddellii), sea lions (e.g. Zaophus californianus, Otaria bryonia), camels 
(Camelus dromedaries), Japanese serow (Capricornis crispus) and deer species (e.g. 
Cervus nippon centralis, Rangifer tarandus tarandus) with parapoxviruses have been 
described with an unclear zoonotic potential (Mercer et al., 2007).  
 
1.4.3 Yatapoxvirus zoonoses 
Yatapoxvirus infection is a rare exotic and mild disease mostly characterized by 
vesicular skin lesions in humans (Tanapox virus) or monkeys (Yaba-like disease virus). 
Most reported cases of infection have been from equatorial Africa (Mercer et al., 2007). 
Approximately a dozen case reports from monkeys and humans have been published 
(e.g. Stich et al., 2002; Dhar et al., 2004). Tanapox is postulated to be transmitted to 
humans by mosquitos that have fed on infected monkeys 
 
1.5 Molluscum Contagiosum Virus 
Viral skin infections are the most common cause of GP visits in the UK, with over a 
million cases per year constituting a high burden of diseases and incurring considerable 
cost to the NHS (Schofield et al., 2011).  After the eradication of variola virus, the only 
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remaining poxvirus with a significant prevalence in the human population is molluscum 
contagiosum virus (MCV), the type member of the genus Molluscipoxvirus. MCV 
causes benign and self-limited tumours of the skin mainly in children and 
immunodeficient individuals. Meta-analysis suggests a point prevalence of MC in 
children aged 0 to 16 years of between 5.1% and 11.5% (Olsen et al., 2013) in the UK. 
The lesions are limited to the epidermis, can persist for years and show only weak signs 
of inflammation (Heng et al., 1989). MCV lesions have been histopathologically 
classified as acanthomas: benign hyperproliferative processes confined to the epidermal 
layers of the skin. Occurence is worldwide and the infection is regarded as specific for 
humans (Fields, 2013). There is no evidence of transmission between humans and other 
animals. MCV has no close relatives and is the only member of the Molluscipoxvirus 
genus (Porter et al., 1992; Murphy et al., 1995).  
 
Four subtypes have been recognized by restriction endonuclease analyses and disease 
presentation appears to be similar (Parr et al., 1977; Scholz et al., 1989; Porter and 
Archard, 1992). Attempts to grow MCV in cell culture have been unsuccessful, though 
limited replication in human foreskin grafted to mice has been reported (Buller et al., 
1995; Fife et al., 1996). The lack of an in vitro replication system has precluded detailed 
molecular biological characterization of MCV. The genome of MCV is similar to that of 
VAC in length and structure but has a much higher GC content (Parr et al., 1977; Porter 
and Archard, 1987; Darai et al., 1986) similar to parapoxviruses. Early studies focused 
on small segments of the MCV genome that had been sequenced (Porter and Archard, 
1987; Bugert et al., 1993; Douglass et al., 1996; Hadasch et al., 1993; Sonntag et al., 
1995; Sonntag and Darai, 1996). However, the complete sequence of the MCV type 1 
genome (190 kbp), with the exception of the terminal nucleotides, is available 
(Senkevich et al., 1996). An initial comparison of the genomes of MCV and OPV 
indicated that their central regions are conserved, whereas the ends are unique and 
contain genus-specific host response evasion genes.  
 
 
 
  
19 
 
1.5.1 MCV replication and pathogenesis 
For a virus to produce infection it must gain entry into an appropriate host with 
susceptible cells. The skin may act as a portal of entry although this may involve breach 
of the barrier function of the integument or by direct inoculation (Rook, 2012). Host 
specificity and tissue tropism are the hallmarks of viral infection. Replicative ability in 
epidermal cells is mainly a feature of DNA viruses; hence the viruses of this group are 
capable of replication after direct inoculation of the skin. Epithelial cells are permissive 
for the molluscum contagiosum virus. Unlike variola virus, Molluscum contagiosum 
does not cause a systemic disease and remains localized at the site of inoculation. Cell 
proliferation caused by molluscum results in localised tumours (Acanthoma).  The 
replication cycle is summarised in Figure 1.4.  
 
 
Figure 1.4. Summary of the replication cycle of Molluscum contagiosum virus. Replication 
occurs entirely in the cytoplasm. A virion containing the double stranded DNA genome, 
enzymes and transcription factors attaches to the cells and facilitates fusion with the cell 
membrane in turn releasing a core into the cytoplasm. The core synthesizes early mRNA which 
is translated into many different proteins including growth factors, immune defense molecules, 
factors for DNA replication and intermediate transcription and enzymes. Uncoating takes place 
and DNA replication takes place to form concatemeric molecules. Intermediate genes are 
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transcribed and the mRNA is translated to form late transcription factors. Late genes are then 
transcribed and the mRNA translated to form virion structural proteins, enzymes and early 
transcription factors.The assembly process is initiated and the concatemeric DNA intermediates 
are packaged into immature virions (IV), followed by maturation leading to formation of 
infectious intracellular mature virions (MV). The genes MC084 and mc133 are associated with 
the surface of IMVs. These MVs are wrapped by the trans-Golgi and endosomal cistrnae to give 
wrapped virions which are transported to the periphery of the cell along microtubules. Fusion 
with plasma membrane leads to release of extracellular enveloped virions (EV). Adapted from 
B. Moss in Field’s Virology. 
 
1.5.2 History and classification 
The typical molluscum lesion, a smooth, dome-shaped, flesh-colored protrusion of the 
skin with a typical central indentation, was first described by Edward Jenner (1749–
1823) as a ‘tubercle of the skin’ common in children. Thomas Bateman (1778-1821) 
first used the name ’molluscum contagiosum’ to describe dome shaped flesh coloured 
papules with a central indentation and a diameter of between 2 and 5 mm (Bateman 
1814). In 1841 W. Henderson and Robert Paterson independently observed 
intracytoplasmatic inclusions in the epidermal tissues of molluscum contagiosum (MC) 
lesions; hence Henderson-Paterson bodies (Henderson and Paterson 1841). In 1911 
Lipschütz observed ‘elementary bodies’-essentially a particular matter, inside of 
Henderson-Paterson bodies (Lipschütz, 1911). Goodpasture, King and Woodruff 
recognized similarities of MC-elementary bodies with Borrel-particles of fowlpoxvirus 
in 1927, and concluded, that the etiological agent of MC must be a poxvirus 
(Goodpasture and King, 1927; Goodpasture and Woodruff, 1931). At the beginning of 
the last century, Juliusberg (1905) demonstrated that the etiological agent of MC cannot 
be removed by filtration through Chamberland filters, implicating a viral etiology 
(Juliusberg, 1905). Filtrates were used to infect human volunteers, who developed MC 
between 25 and 50 days after inoculation. An animal model for MC has not been 
established to this day. Smaller elementary bodies inside the molluscum bodies were 
observed by Lipschutz in 1911 (Lipschütz, 1911). Electron microscopy revealed these 
elementary bodies to be poxvirus particles with dimensions of 360 nm to 210 nm.  
Electron microscopy revealed the dimension of MCV particles with 360 x 210 nm (Pirie 
et al., 1971, Fenner and Burnet, 1957). 
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Table 1.2. Characteristic features of Molluscum contagiosum. 
Members of the genus Molluscum contagiosum virus type 1 – 4 
Host range Human 
Virion morphology (shape, size) Brick 210 x 360 nm 
Genome size (% GC content) 190215 bp + ~100 (63 % G+C) 
Isolate designation and GenBank 
accession 
MCV type 1; U60315 
Major biological features 1. Human host [at present no cell culture 
system] 
2. Epidermal tissue tropism [cellular 
gene acquisition] 
3. Immuneevasion [weak inflammatory 
response] 
4. Induces epidermal dedifferentiation 
5. Induces epidermal hyperproliferation 
6. Induces keratinocyte surface receptor 
upregulation (EGFR and transferrinR) 
7. Analogies to human papillomaviruses 
 
1.5.3 Taxonomy and host range 
Based on its poxvirus-like particle morphology, MCV was first reported as an 
unclassified member of the family Poxviridae (Fenner, 1976; Matthews, 1981). It was 
reclassified as the type member in a separate genus Molluscipoxvirus by the ICTV in 
1991 (Francki et al. 1992), recognizing its poxvirus-like genome structure, in 
particular the terminal inverted repeats, in the absence of significant cross 
hybridization to other poxvirus genomes (Bugert et al., 1989; Bugert and Darai, 1991). 
MCV particle analysis in transmission electron microscopy shows spherical, 
ellipsoidal, brick-shaped, miniature and incomplete forms of MCV (Mihara, 1991). 
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Figure 1.5. MCV infected keratinocytes. 1A: A keratinocyte witb an amorphous shell of 
compressed cytoplasm and the colony of molluscum virions within a separate retracted 
membranous sac. SEM (original <11 000) (Shelley and Burmeister, 1986). 1B: Discrete virions 
within a keratinocyte; the surface of adjacent keratinocytes can be seen at tbe upper right. SEM 
original > 38000. (Shelley and Burmeister, 1986). 2 Negative stain of MCV particles, 
ammonium-molybdate technique. A: loose membrane fragments in virions (Isolate MCV HD 18) 
filtered through 0.45 um Millipore filter (bar 200nm), B: MC virions (isolate MCV HD 18) after 
Optiprep
®
 gradient purification (bar 100 nm), C: MC virions (isolate MCV HD A12) after 
Optiprep
® 
gradient purification (bar 100 nm). Electronmicroscopy: Bugert and Hobot, Cardiff 
University School of Medicine, 2005. 
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1.5.4 Disease: clinical aspects and treatment 
1.5.4.1 Clinical aspects of the MC infection 
The commonest skin infection in humans due to a poxvirus is molluscum contagiosum, 
an infection usually acquired in childhood (Buxton and Morris-Jones 2009). It is a 
superficial skin infection which occurs most commonly on exposed skin of children and 
some in the genital area of some sexually active adults (Brown et al., 2006).  It is spread 
through direct contact, often amongst family members or in schools. The incubation 
period is variable, between 14 days and 6 months (Buxton and Morris-Jones 2009). In 
adults florid molluscum may be an indicator of underlying immunodeficiency such as 
HIV (Schwartz and Myskowski, 1992a). Lesions are often itchy, particularly in patients 
with atopy which may lead to secondary infection. Transmission is by direct contact.  
 
MC is a common infection that can become a public health issue, especially in areas 
with low sanitary and hygienic standards. Despite the benign and self-limited nature of 
the infection, one-third of children have symptoms including pruritus, erythema and, 
occasionally, bacterial super infection with inflammation and pain.  
Figure 1.6. MC clinical presentation and histology. (A) MC on the eyelid margin which may 
result in viral protein spilling into the conjunctiva and causing follicular conjunctivitis. (B) 
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Child with typical MCV distribution on upper extremeties. (C) MCV lesions from an immuno-
compromised patient with DOCK8, showing varying degrees of acute inflammation. NIH 
Clinical Center: Bugert and Turner, 1993. (D) MCV histopathology showing lobular 
hyperplasia of epidermis into dermis forming cup-shaped lesions. Keratinocytes of stratum 
malpighii have acquired Henderson- Patterson bodies. (From biopsy: University of Heidelberg; 
stained Sherwani, 2013). 
 
The characteristic lesion begins as a small papule and, when mature, is a discrete, waxy, 
smooth, dome-shaped pearly or flesh-coloured nodule, often umbilicated (Brown et al., 
1981). There are usually 1–20 lesions but occasionally there may be hundreds. They 
may become confluent along the line of a scratch and satellite lesions are occasionally 
seen. In children, lesions occur mainly on the trunk and proximal extremities. In adults 
they tend to occur on the trunk, pubic area and thighs, but in all cases infection may be 
transmitted to other parts by auto-inoculation (Brown et al., 1981). Individual lesions 
last for about two months but the disease usually lasts six to nine months (Steffan and 
Markman, 1989). More severe and prolonged infection tends to occur in individuals 
with impaired cell-mediated immunity, including HIV infection (Birthistle and 
Carrington, 1997; Schwartz and Myskowski, 1992b). 
 
Lesions of MCV occur almost exclusively in the skin, and only rare reports have 
referred to mucous membrane lesions (Gottlieb and Myskowski, 1994; Lewis et al., 
1997; Epstein, 1992). Lesions of MCV are most commonly seen in young children, 
sexually active adults, and in some immune suppressed patient populations (Gottlieb 
and Myskowski, 1994). Although MCV infections are highest in warm moist climates 
and in populations where personal hygiene is difficult to maintain, they have a 
worldwide distribution (Chen, 2013).  
 
Patients with pruritis spread the virus through scratching (Silverberg, 2003). MC 
frequently occurs around the eyelid, where it is difficult to treat and occasionally causes 
MC conjunctivitis (Ueyama et al., 1985; Khaskhely et al., 2000). Unusual cases of MC 
include an infant with extensive eruptive MC scattered over the back and buttocks that 
became inflamed with blackening, possible haemorrhaging, and then healed 
spontaneously (Ogino and Ishida, 1984) or MCV associated with papillomatosis - 
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common warts (Payne et al., 1997). MC presents with an extensive clinical picture in 
atopic dermatitis (Wetzel and Wollenberg, 2004) and other skin specific and systemic 
immune dysfunctions. Spontaneous regression of MC may occur by non-inflammatory 
and traumatic-inflammatory processes (Pierard-Franchimont et al., 1983). MC in human 
immunodeficiency virus (HIV) infections used to be very common (up to 30% of HIV 
infected individuals in stage 4 clinical disease) before the onset of HAART and 
cidofovir HCMV prophylaxis (Meadows et al., 1997). 
 
In young adults, sexual contact is probably the most common mode of transmission, and 
genital lesions are common (Gottlieb and Myskowski, 1994) In human 
immunodeficiency virus type 1-positive (HIV-11) patients, widespread lesions do occur, 
but head and neck lesions are most common, followed by genital involvement (Smith et 
al., 1994; Schwartz and Myskowski, 1992b). The immune response to the viral 
infection causes ‘molluscum contagiosum’ dermatitis which is an erythematous halo 
with desquamation around the lesion (Brown et al., 1981). Large solitary lesions (Giant 
Molluscum) or infected lesions may have an atypical presentation. Resolving lesions 
may be surrounded by a patch of inflammation. In most affected patients/individuals the 
lesions resolve leaving no marks on the skin. HIV patients exhibit bigger lesions which 
may even be higher in number, as many as 1000 (Cotton et al., 1987). In HIV infected 
individuals large lesions are common on the face (Schwartz and Myskowski, 1992b). 
Spontaneous resolution is rare. 
 
Lesions are characterised by whitish or flesh coloured umbilicated papules (1-2 mm) or 
nodules (5-10 mm) (Elston, 2009). Although the typical umbilicated papules occur in all 
patient populations, in HIV-1 patients, verrucous, warty papules, as well as giant 
molluscum greater than 1 cm in diameter, are also seen (Buckley and Smith, 1999; 
Smith et al., 1994). In patients without severe immune suppression, lesions produced by 
MCV typically regress spontaneously usually within months, rarely years (Schwartz and 
Myskowski, 1992a). MCV is only distantly related to VAR, and lacks DNA cross-
hybridization or immunologic cross-reactivity (Senkevich et al., 1996).  
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Four genetically distinct but clinically indistinguishable viral subtypes of MCV have 
been defined including three MCV-1 variants and MCV-2, MCV-3, and MCV-4 
subtypes (Buller et al., 1995). MCV-1 subtypes dominate worldwide and, in one report, 
MCV-1 subtypes occurred exclusively in children under the age of 15 years (Lewis et 
al., 1997; Porter et al., 1989) however, there is evidence that other MCV subtypes are 
more common in the HIV-11 patient population (Nakamura et al., 1995; Lewis et al., 
1997). There is a predilection for the head and neck, trunk, flexural areas, or the 
genitalia of children and adolescents (Rook, 2009).  
 
Type 1 causes the majority of infections (76-97%) (Porter et al., 1989). The virus is has 
worldwide occurrence although its incidence in areas is not reliably known/documented 
(Fields, 2013). The disease is rare under the age of one perhaps due to maternally 
transmitted immunity and a long incubation period (Postlethwaite, 1970). Its incidence 
reflects an exposure to other humans as well as hygiene conditions. The age of peak 
incidence is reported to be 2-3years in Fiji (Postlethwaite et al., 1967) and 1-4 years in 
Zaire (Torfs, 1959). The annual infection rate for children under the age of ten in New 
Guinea has been reported to be 6% (Sturt et al., 1971). In cooler climates infection is 
rare and correlated with a higher age. Use of swimming pools has been correlated with 
childhood infections in Scotland between the ages of 10-12 years (Postlethwaite et al., 
1967) and in Japan at the age of 8 (Niizeki et al., 1984). In these studies boys were 
affected more than girls perhaps due to frequent use of communal bathing facilities and 
contact sports. A peak associated with a later incidence in adults is attributable to sexual 
transmission. Infection of children through sexual abuse is possible (Bargman, 1986a; 
Bargman, 1986b).  
 
The clinical association of frequency of molluscum contagiosum in patients with atopic 
eczema may be a result of impaired immunity (Dohil et al., 2006; Solomon and Telner, 
1966). Unusually large lesions have been reported in individuals taking 
immunosuppressive therapy (Cotton et al., 1987) and those with HIV. Such clinical 
manifestations suggest the significance of cell mediated immunity in control and 
elimination of infection.  
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The pathogenesis of lesions although unclear suggests the entry of the virus through 
basal keratinocytes causing an apparent increase in cell turnover extending all the way 
to the suprabasal layer. As viral DNA synthesis increases, mitosis in the prickle cell 
layer declines. Cell proliferation produces lobulated epidermal growth that compress the 
papillae until fibrous septa are formed between the lobules giving rise to a pear shaped 
structure with an upward apex. Whereas the basal layer remains intact, cells at the core 
of the lesion exhibit maximum distortion and eventual destruction. These appear as 
large hyaline bodies (up to 25 µm) called molluscum bodies which contain cytoplasmic 
masses of viral materials (Shelley and Burmeister, 1986). These bodies are concentrated 
at the centre of the fully developed lesion and near the surface.  Inflammatory changes 
in the dermis are either absent or very slight. However chronic lesions may show 
granulomatous infiltrate. It has been suspected that the discharge of the contents of a 
papule in to the dermis may trigger/induce an inflammatory reaction (Henao and 
Freeman, 1964). Specific antibodies have been recognised in 60-80% of patients with 
molluscum contagiosum. Also 5-15% controls exhibit these perhaps due to an 
unrecognised infection (Shirodaria et al, 1979; Watanabe et al, 2000). However the role 
of humoral immunity in regression of lesions is as yet unclear.  
 
The incubation period has been estimated as varying from 14 days to six months. An 
individual lesion is shiny, pearly-white, hemispherical umbilicated papule which may 
show a central pore. If less than 1 mm in diameter, the papule may be identified with a 
hand lens. Enlarging slowly it may reach a diameter of 5-10 mm in 6-12 weeks. Plaques 
composed of many lesions (agminate form) occur rarely (Lynch and Minkin, 1968). 
Lesions frequently spread and sometimes the number may be large. After trauma or 
following many months, inflammatory changes result in suppuration; crusting and 
eventual destruction of the lesion.Healing is usually without scarring but occasionally in 
sites with more subcutaneous fat depressed scars may remain (Ghura and Camp, 2001).  
 
There is great variability in the duration of an individual lesion and the attack. Most 
cases are self-limiting in 6-9 months. Some may persist for 3-4 years. These figures 
have been confirmed by follow-up studies in children in Fiji (Hawley, 1970). 
Distribution of lesions is determined by the mode of infection and the type of clothing 
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worn dictated by the climate. Lesions are commonly seen around the neck or trunk, 
particularly around the axillae except for sexually transmitted cases where the 
anogenital area is involved. In tropical regions lesions in children are more common on 
limbs. Widespread and refractory mollusca associated with HIV patients are seen on the 
face (Katzman et al, 1987). In healthy subjects occasional facial lesions are seen, 
especially on the eye lids. Molluscum has also been reported in scars (Isaac, 1980) and 
in tattoos with transfer through pigment (Foulds, 1982). Erythema annulare centrifugum 
has also been reported (Vasily and Bhatia, 1978). Chronic conjunctivitis and superficial 
punctuate keratitis may similarly complicate lesions on or near the eyelid (Haellmigk, 
1966). Conjunctivitis and eczema subside spontaneously with the removal of lesions.  
 
1.5.4.2 Diagnosis, Treatment, and Prevention 
1.5.4.2.1 Diagnosis 
After the eradication of smallpox, MCV is the most commonly diagnosed poxviral 
infection. Ortho and parapoxviral zoonoses are rare by comparison. MCV is readily 
diagnosed by its clinical appearance and by the typical histopathology found in found in 
sections of lesion biopsies (Chan et al., 2004). Molecular diagnostics by in situ 
hybridization and PCR have been described for unclear cases (Forghani et al., 1992; 
Thompson et al., 1990a; Thompson et al., 1990b). MCV ELISAs have been described 
for serological surveys (Konya et al., 1992; Thompson et al, 1998; Konya and 
Thompson, 1999). Virions can usually be seen in large numbers if material expressed 
from the lesion is examined by electron microscopy. The lack of a marked 
inflammatory response and failure to isolate an agent in cell culture or chorioalantoic 
membranes (CAM) should eliminate other poxvirus infections. 
 
Diagnosis is mostly based on clinical appearance although this may be challenging in 
some cases. Biopsy is performed on HIV patients to rule out the invasive fungal 
infections such as cryptococcosis, histoplasmosis, coccidioidomycosis etc. Microscopy 
confirms the typical display pattern of numerous intracytoplasmic inclusion bodies 
called molluscum bodies (Brown et al., 2006).  
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In the differential diagnosis of MC, smallpox must be considered along with other 
ortho- and parapoxviruses. The anamnesis must cover contacts with pets, especially 
gerbils and chipmunks of African origin (monkeypox) as well as local rodents and cats 
(cowpox).  
 
1.5.4.2.2 Prevention and treatment of MCV infection 
Infection is benign and recovery usually spontaneous, but treatment may be sought for 
cosmetic reasons, particularly for facial or multiple lesions. To avoid spread of infection 
patients must be advised to avoid swimming pools, communal baths, contact sports, 
shared towels etc. In many cases a natural resolution is awaited and no therapy is 
required. If resolution is slow, lesions symptomatic or associated eczema is troublesome 
treatment may be desirable. The treatment of molluscum contagiosum is varied, with no 
one modality favoured in any country.  
 
Various treatments have been tried (Birthistle and Carrington, 1997). Treatment 
depends on the age of the patient as well as number of lesions and may range from 
simple reassurance, topical application to a procedure.The induction of an inflammatory 
response by mild trauma or destruction of lesions can hasten clearance, which may be 
due to release of virus-infected cells accessible to the immune system. Prevention is 
based on attention to personal hygiene and, in developing countries, to general 
improvements in living conditions. Although relatively unimportant per se, the 
possibility that molluscum may act as a marker for more serious conditions has been 
raised (Oriel, 1987). 
 
MC is best prevented by exposure prophylaxis. Once acquired, molluscum contagiosum 
lesions are generally self-limiting; it may take between 6 months to 5 years for lesions 
to disappear. Patients with immune dysfunction or atopic skin conditions have 
difficulties clearing lesions. There has been a continued debate about whether 
molluscum contagiosum lesions should be treated or allowed to resolve spontaneously 
(Tyring, 2003). Therapy is recommended for genital MC to avoid sexual transmission 
and should begin with gentle skin care and antipruritics to prevent symptoms 
(Silverberg, 2003). Available treatment options are: 
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1. In-office-Curettage (surgical): classical removal of the lesion with a sharp spoon. 
Occasional scarring: While adults cope well with unanesthetized curettage of lesions, 
children require local anaesthetics or less painful therapeutic options. 
2. In-office-Cryosurgery: current technique combines lidocaine/prilocaine topical 
anesthesia with hyperfocal cryotherapy. Most lesions treated regress without leaving 
scars (Bardenstein and Elmets, 1995). 
3. Novel-at-home painless MCV treatment options in extensive cases are ointments 
containing retinoids, alpha-hydroxy acids and the topical immunomodulators tacrolimus 
(e.g. 0.1% ointment ), pimecrolimus, imiquimod or podophyllotoxin (0.5% ointment). 
However, topical immunomodulators may predispose patients to skin infections 
(Markos, 2001; Berman, 2002; Wetzel and Wollenberg, 2004). Although a variety of 
such at-home therapies are available, no at-home treatment is as effective as surgical - 
in-office therapy. Also a recent study published by Katz and Swetman, documents the 
results of two randomised controlled trials of imiquimod for treatment of MC in 
children and shows its ineffectiveness (Katz and Swetman, 2013). 
4. Antivirals specifically active against MCV DNA polymerase, like acyclic nucleoside 
phosphonates (HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and 
PMPA: tenofovir, Viread). These agents are effective in vivo against a wide variety of 
DNA virus infections (De Clercq, 2003). There is anecdotal evidence that i.v. and 
topical cidofovir works against MCV, however, comprehensive clinical studies are 
lacking (Meadows et al., 1997). Possible alternative MCV specific antivirals that are 
presently not pharmaceutically refined target the viral topoisomerase: lamellarin H, 
coumermycin A1 (50% inhibitory concentration, 32 µM) and cyclic depsipeptide 
sansalvamide-A (Hwang et al., 1998; Hwang et al., 1999; Bailly, 2004). 
 
All surgical treatments are painful to some degree and carry the risk of leaving scars. 
Immunemodulators may predispose to bacterial and fungal infections. Specific 
antivirals are the most expensive treatment option. Further research in large clinical 
trials is required to increase current knowledge on prevention, optimal treatment, and 
long-term outcome with this disease. 
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1.5.4.3 Epidemiology 
1.5.4.3.1 MCV molecular epidemiology 
First available in the early seventies was the method known as DNA fingerprinting, 
which uses bacterial DNA restriction enzymes, to assess genetic variation of viral 
genome nucleic  acids. This method requires access to the viral genome in sufficient 
quantities to be visualized with ethidium bromide stain on agarose gels. The first 
purification of MCV DNA suitable for this purpose was reported by Pierie and co-
workers (Pirie et al., 1971) who found, that MCV can be isolated in large quantities 
from clinical lesion material.  
 
Parr and co-workers first observed in 1977 genetic variations between MCV isolates 
based on differences in restriction enzyme patterns (Parr et al., 1977). Later work in the 
labs of G. Darai and L.C. Archard (Darai et al., 1986; Scholz et al., 1988; Scholz et al., 
1989; Porter et al., 1989; Porter and Archard, 1992) established between 2 and 3 main 
genetic types, respectively, and a number of subtypes, based on their viral genomic 
DNA restriction pattern.  
 
Porter and co-workers reported in two studies of patients seen in London hospitals an 
MCV type 1: type 2 ratio of about 3:1 (Porter et al., 1987; Porter and Archard, 1992). 
Darai and co-workers differentiated MCV types 1, 1 variant (1v), 2, and 2 variant (2v) 
and went on to characterize 222 MCV isolates from the Grampian region in Scotland. 
They found that MCV type 1/1v was about 40 fold more common than type 2/2v in this 
population and that MCV genotypes did not change over time (up to 3 years) in the 
same patient, or when passed on in a contact group, e.g. family (Scholz et al., 1988).  
 
In a study of MCV in Australia for the first time HIV infections were indicated in the 
study group. MCV 1 or 1v were found in 59% of lesions obtained from 75 Australian 
patients, 29% of whom were HIV positive, 32% contained MCV 2 or 2v, and 4% 
contained multiple MCV types, whereas 5% of lesions submitted contained no 
detectable MCV DNA. The overall ratio of MCV 1/1v to MCV 2/2v was determined to 
be approximately 1.75:1. MCV type 2 was more frequently detected in general and 
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specifically in lesions from anogenital areas and immunosuppressed (HIV-positive) 
patients (Thompson et al., 1990).  
 
A Japanese study looked at genomes of 477 Japanese strains of MCV and classified 
four BamHI restriction types, including a newly detected type (MCV type 4). The 
common markers of the variants of MCV 1 were 24 kbp fusion fragments generated by 
the loss of a BamHI site between the D2 and F fragments of MCV 1p. The variants of 
MCV 1 were classified into three groups (MCV 1va, MCV 1vb, MCV 1vc), with the 
variability among them being due to additions and losses of BamHI sites located in the 
right terminus and around the E and I fragments of MCV 1va. Considerable numbers of 
BamHI restriction sites were conserved between MCV 2 and 4, indicating a close 
analogy between them. The prevalence ratios of MCV types (MCV 1 (MCV 1p): MCV-
2: MCV 3: MCV 4), was determined to be 436(0):13:24:4. Thus, the molecular 
epidemiology of MCV in Japan is characterized by the absence of the European 
prototype of MCV 1, the exclusive occurrence and abundance of variants of MCV 1, a 
greater prevalence of MCV 3 over MCV 2, and the presence of MCV 4 (Nakamura et 
al., 1995).  
 
An independent Japanese study of 171 Japanese patients examined whether there were 
geographic differences in the incidence of MCV types and whether a correlation existed 
between MCV types and the age, sex, and clinical status of the patients (Yamashita et 
al., 1996). The ratio of MCV 1 to MCV 2 was 13:1. MCV 1 was commonly detected in 
children (98%) and adult women (92%). MCV 2 was more frequently isolated from 
adult men (44%) and from patients with HIV infection (75%) (Yamashita et al., 1996). 
In a Spanish study of 147 patients 97 (66%) were children under 10 years, of whom 
49% had atopic dermatitis. Atopic patients presented with larger lesions. The MCV 
1/MCV 2 ratio was 146:1 (Agromayor et al., 2002). 
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Table 1.3. Prevalence of MCV sub-types (Bugert, 2007). 
Prevalence of MCV genetic types 
MCV 
type 
England 
[Porter et 
al., 1987] 
N=46 
Scotland 
[Scholz et 
al., 1988] 
N=222 
England 
[Porter et 
al., 1989] 
N=93 
Australia 
[Thompson 
et al.,1990] 
N=75 
Japan 
[Nakamura 
et al., 1995] 
N=477 
Japan 
[Yamashita 
et al., 1996] 
N=171 
Spain 
[Agromayor 
et al., 2002] 
N=147 
Type 1 74 % 96% 1p 76% 59% 1p 91% 1v+ 92% 1p 99.4% 1p 
Type 2 26 % 4% 24% 32% 3%  7% 0.6% 
Type 3     5% [1v]   
Type 4     1% [2v]   
 
1.5.4.3.2 MCV seroepidemiology 
Using protein preparations of MC lesion biopsies an early study looked for molluscum 
contagiosum virus-specific antibodies (Shirodaria et al., 1979). The first comprehensive 
study comparing 35 HIV positive MC cases and a random group of 357 persons (ages, 1 
week-69 years) was done 1992 in Australia using a virus coated MCV ELISA format 
(Thompson et al., 1990). MCV antibody was identified in 77% of persons with 
molluscum lesions: in 17 of 24 HIV-1-negative persons and in 10 of 11 who were HIV-
1-positive. No relationship was evident between the serologic responses and the number 
of lesions or the duration of infection. The population survey revealed an overall 
seropositivity rate of 23%. The lowest antibody prevalence was in children aged 6 
months to 2 years (3%), and seropositivity increased with age to reach 39% in persons 
>50 years old, indicating that MC is a very common viral infection (Thompson et al., 
1992).  
 
In order to optimize ELISAs using recombinant MCV antigens, a library of MCV 
genome fragments was transferred into a cowpox virus expression system and screened 
with 12 sera from MC patients. Two major antigenic proteins of 70 and 34 kDa were 
detected by immunoblotting and mapped to the open-reading frames mc133L (70 kD 
protein: MC133) and mc084L (34 kD protein: MC084), respectively (Vreeswijk et al., 
1976; Vreeswijk et al., 1977). This was confirmed in an independent study using 
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protein preparations of the virus-induced lesions, where three immunoreactive proteins 
of 74/80, 60 and 35 kD were detected. The 35 and 74/80 kD proteins turned out to be 
virus specific, whereas the 60 kD protein band was composed of a mix of human 
keratins (Agromayor et al., 2002). MC133L and MC084L were found to be 
predominantly expressed on the surface of recombinant virus-infected HeLa cells. 
MC084R is also detectable on the surface of MCV virion particles (Watanabe et al., 
1998). The same group assessed the seroprevalence of antibodies against MCV in 508 
Japanese subjects with or without clinical MCV infection using a recombinant truncated 
MC133L ELISA. Antibodies to MCV were present in 7 (58%) of 12 patients with 
molluscum contagiosum, 7 (6%) of 108 healthy controls, 7 (9%) of 76 with atopic 
dermatitis, and 7 (18%) of 39 patients with systemic lupus erythematosus, although no 
clinical MCV infection was observed in the latter 3 groups. Of 7 human 
immunodeficiency virus (HIV)-positive patients with molluscum contagiosum, 1 (14%) 
was antibody positive, compared with 5 (2%) of 266 HIV positive patients without 
molluscum contagiosum (Watanabe et al., 2000).  
 
1.5.4.4 Pathology 
1.5.4.4.1 MCV pathogenesis 
MCV probably enters the epidermis through microlesions. After a variable, sometimes 
lengthy, incubation period, papules develop, formed by epidermal hypertrophy. This 
produces a nodule and also extends the dermis downwards, but the basement membrane 
usually remains intact. The typical MCV lesion contains conglomerates of hyperplastic 
epithelial cells organised in follicles and lobes, which all develop into a central 
indentation towards the surface of the skin. A lesion consists of several inverted lobules 
of hyperplastic squamous epithelium which expand into the underlying dermis. The 
lobules are separated by fine septa of compressed dermis. The central indentation is 
filled with cellular debris, fatty acids and is extremely rich in elementary viral particles, 
creating a waxy plug-like structure. This plug gets mobilized and spreads the infection 
to other areas of surrounding skin or contaminates objects in a process similar to 
holocrine secretion.  
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The periphery of the MCV lesion is characterized by basaloid epithelial cells with 
prominent nuclei, large amounts of heterochromatin, slightly basophilic cytoplasm, and 
increased visibility of membraneous structues, which are larger than normal basal 
keratinocytes. These hyperplastic cells are dividing faster than normal basal cells, the 
cytoplasm contains a large number of vacuoles and they are sitting on top of an intact 
basal membrane (Vreeswijk et al., 1976; Vreeswijk et al., 1977). The lesion is therefore 
a strictly intraepidermal hyperplastic process i.e. acanthoma.  
 
Distinct poxviral factories or inclusion bodies appear about 4 cell layers away from the 
basal membrane in the stratum spinosum (Shelley and Burmeister, 1986). The inclusion 
bodies grow and push cellular organelles including the cell nucleus to the side. Cells 
with inclusion bodies do not show mitoses anymore. The cytoplasm of MCV producing 
cells shows keratinization, which is not expected at that stage of keratinocyte 
differentiation and indicates dyskeratinization in the sense of abnormal differentiation 
(Manabe et al., 1996). Characteristic inclusions (Henderson–Patterson bodies) are 
formed in the prickle cell layer and gradually enlarge as the cells age and migrate to the 
surface. These cells are replaced by hyperplasia of the basal cell layer. The inclusion is 
a well-defined sac packed with virions (Shelly and Burmeister, 1986).  
 
The lesion is circumscribed by a connective tissue capsule and the dermis, apart from 
distortion, remains essentially normal. Occasionally an inflammatory infiltration of the 
dermis may occur (Brown et al., 1981). MCV lesions are conspicuous for the absence of 
immune effector cells. There are actually fewer immune cells, than in surrounding 
uninfected skin, e.g. no circulating tissue macrophages, suggesting a local immune 
evasive effect. MCV infected cells show increased EGFR and transferrin receptor 
surface density (Viac and Chardonnet, 1990).  
 
1.5.4.4.2  MCV pathology and clinical features 
The mean incidence of MC in the general population is 0.1–5%. Seroepidemiological 
studies have shown that antibody prevalence in persons over 50 years of age is 39% 
(Konya et al., 1999). This indicates that MC is a very common viral skin infection, 
which is supported by its common occurrence in dermatological practice. MCV 
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outbreaks occur in crowded populations with reduced hygienic standards. Outbreaks 
with more than 100 cases have been described in kindergartens, military barracks, and 
public swimming pools. MC was found to be very common in the Fiji Islands (Hawley, 
1970).  
 
MC is most often seen as a benign wart-like condition with light pruritus in 
preadolescent children, but can occur in immuncompetent adults. MC is more severe in 
immunocompromised people or individuals with atopic dermatitis, where it can lead to 
giant molluscum and eczema molluscum. The lesions generally occur on all body 
surfaces, but not on the palm of the hand or on mucous membranes. They may be 
associated with hair follicles. MC lesions can grow close to mucous membranes on the 
lips and eyelids. When situated near the eye, they can lead to conjunctivitis. MC is 
transmitted by smear-infection with the infectious fluids discharged from lesions and by 
direct contact with contaminated objects.  
 
MC is not very contagious and therefore infection depends on a high inoculating dose. It 
is a sexually transmitted disease when lesions are located on or in the vicinity of sexual 
organs. MC lesions are generally globular, sometimes ovate, 2–5 mm in diameter and 
sit on a contracted base. Cellular semi liquid debris can be expressed from the central 
indentation at the top of the lesion. The infection spreads via contact with this fluid. 
Histologically, the tumours are strictly limited to the epidermal layer of the skin and 
have a resemblance to hair follicles. They are therefore classified as acanthomas. If not 
mechanically disturbed, MC lesions will persist for months and even years in immune-
competent hosts, but can disappear spontaneously, probably when virus infected tissue 
is exposed to the immune system. To expose the infection by limited (sterile) trauma is 
a way of treatment. Scratching or disturbing the lesions leads to a quicker resolution but 
can complicate the condition through bacterial super infection. This must be avoided in 
severely immunocompromised hosts, who develop widespread MC with hundreds of 
lesions of larger size and can succumb to sepsis following bacterial superinfection.  
 
MCV is a marker of late-stage disease in human immunodeficiency virus (HIV)-
infected individuals, and in HIV-infected populations the incidence of MC was 30% 
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before the onset of human cytomegalovirus (HCMV) prophylaxis with cidofovir. MCV 
probably enters the epidermis through microlesions.  
 
The typical MCV lesion contains conglomerates of hyperplastic epithelial cells 
organized in follicles and lobes, which all develop into a central indentation toward the 
surface of the skin in a process similar to holocrine secretion. The whole lesion has the 
appearance of a hair follicle where the hair is replaced by the virus containing plug. The 
central indentation is filled with cellular debris and is rich in elementary viral particles 
in a waxy plug-like structure. This plug becomes mobilized and spreads the infection to 
other areas of surrounding skin or contaminates objects.  
 
The periphery of the MCV lesion is characterized by basaloid epithelial cells with 
prominent nuclei, large amounts of heterochromatin, slightly basophilic cytoplasm, and 
increased visibility of membranous structures. These cells are larger than normal basal 
keratinocytes, they divide faster than normal basal cells, their cytoplasm contains a 
large number of vacuoles, and they are sitting on top of an intact basal membrane. The 
lesion is a strictly intraepidermal hyperplastic process (acanthoma). Distinct poxviral 
factories (molluscum bodies or Henderson-Patterson bodies) appear about four cell 
layers away from the basal membrane in the stratum spinosum. The inclusion bodies 
grow and obliterate cellular organelles. Cells with inclusion bodies do not divide 
further. The cytoplasm of MCV-producing cells shows keratinization, which is not 
expected at that stage of keratinocyte differentiation and indicates dyskeratinization in 
the sense of abnormal differentiation. 
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Figure 1.7. MCV life cycle and clinical picture. (A) MCV replication in the epidermis. 
Examples of MCV proteins with known functions: a. membrane proteins: MC054L-IL18 binding 
protein, MC162: Hrs binding protein (possible effect on cell surface receptor regulation). 
cytoplasmic proteins: MC159/160-FLICE inhibitors, MC066-glutathione peroxidase, c. 
secreted proteins: MC148R-chemokine antagonist. Virions are shown as blue circles, cell 
surface receptors as triplet of red lines (example EGFR). (B) MCV virion(C)Histopathology of 
MC lesion. 
 
1.5.4.5 MCV tissue and cell tropism 
Classical EM studies (Vreeswijk et al., 1976; Vreeswijk et al., 1977) indicate that MCV 
is a virus infecting keratinocytes. Granular cells of MCV infected epidermis contain 
filaggrin, a skin-type keratin pair (K1/K10), and trichohyalin, a hyperproliferation-
related keratin pair (K6/K16) (Manabe et al., 1996). More recently, eosinophilic 
intranuclear inclusion bodies, resembling poxviral factories, were described in a 
melanocytic nevus and confirmed as MCV specific with reverse transcriptase in situ 
polymerase chain reaction (RT in situ PCR) (Hahm et al., 2002). The latter finding has 
so far not been independently confirmed. 
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1.5.4.6 MCV host range 
While there is a general consensus that MCV is restricted to the human host, two reports 
in the more recent literature describe a MCV-like infection in the equine host: Three 
horses in the Chingola district of Zambia were found to be suffering from a slow 
progressive skin disease with lesions varying from 4 to 20 mm in diameter in various 
areas of the body. Microscopically, cytoplasmic inclusions containing many pox virions 
were found. Attempts at culturing the virus were unsuccessful (Lange et al., 1991). 
There is one report in the literature of ‘Equine MCV’ being closely related to human 
MCV by in situ hybridization using human MCV hybridization probes (Thompson, 
1998).  
 
MCV, like smallpox virus, is considered to be an exclusive pathogen of man. Reports of 
MCV in a number of animals, including horses, chimpanzees, and kangaroos, have not 
been supported by DNA sequence confirmation. Many pox-like infections of 
vertebrates, most of them caused by orthopoxviruses, can be confused with MCV by 
their clinical appearance. Conventional immune-competent laboratory animals, 
including mice, rats, guinea pigs, and tree shrews, do not support MCV replication in 
their skin. MCV infected human keratinocytes have been transplanted into mice with 
severe combined immune deficiency (SCID) and typical MCV lesions have 
subsequently developed in these non-natural hosts. Attempts to passage the virus in 
SCID mice were unsuccessful. However, despite the absence of molecular evidence, an 
animal reservoir of MCV cannot be excluded.  
 
MCV has so far not been grown in conventional human cell lines, including 
immortalized tumorigenic/virus-transformed and non-tumorigenic skin keratinocytes 
(HaCaT, NIKS). Experiments with ex vivo cultures of human skin cells (raft cultures) 
are ongoing. MCV may use a vegetative mechanism for replicating in differentiating 
keratinocytes. In the absence of culturable virus, classical virological research on MCV 
is severely restricted. All progress so far has been made by studying MCV genes in 
isolation, based on the complete MCV genome sequence gained from an overlapping 
redundant MCV genome fragment library. This reagent has been made available to the 
ATCC. The entire MCV gene complement is covered by 18 recombinant bacterial 
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plasmid clones harbouring viral sequences from the EcoRI, BamHI, and HindIII 
restriction fragment libraries of MCV type 1/80. Further research is being carried out 
using abortive cell culture systems.  
 
MCV induces a remarkable cytopathogenic effect (CPE) in human fibroblasts, both in 
primary cells (MRC5) and in telomerase-transduced immortal cell lines (hTERT-BJ-1). 
The CPE starts 4 h post infection (p.i.) and reaches a maximum at 24 h p.i., with the 
cells looking as if they have been trypsinized, partially detaching from the monolayer, 
rounding, and clumping. Cells settle down at 48–72 h p.i., but show a morphological 
transformation from an oblong fibroblast to a more square epithelial-looking cell type. 
MCV transcribes early mRNA in these cells. The CPE is not induced by UV-inactivated 
virions or in the presence of cycloheximide, indicating that expression of viral proteins 
is required. The mRNA transcription can be detected by reverse transcriptase-
polymerase chain reaction (RT-PCR) for months in serially passaged infected cells. A 
productive MCV infection cannot be rescued nongenetically by co-infection with other 
chordopoxviruses in these cells.  
 
MCV can infect human HaCaT keratinocytes and transcribes mRNA in these cells, but 
does not induce a CPE. MCV cannot infect nonhuman cells. It induces type 1 
interferons in mouse and human embryo fibroblasts and IL8 in human lung epithelial 
cells, which it cannot infect, suggesting involvement of surface pathogen-associated 
molecular pattern (PAMP) receptors like TLR2 or TLR4. Removal of interferon 
pathways from cell lines susceptible for MCV infection would be worth investigating, 
in order to exclude interference causing abortive MCV infections. MCV is currently 
isolated from human-infected skin biopsies. MCV purified from biopsy material can be 
used for infection studies, electron microscopy, viral DNA extraction, and analyses of 
early mRNA synthesized by in vitro transcription of permeabilized virions. 
 
1.5.4.7 Cell culture and animal systems 
1.5.4.7.1 Abortive cell culture systems 
Over many years a large number of primary cells and cell lines were tried for replication 
of MCV. MCV does not produce infectious progeny in these cells. Non-genetic 
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reactivation, demonstrated for other chordopoxviruses of different genera does not work 
with MCV (Postlethwaite, 1970; Pirie et al., 1971; Shand et al., 1976; Bugert et al., 
2001). Only human fibroblasts and keratinocytes turned out to be susceptible for MCV 
infection and MCV early mRNAs can be isolated from abortively infected cells 
(McFadden et al., 1979, Bugert et al., 1999, Melquiot and Bugert, 2004). As early as 
1967 Postlethwaite at the University of Aberdeen reported cell culture studies with 
MCV, initially using mouse embryo fibroblasts (Postlethwaite et al., 1967). At the same 
time biological assays for interferon activity were developed using the same mouse 
embryo fibroblasts and encephalomyocarditis virus as a readout system (Postlethwaite 
et al., 1967). It was found that prior infection of mouse embryo fibroblasts with MCV 
interfered with the development of EMCV CPE in a dose-dependent manner. 
Furthermore it was observed, that MCV does not seem to shut down host protein 
synthesis and does in contrast to vaccinia virus not seem to inhibit the cellular type 1 
IFN response. These observations were confirmed recently for human cell lines. MCV 
induces IFN beta, but not IFN alpha or IL8, in human MRC5 and HaCaT cells.  
 
1.5.4.8 MCV lesion core and biopsy material 
Currently MCV is isolated from patient specimens. MCV purified from then debris core 
of MCV lesions or from biopsy material can be used for infection studies, electron 
microscopy, viral DNA extraction, and analyses of early mRNA synthesized by in vitro 
transcription of permeabilized virions (Melquiot and Bugert, 2004). 
 
1.5.4.9 Foreskin xenograft models 
MCV replication was observed in human foreskin grafts to the skin of athymic mice. 
MCV infected xenografts developed morphological changes indistinguishable from 
patient biopsies (Buller et al., 1995). In an independent approach infection with MCV 
type 1 and 2 virions induced similar histological changes in human foreskin fragments 
transferred to the renal capsule of athymic mice. Cytoplasmic inclusions containing 
typical poxvirus particles were seen within 2-3 weeks of implantation. Attempts to pass 
virus from one infected implant to another were not successful. These findings were 
confirmed by Paslin and co-workers (Fife et al., 1996; Paslin et al., 1997). Even though 
the xenograft models seem to work in vivo, the ‘Buller system’ is hampered by low 
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efficiency of MCV infected graft ‘take’ and a long (146 days) delay before the 
development of MCV inclusion bodies. Because only one mouse took the infected 
foreskin graft, there was no attempt to passage the infection. For the ‘Fife system’, 
though lesions developed faster, it was found that infectious progeny is not produced. 
 
1.5.4.10 Virion, genome and evolution 
Molluscum contagiosum virus (MCV) particles have typical poxviral morphology 
(Figure 1.8). The virions are enveloped, pleomorphic, but generally ovoid to brick 
shaped, with a dumbbell-shaped central core and lateral bodies similar to those in 
orthopoxvirus virions. MCV cores show complex structural patterns. Virions are often 
found to have membrane fragments loosely attached to them, indicating a non-
continuous lipid envelope wrapping the core. The genome of MCV is a double-stranded 
DNA molecule of 190289 bp (GenBank accession U60315: MCV type 1/80) with 
covalently closed termini (hairpins) and about 4.2 kbp of terminally inverted repeats 
(Figure 1.8). This excludes 50–100 bp of terminal hairpin sequences that could not be 
cloned or sequenced because replicative intermediates are not apparent in DNA from 
MCV biopsy specimens. The genomes of MCV (genus Molluscipoxvirus, subfamily 
Chordopoxvirinae), crocodilepox virus, and parapoxviruses stand out in the family 
Poxviridae because they have GC contents of over 60%. The MCV genome encodes 
182 non-overlapping open reading frames of more than 45 codons (Figure 5), almost 
half of which have no similarities to known proteins. Hypothetical MCV structural 
proteins and proteins encoding enzymes of the replication and transcription apparatus 
share obvious homologies to other poxvirus proteins.  
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Figure 1.8. MCV genome alignment. Schematic alignment of the genomes of MCV (190 kbp; 
top) and vaccinia virus (191 kbp; bottom). The central conserved portion of the MCV genome 
corresponds to the vaccinia genome between the genes encoding for vaccinia proteins F9L and 
A44L. Genes encoding amino acid homologs of structural proteins (yellow), proteins of the 
DNA expression (red) and replication machinery (blue) are positionally conserved between the 
two poxvirus genomes, genes without significant amino acid homology are interspersed. These 
include host range genes which are unique to both genomes. 
 
Less obvious homologies exist between MCV and avipoxviruses (MC130, MC133, and 
MC131 A-type inclusion body-like proteins) and notably between MCV, 
parapoxviruses, and crocodilepox virus (MC026 modified RING protein and a number 
of proteins shared between only two of the above poxviruses) (Chen et al., 2013).  
 
Unique MCV non-structural proteins that are not involved in replication or transcription 
can be  divided into two functional classes: (1) proteins dealing with the host immune 
system (host-response-evasion factors), such as the MCV chemokine antagonist 
(MC148) and the interleukin-18 (IL18)-binding protein (MC054) and (2) proteins 
supporting MCV replication in the host cell or the host tissue (host cell/tissue-
modulating factors), such as the anti-apoptotic selenoprotein MC066 and the Hrs 
binding protein MC162 (Chen et al, 2013).  
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An epidermal growth factor (Butala et al., 2013) homolog similar to the ones expressed 
by other poxviruses was not found in the genome of MCV. The only other poxvirus that 
does not encode this factor is swinepox virus. However, MCV-infected basal 
keratinocytes seem to increase EGF receptor and transferrin receptor expression, in 
comparison to uninfected epidermis. Inducing EGF receptor expression may be an 
indirect mechanism causing epidermal hyperproliferation.  
 
In a phylogenetic analysis of 26 poxvirus genomes, MCV (representing the 
molluscipoxviruses) formed a group by itself among the subfamily of chordopoxviruses, 
separate from avipoxviruses (fowlpox virus), orthopoxviruses (vaccinia and variola 
viruses), and all other genera. Four main genetic subtypes of MCV have been identified 
by DNA fingerprinting. MCV type 1 prototype is the most common genetic type (98%) 
in immune-competent hosts in Western Europe (Chen et al., 2013). MCV type 1 
(including variants) is the most common genetic type worldwide. MCV types 2–4 are 
relatively more commonly seen in immunocompromised individuals. MCV genotypes 
discernable by DNA fingerprinting do not change when the viruses are transmitted 
between family members or in larger contact groups, indicating a low overall mutation 
rate. 
 
1.5.4.10.1 MCV plasmid clone library and previous limited MCV genome sequencing projects 
Using DNA fingerprinting with selected enzymes and denaturation/rehybridization 
studies, the genome of Molluscum contagiosum virus was found to have a very high 
G+C content of 63%, which differed from vaccinia virus (G+C content of 30%) and 
resembled more viruses of the herpesvirus family and parapoxviruses (Parr et al., 1977, 
Darai et al., 1986). Purified DNA restriction fragments as well as recombinant plasmid 
clones derived by either single or double-digestion of genomic DNA from the subtype I 
of MCV and DNA hybridization were subsequently used for the establishment of the 
viral genetic map (Bugert et al., 1989; Bugert and Darai, 1991; Scholz et al., 1989) and 
for limited genome sequencing using Klenow enzyme, ss phage DNA and the 
radioactive Sanger-ddNTP protocols. Early sequencing studies already revealed that 
there was a centrally conserved poxviral gene arrangement (Blake et al., 1991) unlike 
the terminal regions, where neither significant nucleic acid homologies with the 
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vaccinia standard genome (Copenhagen), nor in fact any known gene sequences were 
found (Bugert et al., 1993). Limited sequencing was carried on until 1996 (Bugert et al., 
1989; Hadasch et al., 1993; Bugert et al., 1993; Moratilla et al., 1997) when the 
complete genome DNA sequence of MCV type 1/80 was determined by fluorescent 
label sequencing at the LVD, NIAID, NIH in Bethesda, MD using the overlapping 
MCV genome fragment library established in the Darai lab in Heidelberg. This library 
has been made availabe to the ATCC in 2004. 
 
1.5.4.10.2 Complete MCV genome sequence and phylogeny 
The genome of MCV is a linear, double-stranded DNA molecule with a high GC (63%) 
content in comparison to vaccinia virus (30%), featuring about 4.2 kbp of terminally 
inverted repeats (ITR: Figure 1.8), typical of poxviral genomes. The genome of MCV 
type 1was completely sequenced in 1996 and found to comprise 190,289 bp (+ ~ 50 bp) 
(GenBank accession U60315: MCV type 1/80) of double stranded DNA with covalently 
closed ends encoding at least 182 hypothetical genes of 45 amino acids and longer 
(Senkevich et al., 1996; Senkevich et al., 1997). Most predicted proteins in the central 
part of the MCV genome show strong homology to structural proteins of other 
poxviruses, whereas all the proteins encoded at both ends and numerous proteins 
interspersed in the centre of the MCV genome are unique. 
 
Initially, the MCV genome was described to encode 164 open reading frames (ORF), 
likely encoding hypothetical proteins: genes mc001R to mc164L, starting at ITRs 
(Senkevich et al., 1996) However, a more detailed analysis subsequently revealed 182 
genes, with 154 that were more likely to be coding genes (Senkevich et al., 1997), 105 
hypothetical proteins have homologues to smallpox virus and other poxviruses. The 
remaining ORFs are unique to MCV and may be involved in the suppression of the host 
response to infection, nucleotide biosynthesis, and cell proliferation (Bugert and Darai, 
1997; Senkevich et al., 1997). Most MCV genes conserved in other poxviruses are in 
the central part of the genome (Figure 1.8) whereas unique MCV genes with cellular 
homologs or no identified homologs are located on the flanks of the genome and 
dispersed between conserved genes (Figure 1.8) (Chen et al., 2013).  
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Only a few MCV genes have been analyzed for function (Figure 1.8) and these have 
been expressed in isolation in bacterial or viral expression systems. In large DNA 
viruses, gene functions are usually provided by several gene units working in a 
functional complex (e.g., the vaccinia entry-fusion complex) (Moss, 2006). 
Conventially poxviral hypothetical proteins with a likely function start with capital 
letters (e.g., MC007) while the genetic unit uses lower case letters (e.g. mc007). As an 
essential reference tool for any work with MCV genes, the Heidelberg MCV type 1/80 
redundant genome fragment library was deposited in the Molecular Genomics Section 
of ATCC in 2004 (Chen et al., 2013). According to their function, these MCV genes 
can be divided into two groups: proteins supporting MCV replication in the host cells 
and genes encoding proteins interacting with the host immune system 
 
1.5.4.10.3 MCV genes supporting replication and survival in the host cell 
Several MCV genes with homologues in the vaccinia virus involved in virus replication 
are especially as targets for antiviral therapy through a variety of different mechanisms: 
 
mc039L is a homologue of the vaccinia virus DNA polymerase E9L gene and is 
presumed to be the target of cidofovir (Magee et al., 2005). MC142R, a membrane 
protein predicted transmembrane helix homologue of vaccinia virus A33R, which is 
expressed on vaccinia virus infected cells and on EV, may be a possible anti-MCV drug 
target (Roper et al., 1996) To test the anti-MCV antivirals, a reporter system based on 
EGFP and firefly luciferase reporter plasmids under the control of a poxvirus consensus 
promoter has recently been established (Sherwani et al., 2012). 
 
The mc007L displays no homology with other poxvirus genes. However, an E7-like 
LxCxE motif was observed and allows MC007L protein to induce a cytosolic 
sequestration of retinoblastoma protein (pRb) at mitochondrial membranes, leading to 
the inactivation of the protein by mislocalization. The deregulation of the pRb pathway 
plays a central role in virus interference with cell cycle and tumor pathogenesis and is 
notably used by human papilloma virus gene E7 (Mohr et al., 2008) 
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mc66L encodes a homologue of selenocysteine-containing glutathionine peroxidase. 
This protects infected cells from peroxide radicals and ultraviolet-mediated apoptosis. It 
may also explain how MCV replicates exclusively in the epidermis: MC66L mediated 
anti-apoptotic activity increases survival time of MCV infected cells in the UV exposed 
epidermis, allowing MCV a longer productive cycle (Shisler et al., 1998). 
 
mc002L, mc161R, and mc162R were identified by Senkevich and coworkers in the 
1996 genome sequencing project and designated a gene family (Senkevich et al., 1996). 
They encode homologues of the human signaling lymphocytic activation molecule 
(SLAM) protein CD150; thus named the SLAM gene family (Bugert et al., 2000) The 
proteins are expressed early as type I membrane proteins and MC002 and MC162 
contain sites of PY motifs in their cytoplasmic domains, capable of interaction with 
cellular ubiquitin ligases AIP4 and NEDD4 and the Hrs endosomal switching protein. 
Overexpression of MC162 causes vesicle anomalies in human and mouse fibroblasts. 
Hypotheses currently investigated include MCV induced over-recycling of surface 
receptors (MC162), including EGFR, as observed in situ, competitive binding of 
cellular SLAM through an extracellular SLAM homology domain (MC002), and T 
lymphocyte activation (Bugert, 2007). This viral gene family may hence have a dual 
role in both the virus life cycle and virus directed immune evasion. 
 
1.5.4.10.4 MCV genes implicated in immune evasion 
MCV immunology will be discussed in terms of what the virus does to evade detection 
and the details of the eventual clearing immune reaction of the host. In MCV biopsy 
material, there is little or no inflammatory cell infiltration of the epidermis or 
surrounding dermis in undisturbed lesions. This changes, once the MCV lesion is 
exposed to the immune system and a full immune response is mounted (Vermi et al., 
2011). It has been proposed that the initial lack of immune responses to MCV in situ is 
due to the activity of a number of host-response evasion genes present in the MCV 
genome and the absence of others found in other poxviruses (Figure 1.9) (Moss et al., 
2000). Analysis of the MCV genome has revealed several candidate genes that could 
contribute to protection against the immune system (Senkevich et al., 1997). 
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Figure 1.9. MCV Immune defense molecules. Schematic of immune-defense molecules 
encoded by Molluscum contagiosum virus. MCV replicates exclusively in keratinocytes within 
the human epidermis. An MCV-infected keratinocyte that is expressing virus-encoded immune-
defense molecules is depicted. The expression of selected antiviral molecules by a macrophage 
and a lymphocyte that have entered the epidermis in response to tissue injury is also shown. UV 
rays from the sun, as well as inflammatory cells, can generate peroxides. Abbreviation; MHC, 
major histocompatibility complex (Adapted from Moss et al. 2000). 
 
MC54L exhibits sequence similarity to human interleukin 18 binding protein (IL-18BP) 
and plays as a decoy receptor for IL18, which decreases the IL18 mediated synthesis of 
interferon gamma, activation of NK cells and Th1 response. Three MCV hypothetical 
proteins, MC051L, MC053L, and MC054L, have 20 to 35% amino acid sequence 
identities with human interleukin-18 (hIL-18)-binding protein (hIL-18BP), a naturally 
occurring antagonist of the proinflammatory cytokine IL18. MC54L is considered to 
participate in the virus evasion of the immune system (Xiang and Moss, 1999). The 
same group subsequently found the functional epitope of MC54L which enable its 
ability and affinity to IL18 (Xiang and Moss, 2001). Full length MC054 might 
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neutralize locally produced IL18, whereas the N-terminal fragment is soluble and free to 
systemically neutralize IL18 (Xiang and Moss, 1999a; Xiang and Moss, 1999b; Xiang 
and Moss, 2001; Xiang and Moss, 2003).  This data has been confirmed and compared 
to the characteristics of other poxviral IL18 binding proteins, including those encoded 
by vaccinia, ectromelia and smallpoxvirus (Smith et al., 2000, Esteban et al., 2004). 
 
MC80R, which has a 24.5% amino acid homology to human major histocompatibility 
complex (MHC) class I was detected in stable endoplasmic reticulum (ER) and Golgi 
compartments with β2-microglobulin. MHC-I molecule on cell surface may affect the 
Cytotoxic T lymphocyte (CTL)-mediated cytolysis and NK cell’s killing ability (Lopez-
Botet et al., 1996). However, direct experimental work with the intracellular MC80R 
has not yet been performed. 
 
MC148R encodes a competitive chemokine receptor antagonist, CCR8, without 
agonistic activity (Chen et al., 2013; Luttichau et al., 2001). This MCV protein is 
probably the best characterized biochemically and in further applications. Initial studies 
suggested that the protein is secreted (Bugert et al., 1998) and demonstrated a broad 
range inhibitory activity against diverse beta chemokine receptors (Damon et al., 1998) 
as well as inhibitory effects on human hematopoietic progenitor cells (Krathwohl et al., 
1997). This, locus chemokine (ILC) is strongly and selectively expressed in the human 
skin (Ishikawa-Mochizuki et al., 1999). ILC has the highest homology to MC148R 
among the known human CC chemokines and is strongly and selectively expressed in 
the human skin (Ishikawa-Mochizuki et al., 1999). However, the observation that 
MC148R can inhibit allograft rejection in transgenic mice supported the theory it may 
possess anti-inflammatory properties (DeBruyne et al., 2000).  MC148 is expressed 
early in the MCV lifecycle (Bugert et al., 1998), and may provide an anti-inflammatory 
activity gradient in the transition zone between epidermal and dermal tissue as a form of 
stand-off defensive device for the virus before other mechanisms engage. The fact that 
MCV produces a CCR8-specific antagonist at the early stage of infection underscores 
the importance of CCR8
+
 peripheral immune surveillance T cells as sentinels in skin 
immunity (Luttichau et al., 2001). In healthy skin CCR8+ T cells make up 50% of all 
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TPS cells whereas in blood CCR8
+
 T cells are scarce (<5%) (Schaerli et al., 2004; 
McCully et al., 2012). 
 
Interestingly, some of the conserved genes that are important for immune evasion in 
other poxviruses and missing in MCV are homologs of the vaccinia virus E3L and K1L 
gene which are critical in the type I interferon induction (Meng et al, 2009) It is unclear 
if any and which MCV genes confer protection against type I interferon to MCV. Initial 
studies by Postlethwaite indicate MCV induces a strong type I interferon response in 
mouse embryo cells (Postlethwaite et al., 1967). However, MCV gene expression is 
abortive in all current in vitro models, and relevant genes may only be expressed in 
MCV lesions in situ and possibly as part of a multi protein complex. 
 
1.5.4.10.5 Immune Response 
In undisturbed MC lesions, histological studies have shown a conspicuous absence of 
effectors of the cellular immune system, in particular skin-specific tissue macrophages 
(Langerhan cells). The absence of macrophages has been attributed to the activity of 
various MCV genes that are suspected to make the MC lesion immunologically 
‘invisible’. This includes a biologically inactive IL8 receptorbinding beta-chemokine 
homolog (MC148), which may suppress the immigration of neutrophils; a major 
histocompatibility complex (MHC) class I homolog that may upset MHC class I antigen 
presentation on the surface of infected cells, or natural killer cell recognition; and an 
IL18-binding protein, which underlines the importance of this cytokine for the local 
immune response in human skin. As for the humoral response, MCV-specific antibodies 
have been detected in several studies, showing a seroprevalence of MCV of up to 40% 
in the general population, much higher than previously expected. However, these 
antibodies do not seem to confer a neutralizing immunity. MCV genes were expressed 
in a cowpox virus expression system and two antigenically prominent MCV proteins 
identified: mc133L (70 kD protein: MC133) and mc084L (34 kD protein: MC084) 
(Watanabe et al., 1998). These proteins are presumably glycosylated and present on the 
surface of MCV virions, where they allow binding of antibodies and detection by 
immune electron microscopy 
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Typical examples of MCV proteins with homologs in other poxvirus genera 
(avipoxvirus, parapoxvirus) are the p37k major capsid protein homolog (Blake et al., 
1991; Sullivan et al., 1994) and the MCV DNA polymerase (Sonntag et al., 1995; 
Sonntag et al., 1996). Unique MCV genes can be divided into two functional classes: 1. 
genes encoding proteins dealing with the host immune system (host-response-evasion-
factor) and 2. genes encoding proteins supporting MCV replication in the host cell or 
the host tissue (host-cell/tissue modulating-factors). MCV-specific host-response-
evasion-factors have been extensively reviewed by several investigators (McFadden, 
1998; Moss et al., 2000). For review of poxviral homologs of cellular genes see (Bugert 
et al., 2000). Typical MCV host cell/tissue modulating factorsare MC066, a 
selenocysteine-containing glutathione peroxidase that inhibits peroxide and UV 
mediated apoptosis and MC159, a FLICE inhibitor presumably inhibiting apoptosis in 
MCV infected keratinocytes. An epidermal growth factor homolog similar to the ones 
expressed by other poxviruses was not found in the genome of MCV-1. However, 
Nanney and coworkers observed that MCV infected basal keratinocytes show an 
increased density of EGF receptor and transferrin receptor expression, in comparison to 
uninfected skin (Nanney et al., 1992). In a phylogenetic analysis of 26 poxvirus 
genomes, MCV turned out to be the second-most divergent poxvirus genome in the 
subfamily Chordopoxviruses, after Avipoxvirues (Gubser et al., 2004). MCV seems to 
have a high degree of homology to crocodile poxvirus, a phylogenetically very old virus 
(G. Smith, personal communication). 
 
1.5.4.10.6 MCV local immune response in the skin 
In addition to the MCV proteins mentioned above which may mediate some degree of 
MCV immune evasion, the MCV viral colony sac (Shelley and Burmeister, 1986) inside 
infected cells in the epidermis also provides a layer of invisibility to the immune 
system, by physically separating MCV antigen from all pathways of presentation to the 
immune system.  
 
Innate immune responses in MCV infection have not been extensively studied. Ku et al. 
revealed that in MC lesions, Toll-like receptor (TLR) 3 and TLR9 were strongly 
expressed on the epidermal keratinocytes; IFN-γ and TNF-α were predominately 
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localized adjacent to the MC bodies (Ku et al., 2008) In a hyper-IgE syndrome patient, 
deficiency of Tyrosine kinase-2 leading to reduced downstream cytokine signals 
involved in innate and acquired immunity explained the susceptibility to infection by 
various microorganisms including MCV (Minegishi et al., 2006). 
 
Extensive MC has been described in patients with autosomal recessive DOCK8 
combined immunodeficiency (Chu et al., 2012). DOCK8-deficient patients suffer from 
bacterial and viral skin infections and an increased incidence of malignancies (Zhang et 
al., 2009). DOCK8 regulates interstitial DC migration (Harada et al, 2012). 
Immunologically, there are two major patterns of response to MCV infection: lesions 
with immune cells absent and lesions with strong immunological activity. Initially, 
dense polymorphic lymphocytes infiltration was described in MC skin biopsies (Guitart 
and Hurt, 1999). However, subsequent studies showed that dendritic cells (DC) were 
absent in MC lesions but were normal or increasing in the perilesional normal skin 
(Bhawan et al., 1986). Lesions in the process of clearance by strong immune responses 
may be typical for the immunocompetent host where MC is self-limiting and benign. 
Patients with immune dysregulation disorders, especially those affecting the cellular 
immune response, are likely to have more extensive manifestations of MC. Atopic 
dermatitis, characterized by a T helper 2 (Th2) cytokine switching pattern, leads to more 
extensive MC lesions, that remain undetected for longer and may be resistant to 
immune therapy. 
 
The above suggests that MCV in an uninflamed lesion is essentially invisible to the 
immune system through these multiple layers of viral defence mechanisms. This state of 
‘Virus suppression of immune responses’ is summarized on the left of Figure 1.9. A 
recent study by Vermi and coworkers has shed light on the mechanism for spontaneous 
regression of MC, once the virus has been exposed to the immune system (Vermi et al., 
2011). The extent of a full immune reaction against MCV followed by ‘Clearance’ is 
shown on the right of Figure 1.9. This response is overwhelming due to the high 
immunogenicity of the MCV virions, and comprises almost all elements of immune 
defense in the human skin.  
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Using histology and immunohistochemistry, Vermi et al. revealed a robust presence of 
CTLs, plasmacytoid dendritic cells (PDC), and a new class of interferon induced 
dendritic cells (IFN-DC) in inflammatory MC lesions, as compared to sparse leukocytes 
in non-inflamed MC lesions (Vermi et al., 2011). Kupper et al. revealed that skin 
resident memory T cells (TRM) are potent effector cells in the mice model after 
localized vaccinia virus (VACV) skin infection (Liu et al., 2010). They are superior to 
circulating central memory T cells at providing rapid long-term protection against 
cutaneous reinfection. But it is unclear if this mechanism applies to human skin. MCV 
induced skin immunity emerges in the study by Vermi et al. as a valuable model to 
study skin specific immune defences.  
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Figure 1.10. Lifecycle of molluscum contagiosum and local immune responses in infected 
skin. MC lifecycle in human epidermis. (A) Arrow indicates direction of differentiation from the 
basement membrane (grey line at bottom) to thetop epidermal layers in the stratum corneum. 
Virions and inclusion bodies are shown in red, epidermal growth factor receptors in green; 
mitotic activity is indicated by chromosomes in metaphase. Viral suppression of immune 
response (B) Lesions are largely devoid of immune effectors in the undetected, non-inflamed 
state. Clearance (C) Lesions show high immunological activity. Immune effectors are indicated. 
IFN=interferon (Chen et al., 2013). 
 
Due to the lack of reagents to detect the virus proteins involved in MCV immune 
defence and replication in infected skin, or a suitable animal model, to date, no study 
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has clearly characterized the interaction between immune cells, keratinocytes, and 
MCV. It is also unclear why spontaneous regression may occur in some clinically 
inflamed lesions but not in others. MCV could be considered as a new poxviral vaccine 
vector due to the minimal and non-neutralizing preexisting immunity in the population. 
Once detected by the immune system it is a powerful immunogen, with the potential to 
enhance the immune reaction against an expressed transgene. 
 
1.6 Research Aims 
As highlighted in the introduction, Molluscum contagiosum virus (MCV) is a 
significant benign but underreported skin pathogen for children and adults.  The 
inability to grow the virus in vitro has hampered biological studies and rendered the 
development of specific therapeutics difficult. The resulting lack of reagents has proven 
a major obstacle in further investigation and research.  My doctoral research project 
focuses on aspects relating to the lifecycle of Molluscum contagiosum virus and the 
human immune response to it. In light of the fact that MCV research has suffered from 
the absence of reagents enabling its further investigation, one of aim of this PhD project 
was also to develop and design MCV gene specific reagents to study MCV lifecycle and 
immunity. The specific aims for each investigative chapter of this thesis are as follows: 
 
Chapter 3 - The MCV lifecycle starts upon entry of the virus particle into human 
epidermal cells. Although it is not entirely clear where this point is exactly but popular 
belief is that it may be epidermal stem cells.  Infections of epithelial type cells in vitro 
are non-productive, but produce early gene products.  First step of any viral lifecycle is 
entry but due to the lack of a cell culture system MCV entry has till now not been 
quantitated so in order to determine whether MCV has entered cells. I have developed a 
GFP and luciferase based reporter assay and also a quantitative assay to calculate MCV 
multiplicity of infection (moi) as MCV is characterised by lack of cpe which are 
detailed in this chapter and have been published as a ‘Methods Chapter’ (Sherwani et 
al., 2012). 
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Chapter 4 - To enter cells Molluscum contagiosum virus uses homologs of a cell fusion 
complex identified in vaccinia virus to gain entry into cells; these are the MCV genes 
mc084 and mc133 both of which I have mostly worked with.  Because of their role in 
entry these proteins are located on the surface of the virion particle, so most human 
antibodies versus MCV are raised against mc084 and mc133. I constructed truncated 
recombinant MCV genes (mc084 and mc133) for overexpression in E. coli and purified 
them. The resulting MC084 antigen was used to develop a sensitive recombinant MCV 
ELISA using water soluble and highly antigenic truncations of MC084L expressed in E. 
coli, which are more suitable for large scale production. MCV ELISAs based on E. coli 
expressed MCV antigen testing have so far not been reported. Using mc084 antigen in 
an ELISA format, we have conducted a study to determine MCV seroprevalence for 
serum collections from Heidelberg and Cardiff. We have used the reporter assay 
developed in chapter 3 to determine whether these antibodies can neutralize a MCV 
infection in vitro and whether there is cross reactivity with orthopoxviruses. This is the 
first such study in Europe (In press; PLOS ONE - PONE-D-13-44356R1).   
 
Chapter 5 – A primary reason for the slow paced research in MCV has been the non-
availability of antibody reagents as till now, no MCV specific antibodies exist. My final 
aim was the production and screening of novel monoclonal antibodies (mAbs) against 
specific MCV virion surface proteins MC084 and MC133. Selected monoclonal will be 
used in immuneohistology of MCV disease tissue/biopsies in an effort to better 
understand the distribution of MCV surface proteins in infected human tissue. These 
valuable reagents will further aid investigation of the virus. 
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Chapter 2 - 
Materials and Methods 
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Chapter 2 - Materials and Methods 
General Methods 
2.1 Cell Culture Technique 
2.1.1 Cell lines 
All cell lines, aside from HaCaT, were obtained from the American Type Culture 
Collection (ATCC). A panel of both animal and human cells were used. The human 
cervical epithelial cell line, HeLa, was established from the cervical adenocarcinoma of 
a black, 31 year old female and contains Human Papilloma Virus 18 oncogenes. HEK 
293T human kidney epithelial cells are highly transfectable derivatives of the 293 cell 
line, into which the temperature sensitive gene for SV40 T-antigen has been inserted. 
The human foreskin fibroblast cell line, BJ-1, has proved useful in transfection studies, 
and has a long lifespan in comparison with other human fibroblast cell lines. Cells of 
the immortalized human skin keratinocyte cell line, HaCaT, were provided by the 
German Cancer Research Centre (DKFZ). The animal cell lines tested included the 
rabbit kidney epithelial cell line, RK13, established from a 5 week old rabbit. It has 
demonstrated susceptibility to several poxviruses, including vaccinia and is positive for 
bovine viral diarrhoea virus (BVDV). The African green monkey kidney fibroblast cell 
line, CV-1, is a suitable transfection host, particularly by SV40 vectors. The 3T3 
fibroblast cell line was established from Swiss mouse embryo culturesand BHK-21 
Syrian Golden Hamster fibroblasts from the kidneys of one day old hamsters.   
 
2.1.2 Preparation of supplemented media 
Dulbecco's Modified Eagle Medium (DMEM) with 4.5 g/L glucose and L-glutamine 
without sodium pyruvate 1X (Gibco, UK), supplemented with 10% (v/v) foetal bovine 
serum (FBS) (Gibco, UK) was used for the culture of all cells.  
 
2.1.3 Sub-culturing of cells 
All cell lines were sub-cultured before reaching confluency (70% confluency), on 
average every 2 to 3 days. In order to propagate adherent cells culture medium was 
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removed and discarded and the cell monolayer was briefly rinsed with trypsin solution 
TrypLETM Express (Gibco, UK) (1 ml per T75 flask) to remove all traces of serum that 
contains trypsin inhibitors. Fresh trypsin solution was added to flask (1 ml per T75 
flask) and the cells were incubated at 37˚C until the cell monolayer was dispersed 
(usually within 5 minutes - inverted microscope observation). The cells were aspirated 
by gentle pipetting. Upon dispersion of the cells, 5 ml Dulbecco’s Phosphate Buffered 
Saline (PBS) without CaCl2 or MgCl2 1X (Gibco, UK) was added as a wash and 
removed. The remaining cells were re- suspended in 10 ml of supplemented media. 
Harvested cells were centrifuged at room temperature for 5 minutes at 500 g. 
Appropriate aliquots of the cell suspension were added to culture vessels in 
supplemented media.  
 
2.1.4 Cell freezing 
Cells were frequently frozen for storage and maintenance of laboratory stocks. 
Trypsinised cells, having reached 80% confluency, were transferred to 10 ml PBS and 
centrifuged at 1200 rpm for 5 minutes. Before placing the cells in liquid nitrogen, the 
cells are exposed to a gradual freezing process; an optimum cooling rate is an important 
factor during this process. When the freezing is slow extracellular ice is produced 
before intracellular ice crystal start to form leading to osmotic imbalance. As a result 
water migrates out of the cell preventing intracellular organelles damage due to ice 
crystal formation and recrystallization during the thawing process. During fast freezing 
less osmotic imbalance is observed however more intracellular ice is produced.  
Eukaryotic cells are therefore frozen at a slow rate with an addition of cryoprotectants 
like dimethyl sulfoxide (DMSO) or glycerol. DMSO acts at two levels; it interferes with 
the lattice structure of the ice reducing the formation of ice crystals and partially 
solubilises the membrane so that it is more resistant to damage. Freezing medium 
contains also high percentage of FBS to dilute DMSO and to reduce its toxic effect 
(Mazur, 1970). The cells (at 50-80% confluency) were suspended in freezing solution 
containing: 10% dimethyl sulfoxide (DMSO) (v/v) (Sigma-Aldrich, UK), 40% FBS 
(v/v) and 50% medium (v/v). The cells were transferred to a cryogenic vial (Nunc, UK). 
Cells were initially frozen at –70˚C for 24 hours in isopropanol containing vessel (for a 
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gradual freezing) before transfer to the vapour phase of liquid nitrogen at -196˚C for 
long-term storage. 
 
2.1.5 Cell thawing 
Cryogenic vial containing cells were removed from storage at -70˚C and snap- thawed 
at 37˚C.  The 1 ml suspension was transferred to 10 ml pre-warmed supplemented 
media with FBS in a sterile T75 flask. After 4 hours incubation at 37˚C the cells 
underwent media change as to avoid potential toxic effects of DMSO.  
 
2.1.6 Determination of cell number 
Cell density was determined using a counting chamber (also known as 
haemocytometer). The entire counting grid of this chamber consists of 9 large squares 
(Figure 2.1). Each square has a surface area of 1 mm
2
, and the depth of the chamber is 
0.1 mm. To determine the final cell density in cells/ml, 15 μl of an aliquot of evenly 
suspended cells was applied to chamber and the cells in one large square were counted 
(using a light microscope). Then the total cell count was divided by 0.1 (chamber depth) 
and divided by 1 mm
2
 (the total surface area counted). The count obtained in cells/mm
3
 
was multiplied by 1000 because there are 1000 mm
3
 per ml.  
 
Cell count calculation example 
Each large square has surface area of 1 mm
2
 and a depth of 0.1 mm, giving it a volume 
of 0.1 mm
3
. If the total cell count in one large square is 80 (number of cells should be 
statistically significant, about 100 cells), then the cell count is 80 cells per 0.1 mm
3
, 
which equals 800 cells per mm
3
. This result needs to be multiplied by 1000 to determine 
cell count per ml. In this example, the final count is 800000 cells per ml. 
 
After trypsinisation, dispersed cells were aseptically removed and transferred to a 25 ml 
universal container. A trypan blue solution was prepared by diluting stock 0.4% trypan 
blue (Sigma, UK) with PBS in a 1:5 ratio. 10 µl of the cell suspension was added to 10 
µl of the solution and left to stand for one minute to ensure adequate staining. A 
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haemocytometer, washed with 70% ethanol, was loaded with 10 µl of the cell/trypan 
mix.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Haemocytometer counting grid. The number of cells in each of four large squares 
was counted with use of light microscopy and an average taken. Allowing for the PBS dilution, 
the cell concentration per ml is the average cell count per large square x 10
5
. 
 
2.2 Virus Preparation 
2.2.1  VACV 
Western Reserve (WR) strain VACV, kindly donated by Bernard Moss, was prepared 
for stock in different eukaryotic cells following adherent cell protocol. The virus yield 
was separated into cellular attached virus and supernatant (sn) two days p.i. For the 
purpose of experiments sn VACV preparations were used. It was decided this was 
sufficient as VACV was only used as a positive control. The various preparations were 
subsequently used in infection experiments to deduce the form that yielded optimal 
signal. 
 
2.2.2  MCV 
MCV preparations were made by Dounce homogenising clinical specimen material, 
taken from a collection of molluscum lesions from Hieldelberg, Germany, collected 
from 1999 to 2003 and available in the Bugert Lab. For the purposes of the reporter 
  
1 sq.Milli- metre 
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assay, it was necessary to establish the quantity of virus required to elicit a robust 
signal. Initially, 4 lesions were used, and then 21. The signal from the latter quantity 
forms the basis of the results.  
 
2.3 Specific Methods 
2.3.1 Preparation of reporter plasmids 
2.3.1.1 Preparation of agar plates and liquid bacterial growth medium 
The 7.8 g of Columbia Agar Base (Oxoid, UK) was dissolved in 200 ml of distilled 
water. Agar solution was sterilized by autoclaving for 20 minutes at 121˚C. In order to 
prepare plates the agar solution was transferred from autoclave to water bath at 45˚C for 
at least 20 minutes and then 20 ml poured into each 8.25 cm diameter plastic disposable 
plate (Sterilin Ltd., UK) (20 ml creates a layer of agar 3.5 mm thick) and plates were 
allowed to cool following overnight incubation at 37˚C. When selective ampicillin 
plates were prepared 1 µl of 100 mg/ml antibiotic stock solution was added for each 1 
ml of media. Ampicillin was added at 42˚C in water bath. 
 
Liquid bacterial growth broth – LB broth (Luria Bertani broth) was prepared by adding 
10 g of Tryptone Soy Broth (Oxoid, UK), 5 g of yeast extract (Bio Gene, UK) and 10 g 
of NaCl to 800 ml of distilled water. pH was then adjusted with NaOH to 7.5 and the 
volume was adjusted to 1000 ml with distilled water. LB broth was sterilized by 
autoclaving for 20 minutes at 121˚C and stored at room temperature. When selective 
ampicillin liquid bacterial growth broth was prepared 1 µl of 100 mg/ml antibiotic stock 
solution was added for each 1 ml of media. 
 
2.3.1.2 Bacterial growth and expansion 
A single bead of transformed E. coli from frozen stock (-70˚C) was smeared repeatedly 
across an agar plate, and incubated overnight at 37˚C. The following day a colony was 
used to inoculate 4 ml growth broth, Luria Broth (LB), containing 4 µl of 100 mg/ml 
ampicillin. The culture was incubated for 8 hours at 37˚C then expanded to 100 ml LB 
with 100 µl ampicillin. Further incubation proceeded at 37˚C for 16 hours in a shaking 
incubator at 80 rpm (Gallenkamp, UK).  
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2.3.1.3 Transformation of bacteria 
The starter culture was grown in 10 ml of LB medium overnight in 37˚C shaker. The 
following day 1 ml of Top 10 bacteria was washed 3 times with endotoxin-free water by 
centrifugation for 1 minute at 500 x g and the pellet was resuspended with 40 µl of 
endotoxin-free water. 10 µl of plasmid DNA in TE buffer were added to bacteria. DNA 
suspended in bacteria was transferred gently to an electroporation cuvette and 
electroporated with a Gene Pulser apparatus (Bio-Rad, UK) that was set at 2.5 kV, 25 
μF, and 400 Ω. 400 µl of LB broth was added immediately to the cuvette and cells were 
incubated in an eppendorf tube for 30 minutes at 37˚C to recover. The electric pulse 
causes the formation of temporary aqueous pores in cell membrane by disruption of 
phospholipid bilayers. This damage results in increased electric potential across the 
membrane so that charged molecules like DNA move through the pores. As this 
movement takes place the cell membrane discharges and the pores quickly close. 
Transformed bacteria were then plated onto ampicillin selective agar plates (ampicillin 
corresponds with the resistance offered by plasmids used in these studies) and the plates 
were incubated overnight at 37˚C. 
 
After incubation a single colony was selected and grown in 10 ml of selective ampicillin 
liquid bacterial broth overnight in 37˚C shaker. 100 µl of this culture were transferred in 
100 ml of selective LB medium and grown again overnight in 37˚C shaker before 
plasmid purification. 
 
2.3.1.4 Purification of reporter plasmids 
All plasmids were purified using the Qiagen
®
 Plasmid Midi Kit (100) (Qiagen, 
Germany). The bacteria were centrifuged at 3000 rpm for 30 minutes, the supernatant 
decanted and the pellet re-suspended in 4 ml of Buffer P1, to which RNase had been 
added. 4 ml of Buffer P2 was added, then 4 ml of Buffer P3. The lysates were cooled on 
ice for 15 minutes then filtered (Whatman, UK). Filtrates were applied to pre-
equilibrated midi columns and washed twice with 5 ml Buffer QC. The cleared lysates 
were applied to pre-equilibrated anion exchange midi columns. DNA interacts with the 
positive charges on the surface of the resin. Under moderate salt condition, plasmid 
DNA binds to the resin while proteins, carbohydrates and other impurities are washed 
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away with wash buffer. The washing was performed twice with 10 ml of wash buffer 
with high salt concentrations. The plasmid DNA was eluted under low salt condition 
with 5 ml of elution buffer QF. The columns were allowed to drain by gravity flow. 3.5 
ml of isopropanol were added to precipitate the plasmid DNA. The DNA preparation 
was centrifuged in Beckman centrifuge tubes at 13500 rpm for 15 minutes at 4˚C using 
JA21 rotor and Sorval high speed centrifuge. The pellet was washed with 3 ml 70% 
ethanol and re-centrifuged. The tube was dried horizontally at room temperature and the 
plasmid DNA resuspended in 100 μl TE buffer. 
 
2.3.1.5 Determination of DNA concentration 
Plasmid DNA concentration was measured using an ND1000 V3.3.0 Nanodrop 
Spectrophotometer and the corresponding ND1000 V3.3 computer program. An 
example of the readout obtained can be seen in Figure 2.2. 
 
 
 
Figure 2.2. Measurement of DNA concentration. Report obtained for measurement of DNA 
concentration of plasmid #240 using Nanodrop 1000 Spectrophotometer. 
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2.3.1.6 Restriction digest analysis and agarose gel electrophoresis 
20 units of XhoI and BamHI restriction enzymes plus 10x Surecut buffer B (Roche, 
Germany) were used to digest the 5 µL of DNA in TE Buffer, in a total volume of 50 μl. 
This was incubated at 37˚C for 2 hours. The digested DNA was combined with 10 µl 
loading buffer and inserted into a corresponding well of a vertical gel electrophoresis 
instrument (Hoeffer-Pharmacia SE280, UK).  1X electrophoresis buffer (EPB) was used 
as a running buffer.  Two molecular weight ladders (1 kbp and 100 bp) were used as 
size markers (Fermentas, UK).  Electrophoresis on 2% agarose gel took place for 90 
minutes at 100V and was stained with ethidium bromide solution (200 µg/ml). A 
BIORAD UV transiluminator was used to view the DNA.  
 
2.3.2 Dual luciferase reporter assay 
The Dual-Luciferase
®
 Reporter Assay System (Promega, UK) allows for simultaneous 
measurement of two reporter enzyme activities (luciferases) within a single sample. One 
enzyme is derived from the light-emitting organ of the firefly (Photinus pyralis) another 
from sea pansy (Renilla reniformis). The reporter gene is under the control of the target 
promoter. The luciferase activity correlates with the target promoter activation. The 
Renilla reporter gene is under the control of the herpes simplex virus (HSV) thymidine 
kinase (TK) promoter. The Renilla luciferase activity provides an internal control to 
normalise against transfection efficiency. Firefly protein is a 62 kD molecular weight 
oxidase. This enzyme requires ATP, molecular oxygen, Mg
2+
 and firefly luciferin as a 
substrate to generate light. Renilla luciferase is 36 kD protein which catalyses 
coelenterazine oxidation by oxygen to produce light (Figure 2.3). 
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Fig. 2.3. Bioluminescent reactions catalysed by firefly and Renilla luciferases (Adapted from 
Promega). 
2.4 Assessment of Molluscum contagiosum virus infectivity 
2.4.1 MCV Luciferase Reporter Assay 
Molluscum contagiosum virus isolated from human tissue specimen was integrity 
checked, quantitated by PCR and used to infect a series of epithelial and fibroblast type 
cell lines of human and animal origin. The cells were subsequently transfected with a 
reporter plasmid encoding firefly luciferase gene under the control of a synthetic 
early/late poxviral promoter and a transfection control plasmid. After 16 hours cells 
were harvested and tested for MCV infection, interferon production and luciferase 
expression. If eukaryotic cells are transfected with reporter plasmid followed by virus 
entry into cells, the MCV early transcription complex should recognize the E/L 
synthetic poxviral promoter (pE/L) of the reporter plasmid resulting in firefly luciferase 
expression, which can also be quantified. Reaction of firefly luciferase present in the 
cell lysate with firefly luciferase substrate (Beetle Luciferin) produces luminescence, 
which can be quantified as an indirect measurement of virus uptake.  
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2.4.1.1 Plasmids  
All experiments involving the use of genetically modified materials were performed in 
the Bugert lab (L2) under the GM permissions GM 130/53 and GM 130/07.5. All 
plasmid DNA was purified using 100 μg capacity midiprep-columns (HPVNA kit - 
Roche) and then stored in elution buffer at −20˚C until used. 
 
1. PCR control plasmid. The complete MCV-1 genome was cloned (Bugert and Darai, 
1991) and sequenced (Senkevich et al., 1996; Senkevich et al., 1997) and the redundant 
MCV genome fragment library of MCV type 1 was submitted to ATCC for safekeeping 
in 2003 and 2008. For the quantitative PCR assay, the genomic MCV-1 EcoRI fragment 
C (25,516 bp) cloned into bacterial plasmid vector pACYC184 was used as a MCV 
target control (pyMCV1-E-C, Figure. 2.4a). 
 
2. Transfection control plasmid. Plasmid phRG-TK (Promega GenBank accession 
number AF362545: 4,045 bp), expressing renilla luciferase under the control of the 
herpes simplex virus TK gene promoter. In this protocol, this plasmid is called p238 and 
used as plasmid transfection control (p238 Promega; Figure. 2.4b). 
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Figure 2.4. Plasmid constructs. VectorNTI drawings for the recombinant plasmids (a) 
pyMCV1-EcoRI-fragment C (pyMCV1-E-C; available from ATCC molecular section), (b) 
phRG-TK (Promega; Internal lab reference number p238), (c) pRB21-pE/L-FF luciferase 
(p240), and (d) pRB21-pE/L-EGFP-SFX (p300) (Sherwani et al., 2012). 
 
3. Poxviral luciferase reporter plasmid. The coding sequence of firefly luciferase ( 
Photinus pyralis GenBank accession number M15077) was amplified with a modified 
Kozak sequence by PCR and ligated into the pRB21 donor plasmid (kind gift of B. 
Moss) (Blasco and Moss, 1991) using the EcoRI and HindIII restriction sites in the 
donor plasmid multiple cloning site, resulting in the pRB21-E-Koz-Firefly luciferase-H 
(also called pRB21-pE/L-FF luciferase) construct of 7,178 bp with the internal lab 
designation p240 (p240, Figure. 2.4c). 
 
4. Poxviral EGFP reporter plasmid. The coding sequence of EGFP was amplified from 
a commercially available plasmid with a modified Kozak sequence by PCR and ligated 
into the pRB21 donor plasmid using the EcoRI and NheI restriction sites in the donor 
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plasmid multiple cloning site, resulting in the pRB21-E-Koz-EGFP-X-flag-strepII-N 
construct (also called pRB21-pE/L-EGFP-SFX) of 6,333 bp with the internal lab 
designation p300 (p300, Figure. 2.4d).  
 
5. IFN-β firefly reporter plasmid. This plasmid was referred to by us as IFN-β firefly 
reporter plasmid (ILR#231). The pGL3-IFN-β-Luc plasmid was generated by Lin and 
co-workers (Lin et al. 2000) by cloning the EcoRI-TaqI fragment (−280 to +20; filled in 
with the Klenow enzyme) from pUCβ26 into the NheI site (filled in with the Klenow 
enzyme) of the pGL3 basic vector (Promega) (Figure 2.5).  
 
 
Figure 2.5 IFN-β firefly reporter plasmid (ILR#231) Schematic showing firefly luciferase 
reporter gene. 
 
2.4.2. Infection – Transfection: Luciferase assay 
2.4.2.1 Infection/ Transfection 
Enough 12-well plates were prepared containing human HEK293 (ATCC CRL1573) 
cells in growth media (DMEM, high glucose with glutamine –Life Technologies, 10% 
FCS - Gibco) to allow for infection/transfection in triplicate for each experimental 
condition (including a mock that will be transfected but not infected, as well as wells 
that will be harvested at 16 h and wells that will be continued to be incubated for days). 
Transfection efficiency can vary considerably from cell batch to cell batch. Passage 
number (best low), cell confluence (best below 60%), and time of culture prior to 
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experiment (best no longer than 24 h) are determinant factors. Virus aliquots are 
thawed, sonicated, and kept on ice. Plasmid DNA is thawed and and kept on ice. 
Transfection reagents OptiMEM (Life technologies) and Lipofectamine 2000 (Life 
technologies) at room temperature (RT) are used to prepare transfection mixes by 
adding a dilution of 2 μl of Lipofectamine 2000 in 50 μl of OptiMEM to a dilution of 
0.3 mg of each plasmid DNA (p240 FF reporter and p238 transfection control plasmid, 
p300 EGFP reporter) in 50 μl of OptiMEM. These are mixed gently for 15 min at RT in 
the dark to allow formation of transfection complexes. The growth medium is removed 
from HEK293 cells and 100 μl of transfection mix is added in each well. 100 μl each of 
ice-cold virus in PBS and 100 μl of transfection mix at RT are combined and the 
mixture is transferred into appropriate wells of HEK293 cells. While this protocol has 
included transfection of adherent cells, we have found that for some harder-to-transfect 
cells (e.g., human fibroblasts) we can get higher transfection efficiency when cells are 
in suspension. The assay depends to a significant degree on the transfectability of the 
cell cultures involved. Human keratinocytes and fibroblast cell lines are most interesting 
as possible natural hosts for MCV, but they are also hard to transfect. The cells are 
incubated for 16 h at 37˚C in 5% CO2 atmosphere. The incubation time of 16 h allows 
for a robust signal from the transfection control plasmid p238, so firefly signal readings 
can be adjusted to renilla transfection efficiency readings between experiments. 
 
2.4.2.2. Microscopy and collection of cells for luciferase assay 
At 16 h post infection (p.i.), cells transfected with the GFP reporter plasmid are 
inspected using live cell microscopy and GFP-positive cells are documented noting that 
MCV does not show GFP positive cells after 16 h, whereas WR shows multiple GFP 
positive cells. Upon further incubation for another 4 days (5 days p.i.), some individual 
cells in the MCVinfected wells will show medium to strong GFP signals.For luciferase 
assay, at 16 h p.i., adherent cells in wells are washed once with PBS and 100 ml of 1× 
passive lysis buffer (part of the Dual-Luciferase
®
 Reporter Assay System from 
Promega) is added to each well. The samples for the luciferase assay are collected at 16 
h post infection. This allows the control plasmid ILR#238 to get to the nucleus and be 
expressed to yield a robust control signal. In HEK 293 cells, the Renilla luciferase 
signal can be seen in vaccinia infected cells after 2 h, and is seen in the MCV infected 
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cells after 8 h. The 12-well plate is covered with clear film plate protectors to stop 
evaporation and incubated with agitation on a belly-shaker at RT for 15 min. Plates are 
then frozen at −20˚C for at least 15 min or stored overnight or for up to 2 weeks before 
assayed. Cell lysates are tested for luciferase activity by adding 100 μl Dual Luciferase 
Assay Substrate (part of The Dual-Luciferase ® Reporter Assay System from Promega) 
to each well. If one does not have instrumentation that can add 100 μl of PROMEGA 
Dual luciferase firefly substrate and pipette series of four samples in a row, then load 
the plate, and read. The reading time, including the initial shake for four samples, is 20s. 
This results in a signal loss per reading of <1%, which is less than the sample-to-sample 
variation in triplicate samples, when compared to machine pipetting sample per sample. 
Luciferase activity is then measured in a FLUOROSTAR Luminometer. Data is 
compiled in a Microsoft EXCEL file and evaluated using standard statistical protocols 
(average, standard deviation, Student’s P test). It is worth noting that the incubation 
time of 16 h allows for a robust signal from the transfection control plasmid p238, so 
firefly signal readings can be adjusted to renilla transfection efficiency readings 
between experiments. The signal from early poxviral promoters can be used as a 
surrogate parameter of viral infectivity. The signal can be further dissected and used to 
look at early and late transcription activity using transfected plasmids with a reporter 
gene behind the respective promoters in isolation. 
 
2.4.3. Quantitative PCR assay 
2.4.3.1 PCR design 
To design a MCV quantitative PCR we needed to correlate MCV genome units with 
genome units of a sister virus which could be titrated i.e. vaccinia virus. MCV and 
VACV genomes shown below were assessed for homology using BLAST2N (Figure 
2.6). 
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Figure 2.6. BLAST 2N – MCV vs VACV. 
 
Group 1 consisted of genes mc128 and mc129. Of these the hypothetical ORF mc129R 
(Figure 2.7), which is the putative second largest subunit of DNA-dependent RNA 
polymerase, was selected for the design of primers (Figure 2.8) which could be used to 
detect identical reaction rates in MCV as well as VAVC 
 
 
Figure 2.7. MC129R. Putative second largest subunit of DNA-dependent RNA polymerase. 
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Figure 2.8. qPCR primer design 
 
2.4.3.2. Virus and DNA preparation 
Equal volumes of freshly thawed virions (100 μl aliquot) are incubated in 100 μl 
DNAse/BamHI buffer for 30 min at 37˚C. Viral genomic DNA is extracted using a 
HPVNA kit (Roche) following the manufacturer’s instructions. The control plasmid 
pyMCV1-EC (Figure. 2.1a) was prepared using the same procedure. The DNA 
concentration of the control plasmid was determined using a Nanodrop 
Spectrophotometer or a similar device. Molecule numbers were calculated using the 
average molecular weight of DNA molecules and Avogadro’s number (6.02 × 1023 per 
mole). The molecular weight of a plasmid (in Daltons) can be estimated as MW of a 
double-stranded DNA molecule (http://www.epibio.com/techapp.asp) = (# of base 
pairs) × (650 Da/base pair). The plasmid pyMCV1-E-C has 29,760 bp. Thus, the 
molecular weight is calculated as 19.344 MDa and thus 19.344 ng of plasmid would be 
6.02 × 10
8
 mol. The actual plasmid concentration was 21 ng/μl (±1.7) and, thus, 
represented 6.5 × 10
8
 mol/μl. From this value, the molecule numbers for the pyMCV1-
E-C twofold dilution series are calculated. The molecule numbers are then correlated to 
the pixel numbers of bands on a gel quantitated by the software ImageJ. 
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2.4.3.3. PCR reaction 
MCV was isolated from human skin biopsy material as described previously (Melquiot 
and Bugert, 2004) and kept in 100 μl aliquots frozen at −70˚C in PBS. VACV-WR, 
vaccinia virus, strain WR (gift of B. Moss) was prepared and purified from infected 
HeLa cells, titrated in BSC-1 cells, and kept in 100 μl aliquots frozen at −70˚C in PBS. 
We prepared vaccinia virus and MCV preparations in 1 ml PBS and then immediately 
made ten 100 μl aliquots which were frozen. The vaccinia virus stock was generated by 
infecting one T150 flask containing adherent HeLa cells. Harvesting of the infected 
cells and resuspending them in 1 ml PBS yielded a titer of 2 × 10
7
 pfu/ml. Thus, each of 
the ten 100 μl aliquots of vaccinia virus used here contained 2 × 106 pfu. The 100 μl 
aliquot of MCV contained an unknown number of MCV particles, but is quantified 
using the described PCR method. Primers outlined in Table 2.1 were suspended in 
injection-grade water to a final concentration of 100 pmol/μl and stored at −20˚C. 
 
Table 2.1.MCV–VACV quantitative PCR assay primers (Sherwani et al., 2012). 
 
 
Two-fold dilutions of viral genomic DNA and plasmid control were prepared in 
injection-grade water and store at −20˚C. PCR assays were prepared as outlined in 
Table 2.2. PCR reaction conditions are included in the table. 
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Table 2.2 PCR Reaction (Sherwani et al., 2012) 
 
 
PCR reaction: 2 min of denaturation at 96˚C; and then 45 cycles of 1 min at 96˚C, 2 min 
at 55˚C, and 3 min at 72˚C. Block and then cool to 10˚C. For MCV Primer 1-2F and 
Primer 1-3R, use MCV129 1-2F149275 and MCV129 1-3R149850, respectively. For 
WR Primer 1-2F and Primer 1-3R, use VACV-WR 1-2F132482 and VACV-WR 1-
3R133054, respectively (Sherwani et al., 2012). 
 
PCR bands were visualised by loading a 2% agarose gel with 10 μl from each PCR 
reaction and running gel for 1 h at 100 V (constant voltage). This was stained with 
ethidium bromide, photographed with a digital unit and export into a jpeg file. The 
source template of the PCR products produced can also be determined by XhoI digest, 
which cleaves the MCV product into 227- and 349 bp sub-fragments but does not 
cleave the VACV-WR PCR product. To quantitate the PCR product, one can use the 
captured bands on the jpeg photograph with a series of identical gates using the Image J 
software (Wayne Rasband - wayne@codon.nih.gov) Research Services Branch, 
National Institute of Mental Health, Bethesda, Maryland, USA).  The conventional PCR 
assay described has the problem ofassay-to-assay variation due to agarose gel and 
staining artefacts.Future advances may be the development of a real-timePCR assay 
using molecular Taqman probes (Life technologies) specific to eitherVAVC-WR or 
MCV and binding in the internal section of therather large PCR product (550 bp). 
Quantitative results of digital imaging (quantified pixel output) of a two-fold dilution 
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series of plasmid pyMCV1-E-C are plotted against molecule numbers using Microsoft 
EXCEL software. The molecule/genome equivalent numbers are taken from the 
calibration plot and compared to the pixel readings obtained for VACV-WR. Results are 
tabulated and evaluate using standard statistical protocols (average, standard deviation, 
Student’s P test). 
 
2.5 MCV gene specific constructs 
2.5.1 Bioinformatics 
NCBI Blast was used to establish amino acid homologies between mc084 and vaccinia 
H3L (VACV097). Vector NTI (vNTI) was used to produce virtual molecules and 
schematic diagrams of constructs prior to molecular cloning (InforMax, Inc), TMHMM 
was used to determine hydrophobic and transmembrane regions whereas the Kyte 
Doolittle plot was used to identify hydrophilic regions with predicted high antigenicity. 
 
2.5.2 MCV expression constructs 
The MCV genes of interest (mc084 and mc133) were cloned with different promoters 
and different combinations of four epitope tags to allow a rational optimization of 
overexpressed protein purification and protein detection. These recombinant plasmid 
constructs would be used to generate recombinant vaccinia viruses (vWR-delta F13L-
RB12) and infect mammalian cells (BSC-1, CV-1) and express specific MCV genes. 
Expression has been achieved in vaccinia virus infected cells (v/pRB system) and in E. 
coli (pGEX2TK). These are being compared with an aim to optimize protein production 
for ELISA, immunization of animals and selection of T cell clones. All plasmid 
constructs have been confirmed by DNA nucleotide sequencing. The constructs made 
are listed in Table 2.3. 
 
The two expression systems used were 
 
1. Vaccinia virus vRB12/ pRB21 plaqueless mutant system (cell infection/ 
infection controls). Construction of recombinant vaccinia WR (vRB12 
system)/MVA and overexpression of protein in a poxviral background (vWR) to 
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express full length proteins with posttranslational modifications similar to in 
vivo MCV infection. To be used as infected cell controls, neutralisation assays 
and hybridoma screening. 
 
2. pGEX-2TK  GST fusion system (antigen for ELISA and mAb) in E. coli (RIL+) 
 
Table 2.3. MCV Expression constructs 
 
 
2.5.2.1 Construction of recombinant vaccinia virus WR expressing mc084S 
The full length surface protein gene mc084S of MCV was cloned intothe donorplasmid 
pRB21 plasmid under the control of the synthetic optimized early/late poxviral 
promoter, to complement the plaqueless phenotype virus vRB12 delta F13L and rescue 
recombinant virus producing normal sized plaques (Blasco and Moss, 1991). MC084 
was amplified by PCR using specific primers tailed with restriction enzyme sites and C-
terminal StrepII epitope tag (Forward primer: 5’- 
CTTCGTgaattcgccaccatggccgagagcgaaagcacg and reverse primers: 5’-
CTTCGTgctagcaagcttTTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAG
GCTTACCAGATCCACGCGGAACCAGCTGGAGCAGCCCCGACGC and 
5’CTTCGTgctagcaagcttTTATTTTTCGAACTGCGGGTGGCTCCACGTAGAATCGA
GACCGAGGAGAGGGTTAGGGATAGGCTTACCAGATCCACGCGGAACCAGCT
gGAGCAGCCCCGA respectively. The donor plasmids p316 and p319 were sequenced 
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using the ABI Prism 3.1 reagent kit (Applied Biogenes), and the recombinant virus 
v316 and v319 (Figure 2.9) rescued by infection/transfection of BSC-1 cells and three 
subsequent plaque purifications (1-1-1) using the LMP agarose overlay method. Virus 
stocks (IMV) were produced in adherent HeLa cells following the procedure outlined 
by Townsley and coworkers. v319 expression characterised in figures 2.10 and 2.11. 
 
 
Figure 2.9. vNTI virtual mc084 constructs of the donor plasmids pRB21. Each construct 
was cloned with strong Early/Late synthetic promoter and inserted MCV gene mc084 used to 
construct v316 (pE/Lmc084XV5) and v319 (pE/Lmc084XSV5). 
 
 
 
 
 
Figure 2.10. Western Blot detection of viral MC084S. vMC084S(34 kD) detected using Strep-
Tactin HRP conjugate antibody (1:100).  
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Figure 2.11. Immunofluorescent detection of expression of vmc084. Detection of expression 
of v319 using (A) anti V5–anti mouse 488 (1:100) (10x), (B) Classic strep MAB (1:100) (10x) 
and (C) Mock+/- DAPI in CV-1 cells. 
 
2.5.2.2 Construction of recombinant vaccinia virus WR expressing mc133FS 
The full length surface protein gene mc133FS of MCV was cloned intothe 
donorplasmid pRB21 plasmidunder the control of the synthetic optimized early/late 
poxviral promoter, to complement the plaqueless phenotype virus vRB12 delta F13L 
and rescue recombinant virus producing normal sized plaques (Blasco and Moss, 1991). 
Mc133 was amplified by PCR using specific primers tailed with restriction enzyme sites 
and C-terminal Flag StrepII epitope tag (Forward primer:5’- 
CTTCGTgaattcgccaccATGGCTGATAGCGAGGCTGTCGAT and reverse primer: 
5’CTTCGTaagcttgaattcTTATTTTTCGAACTGCGGGTGGCTCCACTTATCGTCGT
CATCCTTGTAAGATCCACGCGGAACCAGCTCGTATACCATGTCGTCTCTGTAG
CCT).The donor plasmid p343 was sequenced using the ABI Prism 3.1 reagent kit 
(Applied Biogenes), and the recombinant virus v343 (Figure 2.12) rescued by 
infection/transfection of BSC-1 cells and three subsequent plaque purifications (1-1-1) 
using the LMP agarose overlay method. Virus stocks (IMV) were produced in adherent 
HeLa cells following the procedure outlined by Townsley and coworkers. Expression of 
MC084S in CV-1 cells infected with v319 is characterised in figures 2.13 and 2.14. 
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Figure 2.12. vNTI virtual mc133 construct of the donor plasmid pRB21. Constructs with 
strong Early/Late synthetic promoter and cloned MCV gene mc133-V5S. 
 
 
 
 
Figure 2.13. Western Blot detection of viral MC133. vMC133S (61 kD) detected using Strep-
Tactin HRP conjugate antibody.  
 
 
 
 
 
Figure 2.14. Immunofluorescent detection of expression of vMC133. Immunofluorescent 
detection of vMC133S (aa1-546) using (A) Classic Strep MAB (10x), (B) Anti flag mouse 488 
antibodies (10x) and (C) mock (10x) in BSC-1 cells +/- DAPI.  
pRB21 pEL EcoRI mc133 V5S HindIII
7238 bp
F13l  ORF vWR 052
mc133 V5Sf13L-flank-2
f13l-flank-1 estimate
pRB 5'
F13L R flank primer
pRB21 upstream
pRB21 downstream
pRB 3'
pRB21 -1705
pRB21 -2061
vaccinia strong E/L synthetic promoter
vaccinia early transcription terminator
Afl  II (1814)
Hind III (3599)
Nhe I (3349)
BamH I (3253)
BamH I (3634)
Cla I (230)
Cla I (4032)
EcoR I (1874)
EcoR I (3593)
Pst I (3386)
Pst I (3496)
Xho I (1826)
Xho I (3329)
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2.5.2.3 Expression of recombinant vaccinia viruses in cell culture  
BSC-1 cells (ATCC CCL-26) were used to rescue recombinant vaccinia virus.  HeLa 
cells (ATCC CCL-2) (gift of Norbert Fusenig, DKFZ, Heidelberg) were used for 
vaccinia virus stock production. HaCaT cells were used to demonstrate mc084 
expression in immortalized human keratinocytes infected with recombinant vaccinia 
virus v319. Similarily HaCaT cells were also used to demonstrate mc133 expression in 
cells infected with recombinant vaccinia virus v343. All cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM; Invitrogen, Life technologies, Paisley, UK) with 4.5 
g/L glucose and L-glutamine without sodium pyruvate 1X (Gibco, Life technologies, 
Paisley, UK), supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS; 
Gibco) was used for the culture of all cells. Cells were cultured in the absence of 
antibiotics until used for assay, when penicillin/streptomycin was added (Gibco). 
Visibly contaminated cultures were discarded, mycoplasma contamination was ruled 
out following lab standard procedure (Mycoplasma PCR kit, Geneflow, UK). 
 
2.5.2.4 Constructon of GST-MC084S (V123-R230) fusion vector 
The mc084S (V123-R230) (originally cloned in the vector pRB21) was digested with 
EcoRI and BamHI to generate a 1049 bp (14 kD) fragment. The same restriction 
enzymes were also used to cut the expression vector pGEX-2TK to obtain a 4965 bp 
fragment. Both fragments were purified after electrophoresis on 2% agarose gel using 
Qiagen gel extraction kit and ligated overnight at 4˚C using T4 DNA Ligase (Promega). 
The ligation product was used to transform competent BL21 RIL
+ 
E. coli cells. Five 
independent transformants were selected for plasmid DNA analysis by restriction 
enzyme digestion, confirmed by sequence analysis and tested for protein expression.  
 
2.5.2.5 Constructon of GST-MC084v5 (V33-G117) fusion vector 
The mc084S (V33-G117) (originally cloned in the vector pRB21) was digested with 
EcoRI and BamHI to generate a 998 bp (10 kD) fragment. The same restriction enzymes 
were also used to cut the expression vector pGEX-2TK to obtain a 4965 bp fragment. 
Both fragments were purified after electrophoresis on 2% agarose gel using Qiagen gel 
extraction kit and ligated overnight at 4˚C using T4 DNA Ligase (Promega). The 
ligation product was used to transform competent BL21 RIL
+ 
E.coli cells. Five 
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independent transformants were selected for plasmid DNA analysis by restriction 
enzyme digestion, confirmed by sequence analysis and tested for protein expression.  
 
2.5.2.6 Constructon of GST-MC133S (M1-N370) fusion vector 
The mc084S (M1-N370) (originally cloned in the vector pRB21) was digested with 
EcoRI and BamHI to generate an 1835 bp (40 kD) fragment. The same restriction 
enzymes were also used to cut the expression vector pGEX-2TK to obtain a 4956 bp 
fragment. Both fragments were purified after electrophoresis on 2% agarose gel using 
Qiagen gel extraction kit and ligated overnight at 4˚C using T4 DNA Ligase (Promega). 
The ligation product was used to transform competent BL21 RIL
+ 
E.coli cells. Five 
independent transformants were selected for plasmid DNA analysis by restriction 
enzyme digestion, confirmed by sequence analysis and tested for protein expression.  
 
2.6 Protein expression and purification 
2.6.1 Recombinant protein expression 
Single colonies of E. coli strain BL21 RIL
+
 transformed with the truncated and C-
terminal epitope tagged GST-MC084S (V123-R230)/GST-MC084v5 (V33-G117)/ 
GST-MC133S (M1-N370) fusion vector were inoculated into 500 ml LB medium 
containing 500 µl Ampicillin (100 µg/ml) as the selection marker. Bacterial cultures 
were grown overnight at 30˚C (approx. 8 h) in a shaking incubator set at 70 rpm. The 
following morning these cultures were checked and when the bacteria attained log 
phase (A550 of 0.5-0.7) expression of recombinant protein was induced by addition of 
IPTG to a final concentration of 1.5 mM. The cultures remained at 37˚C and 70 rpm and 
after 3 h bacteria were harvested by centrifugation at 10000 rpm for 20 min. The 
supernatants were discarded and pellets resuspended in 20 ml Lysis buffer (PBS, 
Lysozyme, triton-X and protease inhibitor cocktail), sonicated on ice for five to eight 
cycles of 15 sec using a probe sonicator followed by 30 second cooling on ice and 
centrifuged at 5000 rpm for 15 min. The supernatant was used as a source of soluble 
protein. Cultures grown under identical conditions but without IPTG addition served as 
uninduced controls. Presence of the recombinant fusion protein was confirmed by SDS-
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PAGE analysis on 4-12% Bis-Tris NuPAGE gels followed by staining with Coomassie 
Brilliant Blue.  
 
2.6.2 Purification of GST-MC084S (V123-R230), GST-MC084v5 (V33-G117) and 
GST-MC133S (M1-N370) on glutathione sepharose beads 
Appropriate volumes of glutathione sepharose 4B beads (GE Healthcare) washed with 
PBS-Triton X and equilibrated with 1xPBS were mixed with the solubilised protein in a 
batch reaction and incubated with gentle agitation at 4˚C for 24 hrs. The mixture was 
centrifuged at 3000 rpm for 5 min to sediment the matrix. Unbound protein was 
removed by washing the gel pellet three times with GST Bead wash (PBS-Triton X) and 
three times with 1xPBS.  
 
2.6.3 Purification of GST-MC084S (V123-R230) 
The fusion protein GST-MC084S (V123-R230), bound matrix was equilibrated by 
washing with 10 bed volumes of Thrombin cleavage buffer consisting of 20 mM Tris 
pH 7.5, 150 mM NaCl, 1 mM DTT and 0.5 mM EDTA at 4˚C. The matrix bound fusion 
protein was suspended in one bed volume of fresh cleavage buffer containing Thrombin 
(Pharmacia) and incubated with gentle agitation at 4˚C. After 4 h of incubation, the 
supernatant was collected by centrifugation at 500 g for 5min and analysed by SDS-
PAGE.  The protease cleaved 14 kD MC084S was further purified via AKTA-FPLC 
using Superdex S200 column (GE Healthcare). Final protein concentrations were 
estimated spectrophotometrically using NanoDrop (Nanodrop Limited). To compare the 
reactivity of components in fusion protein with tested sera, pure GST was obtained by 
expressing pGEX-6P-1 without an insert in BL21 (RIL
+
) chemically competent E. coli. 
 
2.7 Protein visualisation and detection 
2.7.1 SDS-PAGE 
Protein preparations were separated using denaturing sodium dodecyl sulphate 
polyacrylamide electrophoresis (SDS-PAGE) in NuPAGE Novex 4-12% Bis tris Gels 
(Life technologies) and MOPS SDS running buffer (Invitrogen). Protein bands were 
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visualised by staining with 0.01% Coomassie Brilliant Blue R-250 (Sigma-Aldrich) 
followed by destaining in Coomassie destaining solution (40% Methanol and 10% 
glacial acetic acid). 
 
2.7.2 Western transfer and immunodetection 
For immunodetection proteins prepared by SDS-PAGE were electrotransferred onto 
nitrocellulose and probed with Strep tactin-HRP conjugate (1:100) (IBA Lifesciences) 
or Strep MAB Classic-HRP conjugate (1:100) (IBA Lifesciences). Detection by 
chemiluminescence was performed using Super Signal West Pico Chemiluminescent 
Substrate (Thermo Scientific) according to the manufacturer’s recommendations.  
 
2.8 Recombinant MC084S – ELISA screening methods 
2.8.1 Human serum/ tissue samples 
522 serum samples (aged 2 months -101 years) were collected for routine screening and 
medical diagnosis at University Hospital Heidelberg, Germany as well as 44 serum 
samples (aged 8-62 years) from patients undergoing treatment for various diseases at 
the University of Heidelberg, Germany, between 2007-2011. Lesion material from 
patients with molluscum contagiosum was obtained from the University Hautklinik, 
Heidelberg, Germany. Sample collection was approved by the Human Ethics 
Committee of the University (Ethikvotum S-091/2011 Hautklinik Heidelberg). 149 sera 
samples (aged 2-69 years) were from a UK population collected as part of a study on 
MS at Cardiff University ('An Epidemiological study of Multiple sclerosis and other 
neuroinflammatory demyelinating disorders in South Wales', 05/WSE03/111). Twelve 
serum samples were collected from MCV patients (4 Male and 8 Female, aged 2-62 
years). Of these 10 were collected at the Dr P N Behl Skin Institute and School of 
Dermatology, New Delhi, India and two were collected in South-western UK (Bath, 
Cardiff).   
 
2.8.2 MCV direct binding ELISA 
Ninety six well Maxisorp ELISA plates (Nunc) were coated with 3 µg/ml of FPLC 
purified recombinant truncated MC084S (aa123-230) protein per well in 100 µl of 0.05 
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M carbonate-bicarbonate buffer (pH 9.6) and incubated  at 37˚C for 2 hours and then 
overnight at 4˚C. Plates were washed three times with PBS containing 0.05% Tween-20 
(Fischer Scientific) prior to the addition of 200 µl/well of 5% skim milk (Vitamel Skim 
Milk). The plates were incubated for 2 h at 37˚C and washed eight times with PBS-T. 
Test sera, diluted 1:100 in dilution buffer were coated across the plate (100 µl/well). 
The plate was incubated at 37˚C for 2 h and washed ten times with PBS-T. Secondary 
anti-human IgG (raised in sheep) conjugated to horseradish peroxidase (GE Healthcare), 
diluted 1:2000 in dilution buffer was subsequently added (100 µl/well). After incubation 
at 37˚C for 2 h the plate was washed ten times with PBS-T and 100 µl of BD OptEIA™ 
substrate reagents (TMB in 0.05 M phosphate citrate buffer containing hydrogen 
peroxide - BD Biosciences) was added to each well. 50 µl of 1M H2SO4 was used to 
stop the enzyme reaction after 20 min incubation at RT. The OD of the reaction product 
was read at 450 nm on an FLUROSTAR OPTIMA - ELISA plate reader (BMG 
Labtech).  
 
2.8.3 Plate description 
Forty two sera samples were tested in duplicate on each plate along with a panel of four 
control sera consisting of two negative and two positive as well as four blanks, all in 
duplicate. The results were expressed as δODU (δODU =mean of duplicate wells minus 
mean of the blank wells). 
 
2.8.4 ELISA performance 
Plate to plate variation was monitored by comparing the control panel results between 
the different wells of the same plate; same sera samples run on different plates on the 
same day as well as on different days.  
Intra-assay variation was tested by running eight sera samples (of varying 
concentration) in replicates of 10 across the microtitre plate and determining the percent 
coefficient of variation (CV). Acceptable criteria are typically CVs of 80-120%. 
Inter-assay variation was again determined by evaluating at least eight sera samples 
(of varying concentration) in duplicate on at least three different microtitre plates on 
different days using the same reagent lots. The percent CVs are then calculated.  
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CV=SD/AVG x 100 
 
2.8.5 Cut-off value determination  
We defined the cut-off for ELISA based on the 66 sera samples from infants aged 0-
1years which were tested on ELISA plates coated with MC084S (aa 123-230) and the 
mean of their δODU readings was 0.12043 and the SD was 0.08300. In comparison the 
mean δODU for 12 MCV infected patients was 0.833 and the S.D. 0.571. The infant 
group was therefore used to define negativity with the upper limit being the mean 
δODU plus 3 S.D. (i.e. 0.36). Assuming that these values are indicative of a negative 
response to the recombinant protein, we defined a positive antibody response as being a 
value greater than mean plus 3 SDs i.e. 0.36.  
 
2.8.6 Binding Affinity - Direct ELISA 
Direct binding ELISA was performed on flat-bottom 96-well polystyrene immunoplates 
(Maxisorp TM; Nalgene Nunc International, Roskilde, Denmark), as described above. 
Briefly, plates were coated with 100 µl of antigen (5 µg/ml) for 2 h at room temperature 
and overnight at 4˚C. Plates were washed three times with PBS containing 0.05% 
Tween-20 (Fischer Scientific) and unoccupied sites were blocked with 200 µl of 5% 
bovine serum albumin in PBS-T for 2 h at room temperature. The test serum (diluted 1: 
100) in PBS-T (100 µl per well) was adsorbed for 2 h at room temperature and 
overnight at 4˚C. Bound antibodies were assayed secondary anti-human IgG (raised in 
sheep) conjugated to horseradish peroxidase (GE Healthcare); diluted 1:2000 in dilution 
buffer was subsequently added (100 µl/well).After incubation at 37˚C for 2 h, the plate 
was washed ten times with PBS-T and 100 µl of BD OptEIA™ substrate reagents 
(TMB in 0.05 M phosphate citrate buffer containing hydrogen peroxide - BD 
Biosciences) was added to each well. 50 µl of 1M H2SO4 was used to stop the enzyme 
reaction after 20 min incubation at RT. The OD of the reaction product was read at 450 
nm on an FLUROSTAR OPTIMA - ELISA plate reader (BMG Labtech).  
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2.8.7 Specificity – Inhibition ELISA 
The antigenic specificity of the antigen was determined by competition ELISA. Varying 
concentrations of inhibitors such as BSA and human IgG (0–10 µg/ml) were allowed to 
interact with a constant amount of antiserum for 2 h at room temperature and overnight 
at 4˚C. The immune complex thus formed was incubated in the wells (instead of the 
serum taken in direct binding ELISA) and the bound antibody levels were detected as in 
direct binding ELISA. The percent inhibition was calculated using the formula: Percent 
inhibition = [1 – (A inhibited /A uninhibited)] x 100 where A inhibited is the 
absorbance at 1 µg/ml of inhibitor concentration and A uninhibited the absorbance at 
zero inhibitor concentration. 
 
2.8.8 Comparison of antigen reactivity  
Purified GST or GST-tagged fusion proteins (100 μl/well) were applied to the 
Glutathione Immobilizer plates (Thermo scientific) in concentrations of 5 µg/ml in PBS, 
without any mixing. The plates were incubated at 4˚C overnight. The plates were 
washed three times with 300 μl/well PBS-T (0.05% Tween v/v). The use of blocking 
solution is not recommended.  Anti-Strep II (100 μl/well) diluted 1: 100 in PBS-T is 
applied to the plates and these are incubated at room temperature for one hour. The 
plates were washed three times with 300 μl/well PBS-T again. The OD of the reaction 
product was read at 450 nm on a FLUROSTAR OPTIMA - ELISA plate reader (BMG 
Labtech). 100 µl of BD OptEIA™ substrate reagents (TMB in 0.05 M phosphate citrate 
buffer containing hydrogen peroxide - BD Biosciences) was added to each well. 50 µl 
of 1 M H2SO4 was used to stop the enzyme reaction after 20 min incubation at RT. The 
OD of the reaction product was read at 450 nm on an FLUROSTAR OPTIMA - ELISA 
plate reader (BMG Labtech).  
 
2.8.9 Immunofluorescent detection of MC084S in v319-MC084 infected 
keratinocytes 
HaCaT cells were seeded at low cell density on glass coverslips. Cells growing on 
coverslips were allowed to adhere for 24 hours and were infected with recombinant 
vaccinia virus v319 expressing MC084. At 24-48 h post infection, cells were washed 
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three times with PBS and fixed by immersing coverslips in 100% methanol at -20˚C for 
5minutes.  These were then blocked with IF block buffer for 45 min at 37˚C. Coverslips 
were washed three times in PBS and then cells were stained with human high tire 
antiserum HD V0901071 or mouse anti Strep II tag diluted 1:100 in IF blocking buffer 
for 45 min at 37˚C, washed extensively in PBS again and incubated for 30 min at 37˚C 
with a secondary Alexa Fluor 488 goat anti-human IgG (H+L) (1:1000) (Invitrogen). 
Samples were washed several times with PBS and mounted with Vectashield
®
 mounting 
medium containing DAPI (Vector Laboratories) on glass slides.  
 
2.8.10 Confocal scanning laser microscopy 
Samples were analysed for fluorescence emission properties in green and blue regions 
at excitation wavelengths of 458, 488 and 543 nm by using confocal scanning laser 
microscopy (CSLM) (Leica TCS SP2 AOBS) mounted on a Zeiss Axiovert 200M on an 
inverted-based microscope with a 63x objective.  
 
2.8.11 Immunohistochemistry 
Paraffin embedded sections were deparaffinized and rehydrated. Staining was done 
using the Dako Cytomation Envision
®
+Dual Link System-HRP (DAB+) kit (Dako) as 
per manufacturer’s instructions. For staining of tissue with high titre or low titre human 
sera, ECL Anti-human IgG (1:2000) (GE Healthcare) was used in conjunction with the 
kit. Staining was completed with counterstaining with Mayers haematoxylin and eosin. 
Slides were fixed with coverslips. All sections were analysed using an Olympus BX51 
light microscope. Expression of MC084S specific antibodies were considered positive 
in the epidermis when the tissue showed golden-brown staining in a focal or diffused 
pattern. 
 
2.8.12 Statistical Analysis 
Serological data was stratified by age or diagnosis. Statistical significance of differences 
between the ELISA responses of different groups was assessed by one way ANOVA. 
Tukey post hoc anova was used to identify and compare statistically significant means 
and differences of different group. 
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2.8.13 MCV serum neutralisation test  
Reporter assays were conducted as per protocol described by Liu and coworkers (Liu et 
al., 2012). Neutralisation was measured using the neutalisation assay developed by us 
using the poxvirus reporter system v3, where virus was inhibited by neutralizing 
antibodies present in serum samples. HeLa cells were added as trypsinized single cell 
suspensions. Viral progeny were allowed to grow in the cells for up to 24 h after 
infection. Cell densities were determined to be 10
4
 cells per well. Varying dilutions of 
serum as 1:3, 1:9, 1:27, 1:81, 1:243 and 1:729 containing neutralizing antibodies and 
400 PFU/50 µl diluted virus. Diluted serum (100 µl) was distributed into the 
corresponding wells in a 96 well plate and 50 µl of VAC was added to each well. Plates 
were incubated at 37˚C, 5% CO2 for 1 h. Following incubation, 100 µl cells were added 
to each well. Plates were placed on a plate shaker for 1 min and further incubated at 
37˚C, 5% CO2 for 24 h. After incubation cell lysates were tested for luciferase activity 
by adding 100 μl Dual Luciferase Assay Substrate (part of The Dual-Luciferase® 
Reporter Assay System from Promega) to each well. Luminescence was measured on 
aFLUOStar Luminometer. The 50% neutralization titre (NT50) for each serum sample 
was defined as the serum dilution at which the relative light unit (RLU) was reduced by 
50% compared to virus containing control wells. Titres greater than 1:9 were considered 
positive. 
 
2.8.14 MCV plaque assays 
The plaque assay remains the gold standard for virus quantification. The plaque itself 
can be described as an area of dead cells or as area of infected cells in a cell monolayer. 
The production of plaques representing original titre under liquid medium is impossible. 
Plaque reduction neutralisation tests were conducted as per protocol described by Liu 
and coworkers (Liu et al., 2012). Sera were serially diluted to five-fold dilutions in the 
range of 1:40 to 1:25000, depending on the expected titre. Wells containing 550 µl of 
each dilution and an equal volume of vaccinia virus (400 pfu/ml) were mixed. After 
incubation at 37˚C, 5% CO2 for 1 h, 550 µl was added to Vero cells in duplicate and 
plates were incubated for 2 h at 37˚C, 5% CO2 with intermittent rocking, followed by 
the addition of 3 ml of overlay containing 0.5% agarose. On day 4, viral plaques were 
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visualised by staining with 0.1% crystal violet in PBS containing 0.2% formalin and 
counted. The NT50 was defined as the reciprocal of the serum dilution required for 50% 
reduction in vaccinia plaques. 
 
2.9 Monoclonal Antibody Production 
2.9.1 Antibody Production 
 
Immunization 
 
 
First Boost 
 
 
Second Boost 
 
 
IP Boost 
 
 
Hybridoma fusion 
 
 
Hybridoma screening 
 
 
First cloning 
 
 
Screening of clones 
 
 
Second cloning 
 
 
Screening of clones 
 
Figure 2.15. Monoclonal antibody production. 
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 Each immunization/boost with 50 μg purified MC084S (V123-R230) protein or 
GST-MC133S per BALB/c mouse.  
 Each blue arrow represents approximately two weeks 
 The green arrow represents 2-3 days. 
 
2.9.2 Immunisations  
Adult mice of theBALB/c strainwere used for immunisations and fusions and were 
either purchased from The Jackson Laboratory (Bar Harbor, Maine) or were produced 
in the animal colonies by members of the Morgan Lab.  The primary immunization was 
performed by intramuscular injection of 50 µg of antigen. Boosts with 50 µg of the 
same antigen were given at a variety of intervals as indicated in Figure 2.15. Fusion was 
performed at 2 days after the final intraperitoneal (IP) boost, also as indicated in Figure 
2.15 
 
2.9.3 Hybridoma fusion 
A day prior to fusion, SP2/0 myeloma cells, were split to ensure they will be in log 
phase growth on day of fusion. The immunized mice spleen cells were mixed with 
myeloma cells (SP2/0) at a 2:1 (spleen:myeloma) ratio in the presence of polyethylene 
glycol (PEG) 2000 (Molecular weight) (Roche) and a volume of 200 μl is pipetted in to 
each well of 96-well plates in RPMI + 15% FBS/HAT + 1% 3A(L-glutamine, pen/strep, 
sodium pyruvate) medium and incubated at 37 °C in an atmosphere of 5% CO2. These 
plates are left incubator for hybridoma clones to grow and after 6-7 days fusions are fed 
by adding 1 ml/well fresh complete RPMI + 1X HAT. 
 
2.9.4 Screening and subcloning of monoclonal hybridomas 
Nine or ten days after the fusion process, the individual hybridomas begin to make the 
media slightly acidic. Hybridomaswere screened by ELISA after 10 days for antibodies 
against MC084S (aa123-230). Hybridomas showing significant MC084S (aa123-230) 
specific inhibition, were cloned three times by limiting dilution. The cells from this 
point on are grown in complete RPMI media with HT. These cells are expanded to T25 
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10 ml flasks containing RPMI with HT and at least two lines of each subclone are 
frozen down.One clone was chosen for further study. 
 
Selected positive wells are fed as appropriate with complete RPMI medium+1xHAT 
(fusion should be fed with HAT containing medium for approximately 2 weeks and then 
only with HT (Gibco) containing medium. The hybridomas usually become visible 
colonies at day 7-8, and the supernatants are harvested and tested generally between day 
10-15 days following the fusion. 
 
ELISA plates are prepared according to the number of wells showing growth. A stock 
solution of antigen is prepared for screening by add 5 μg of protein to 10 ml PBS. This 
is mixed well and 100 μl of antigen is coated per well. A positive (polyclonal sera) and 
negative (BSA) control are also used. The wells that are ELISA positive are 
immediately transferred to a 24 well plate with 1 ml of HAT media and the 96 well 
plates are also refed. The day before subcloning, the SP2/0 cells are counted and plated 
at a density of 2 X 10
4
 cells per well in 100 μl of complete RPMI. Two 96 well plates 
must be prepared for every hybridoma that will be subcloned and placed at 37˚C in an 
incubator. Peritoneal macrophages are isolated from two mice in RPMI media, washed 
and resuspended in 1xHT-complete RPMI out of which 100 l/well is added in x ( of 
fusion wells to clone x 2) 96-well plates and incubate at 37˚C. 
 
2.9.5 Crypreservation of cell lines 
Before freezing, cells are checked using an inverted microscope and should appear 
>90% viable. Lower cells counts may not be able to recover from the freezing process. 
Cells are counted with hemocytometer. If cells are in normal density range these are 
pelleted in a sterile centrifuge tube by spinning between 1200-1500 rpm for 10 minutes, 
after which the supernatant was removed with a pipette and discarded. The bottom of 
tube is tapped to dislodgecells and they are resuspended in an appropriate amount of 
cold Freezing Media to obtain necessary density.  
Freezing Media: for 200 ml 
120 ml RPMI 1640 medium (Invitrogen) 
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60 ml of foetal calf serum (FCS-Gibco) (Final concentration 30%) 
20 ml dimethylsulfoxide (DMSO) (Final concentration 10%) 
The medium is filter sterilized and then aliquoted to 15 ml conical tubes and stored 
frozen at -20˚C. Before use the media should be defrosted and placed in the ice bucket 
covered with ice for at least 10 minutes to ensure it is cold before use.  The DMSO 
should not be added directly to FCS as precipitation may occur. Cells should be 
resuspended in 1 ml of media per cryovial and should have a density between 3 x 10
6
 
and 7 x 10
6
 cells/ml. As an example, if in 10ml, the cell count is 4 x 10
5
 cells/ml, then 
the cell count is actually 4 x 10
6
 cells total in the flask. So after pelleting, the cells 
should be resuspended in 1 ml of Freezing Media to maintain this density. Cells should 
be transferred immediately in cell suspension to appropriately labelled cryovial and put 
on ice until they can be frozen. Also these vials should be transferred to -80˚C freezer 
and left overnight. The cells should never be stored at -20˚C for any period of time and 
never transferred directly to Liquid N2 tank, as this will be too great of a temperature 
change and cause loss of viability. After 24 hours, the cell line may be transferred to 
liquid nitrogen storage.  
 
2.9.6 ELISA assay 
96 well Maxisorp ELISA plates (Nunc) are coated with appropriate antigen 
(MC084S/vMC084/MC133S/GST) and incubated overnight at 4˚C. The antigen is 
removed and plates washed with PBS-T (PBS - 0.1M sodium carbonate-Fisher 
Scientific, pH 7.5 + Tween 20) once. These are then blocked with 200 μl of blocking 
solution (5% Vitamel skim milk) for 1-2 hours. The blocking solution is decanted and 
the plate washed two times with PBS-T using 200 µl volumes per well. After each wash 
the plate is inverted onto tissue to blot dry. Primary antibody or hybridoma supernatant 
is transferred undiluted to the ELISA plate, 100 μl/ well, using sterile tips in a hood and 
the plates are incubated for 1½ -2 hours at room temperature. The plate is washed with 
100-200 μl of PBS-T three times and on the third wash let to stand for ten minutes. The 
secondary antibody i.e. Polyclonal Goat Anti-mouse IgG-HRP (Dako) is prepared in 
PBS (1:2000) and 100 µl/well of the secondary antibody is plated out using a 
multichannel pipette and plates incubated for 1½ -2 hours. The plates are washed with 
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PBS-T five times. After removal of all liquid from the final wash, 100 µl volumes of 
BD OptEIA™ substrate reagents A+B (BD Biosciences), in a ratio of 1:1, are added to 
each well and plates incubated at RT for 20 min, avoiding direct light.Colour change 
from colourless to blue is observed. The reaction is stopped by adding 50 µl volumes of 
stop reagent (2 N H2SO4) to each well allowing yellow colour to develop.Plate is read 
on FLUROSTAR OPTIMA - BMG Labtech plate reader at 450 nm (Table 1) and 570 
nm (Table 2). Values obtained at 570nm are subtracted from readings obtained at 450 
nm to give final readout (Table 3) and corrected for optical imperfections in the ELISA 
plate. Readings with a δODU≥0.6 are considered positive.  
 
2.9.7 Binding affinity - Direct ELISA 
Direct binding ELISA was performed in flat-bottom 96-well polystyrene immunoplates 
(Maxisorp TM; Nalge Nunc International, Roskilde, Denmark). Plates were coated with 
100 µl/well MC084S (aa123-230) antigen at a concentration of 5 µg/ml for 2 h at room 
temperature and overnight at 4˚C. Plates were washed three times with PBS containing 
0.05% Tween-20 (Fischer Scientific) and unoccupied sites were blocked with 200 µl of 
5% skim milk (Vitamel) in PBS-T for 2 h at room temperature. Plates were washed 
three times with PBS-T. The serum collected from immunised sacrificed miceas well as 
from a normal healthy non-immunised mouse serving as control serum was pipetted 
into the plate wells and adsorbed for 2 h at room temperature and overnight at 4˚C. 
Plates were washed three times again with PBS-T. Bound antibodies were assayed using 
secondary anti-mouse IgG (raised in sheep) conjugated to horseradish peroxidase 
(Dako); diluted 1:2000 in dilution buffer was subsequently added (100µl/well).After 
incubation at 37˚C for 2 h, the plate was washed ten times with PBS-T and 100 µl of 
BD OptEIA™ substrate reagents (TMB in 0.05M phosphate citrate buffer containing 
hydrogen peroxide - BD Biosciences) was added to each well. 50 µl of 1M H2SO4 was 
used to stop the enzyme reaction after 20 min incubation at RT. The OD of the reaction 
product was read at 450 nm on an FLUROSTAR OPTIMA - ELISA plate reader (BMG 
Labtech).  
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2.9.8 Specificity – Inhibition ELISA  
The antigenic specificity of the antigen was determined by competition ELISA. 
Increasing concentrations of inhibitorMC084S (aa123-230) (0.01–10 µg/ml) were 
allowed to interact with a constant amount of immunogen MC084 (4 µg/ml) for 2 h at 
room temperature and overnight at 4˚C. The immune complex thus formed was 
incubated in the wells (instead of the serum taken in direct binding ELISA) and the 
bound antibody levels were detected as in direct binding ELISA. The percent inhibition 
was calculated using the formula: Percent inhibition = [1 – (A inhibited /A uninhibited)] 
x 100 where A inhibited is the absorbance at 1 µg/ml of inhibitor concentration and A 
uninhibited the absorbance at zero inhibitor concentration. 
 
2.9.9 Immunohistochemical detection using MC084-6C in MC biopsy paraffin 
sections and frozen sections 
Paraffin embedded sections were deparaffinized and rehydrated. Staining was done 
using the Dako Cytomation Envision
®
+Dual Link System-HRP (DAB+) kit (Dako) as 
per manufacturer’s instructions. Staining was completed with counterstaining with 
Mayers haematoxylin and eosin. Coverslips were fixed over the stained sections. All 
sections were analysed using an Olympus BX51 light microscope. Expression of 
MC084S specific antibodies were considered positive in the epidermis when the tissue 
showed golden-brown staining in a focal or diffused pattern. 
 
2.9.10 Immunofluorescent detection of MC084S in v319-MC084 infected 
HaCaT/BSC-1 cells 
HaCaT/BSC-1 cells were seeded at low cell density on glass coverslips. Cells growing 
on coverslips were allowed to adhere for 24 hours and were infected with recombinant 
vaccinia virus v319 expressing MC084. At 24-48 hrs post infection, cells were washed 
three times with PBS and fixed by immersing coverslips in 100% methanol at -20˚C for 
5minutes.  These were then blocked with IF block buffer for 45 min at 37˚C. Coverslips 
were washed three times in PBS and then cells were stained with MC084 monoclonal 
antibody MC084-6C or Classic Strep MAB (IBA Lifesciences) diluted 1:100 in IF 
blocking buffer for 45 min at 37˚C, washed extensively in PBS again and incubated for 
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30 min at 37˚C with a secondary antibody Alexa Fluor 488 (Green) chicken anti-mouse 
IgG (H+L) (1:1000) (Invitrogen). Samples were washed several times with PBS and 
mounted with Vectashield
®
 mounting medium containing DAPI (Vector Laboratories) 
on glass slides.  
 
2.10   IT equipment and software 
Immunofluorescence was examined using the fluorescence microscope Olympus BX5I 
and AxioVision software version 4.4. Confocal scanning laser microscopy was done on 
the Leica TCS SP2 AOBS. Plates with plaque assays were scanned on a flat bed scanner 
HP Scanjet 5470C, using HP Precisionscan Pro software version 3.1 and examined by 
using COREL
®
 PHOTO – PAINT® X3 software version 3. Luciferase activity was 
measured using FLUOROstar OPTIMA Luminometer BMG LABTECH and 
FLUOROstar* OPTIMA software. Statistical analysis was performed using SPSS 
software version 12, assessed by one way ANOVA. Tukey post hoc anova was used to 
identify and compare statistically significant means and differences of different groups. 
Bibliography was created using End Note version x7.  
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Chapter 3 - Development of a new method for the assessment 
of Molluscum contagiosum virus infectivity 
 
Introduction 
Molluscum contagiosum is a viral infection of differentiating epidermal keratinocytes 
resulting in cutaneous tumours. Clinical presentation as an acanthoma with large 
keratohyalin granules and the lack of reactivity of these granules to antiflaggrin 
monoclonal antibodies suggest that the pathogenesis involves abnormal differentiation 
of epidermal cells (Takahashi, Izutani et al. 1999). MCV replicates well in the human 
skin in vivo, but not in vitro in standard monolayer cell culture. It has a large genome 
which has many genes which may encode function for its survival in human skin.  
 
The MCV lifecycle starts with the entry of virus particles into human epidermal cells. 
Although it is not entirely clear in which cells the virus replicates, the point of 
replication is thought to be epidermal stem cells. Infections of epithelial type cells in 
vitro are non-productive, but produce early gene products. Molluscum contagiosum 
virus (MCV) does not produce a quantifiable cytopathic effect and does not produce 
viral progeny in infected standard cell cultures. The lack of a cell culture system has 
further limited MCV research. Consequently, all stages of MCV viral life-cycle have 
been under-investigated, accounting for the sizeable gaps in the literature. Small 
amounts of viral mRNA and protein expression can be detected indicating that MCV 
virions are transcriptionally active (Bugert et al., 1999; Bugert et al., 2001, Mohr et al., 
2008).  
 
The first step of any virus lifecycle is entry. The MCV lifecycle in vivo as well as in 
vitro is summarised in Figure 3.1. In order to determine whether MCV has entered cells 
we have developed a combination of GFP and luciferase based reporter assays. This 
new method, developed in the Bugert lab, was published in 2012 (Sherwani et al., 
2012), and enables measurement of early transcriptional activity of MCV in a luciferase 
reporter assay, and has allowed us to make an initial contribution to addressing the basic 
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question of MCV entry into target cells. The present research concerns the first step of 
the viral life cycle, entry. 
 
 
Figure 3.1.  Summary of the replication cycle of Molluscum contagiosum virus. Replication 
occurs entirely in the cytoplasm. A virion containing the double stranded DNA genome, 
enzymes and transcription factors attaches to the host GAGs on cells and facilitates fusion with 
the cell membrane in turn releasing a core into the cytoplasm. In the natural life cycle in vivo 
the core synthesizes early mRNA which is translated into many different proteins including 
growth factors, immune defence molecules, factors for DNA replication and intermediate 
transcription and enzymes. In vitro the life cycle is arrested at this stage with the transcription 
of early gene products in detectable levels. Uncoating takes place in vivo and DNA replication 
takes place to form concatemeric molecules. Intermediate genes are transcribed and the mRNA 
is translated to form late transcription factors. Late genes are then transcribed and the mRNA 
translated to form virion structural proteins, enzymes and early transcription factors. The 
assembly of progeny virions is initiated in cytoplasmic viral factories and the concatemeric 
DNA intermediates are packaged into immature virions (IV), followed by maturation leading to 
formation of infectious intracellular mature virions (MV). These MVs are wrapped by the trans-
Golgi and endosomal cisternae to give wrapped virions which are transported to the periphery 
of the cell along microtubules. Fusion with plasma membrane leads to release of extracellular 
enveloped virions (EV). Adapted from B. Moss in Field’s Virology. 
  
100 
 
In order to determine the nature of the replication deficiency in vitro, the MCV infection 
process in standard cell culture has to be studied step by step. We developed a method 
which uses luciferase reporter constructs to measure poxviral mRNA transcription 
activity in MCV infected cells in standard culture.  
 
Many investigators have observed that poxvirus transcription complexes can drive 
luciferase reporters under the control of poxviral promoters in plasmids in poxvirus 
infected cells. A recent paper uses this as a method to diagnose orthopoxvirus infections 
(Levy et al., 2010). We introduce a luciferase reporter expression in trans as a new 
surrogate marker of infectivity and gene expression for MCV. To compare the 
infectivity of MCV with other poxviruses (Bengali et al., 2009), the number of virions 
must be determined. Quantitation by EM or OD300 can be used (Melquiot and Bugert, 
2004), but requires relatively large amounts of gradient purified virons. However, 
currently, MCV can only be isolated from clinical specimens and thus is difficult to 
obtain amounts sufficient for gradient purification (Melquiot and Bugert, 2004). PCR is 
an alternative method of quantification of smaller amounts of poxviruses from clinical 
specimens, which is both reliable and highly specific for individual poxviruses. This 
method uses a novel PCR target in an area with significant DNA homology (~65%) 
between MCV and vaccinia virus strain WR (VACV-WR). The MCV gene mc129R, 
which is homologous to the VAVWR144 (also called A24R gene encoding RPO132, 
the large subunit of the DNA-dependent RNA polymerase). The method provides a 
means to quantitate poxviral genome units in the same virus preparations used to 
compare transcriptional activity and infectivity of MCV and VACV-WR. 
 
Despite the general consensus that MCV is highly specific to both humans and the skin, 
MCV lesions have been reported in various animals. As early as 1967, molluscum 
lesions were reported in chimpanzees by Douglas and colleagues (Douglas et al., 1967). 
Post this observation others were reported in red kangaroos and horses (Bagnall and 
Wilson, 1974; Lange et al., 1991). In spite of these observations no in vitroor in 
vivomodel exists which would allow molecular biological analysis of MCV. The 
present work also aims to address questions about MCV entry and the possible 
development of in vitro MCV cell culture model (MINUCELL) which may be 
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developed to facilitate specific therapeutic strategies for MCV infection as well as 
possible vaccine delivery strategies. 
 
The main aims that this chapter addresses are the development and optimisation of 
methods to achieve a luciferase reporter entry assay that produces sufficient luminescent 
signal for MCV entry from which conclusions may be drawn. Also the development of 
a quantitative assay to calculate MCV multiplicity of infection (moi) as MCV is 
characterised by lack of cpe and hence difficult to quantitate on entry and using both of 
the above mentioned, the testing and quantification of MCV entry into a panel of human 
and animal cells in order to identify the host cell line with maximal virus entry.  
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Results 
3.1 Determination of optimal VACV 
In virus titrations RK13 cells (p45 05.03.10) at a quantity of 1x10
4 
cells/well were 
infected with five different preparations of VACV in 10
-2
 dilution. The VACV 
supernatant (sn) preparations used and corresponding titres are shown in Table 3.1.  
 
Table 3.1. VACV preparations and titrations. 
VACV preparation Viral titre (pfu/ml) Multiplicity of infection 
(MOI) 
 vWR RK13 sn  8/211-1 (25.1.08) 4.0x10
6
 
4 
 vWR BSC-1 sn  8/221-1 (25.1.08) 1.4x10
5
 
0.14 
vWR HeLa sn 7/1412-11 (7.12.07) 3.6x10
6
 
3.6 
vWR CV-1 sn (13.12.06) 2.8x10
6
 2.8 
vWR BJ-1 sn (16.11.06) 2.0x10
4
 0.02 
 
Viral titres were calculated by using VACV-infected BSC-1 cells seeded in 24 well plates. 
Infected plates were incubated at 37˚C and 5% CO2 for 45 mins. 500 μl microcrystalline 
cellulose 1.2% was added to each well before incubation for an additional 3 days. Wells were 
washed twice with PBS, stained with 400 μl crystal violet solution and incubated at RT for 3 
hours. After rinsing with cold water and passively drying, the plates were examined. The 
number of plaques was counted for each VACV preparation to achieve a titre in plaque forming 
units pfu/ml. MOI, the ratio of pfu of virus to the number of cells being infected, was calculated 
using a viral volume of 10 μl and a cell number of 1x104. 
 
VACV infected cells were collected 16 hours p.i. and measured for luciferase activity. 
Luminescent firefly signals achieved were corrected to MOI=3 and normalised to renilla 
values as a well-to-well transfection control. Values varied markedly between the five 
viral preparations demonstrating that the cell type from which the viral preparation was 
acquired does appear to have an effect on the entry capacity of the virus. vWR BJ-1 
(16.11.06) produced the greatest quantity of luminescence, averaging 35,850 RLU, 
when corrected for MOI. However, as the MOI for this VACV preparation was very 
low (MOI=0.02). The MOI for vWR RK13 (MOI=4) was considered more appropriate 
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for use as a positive control. No differences in CPE between infected cell lystates were 
evident upon photographic observation. 
 
In order to achieve optimal signal (ideally less than 10,000RLU) due to VACV at 16 
p.i., 100 µl vWR RK13 was diluted in a series of 900 µl DMEM P/S pools as to produce 
viral preparations of different dilutions (10
-1
 to 10
-6
). These corresponded to MOIs of 40 
to 0.0004. RK13 cells (p45, 05.03.10, p32 15.01.10), numbering 1x10
4
/ well, were 
transfected, infected with VACV and measured for luminescence. Formation of a 
standard curve allowed for deduction of a suitable dilution for use in subsequent 
experiments, which would provide a more comparable signal to MCV as well as help to 
preserve viral stocks. Figure 3.2 illustrates that cells infected with VACV at an MOI of 
4 produce a luminescent signal which appears exceptionally large when compared to 
readings gained from MCV infected cell lysates in preliminary experiments. The figure 
also shows movement towards a plateau effect in signal from MOI 0.004 onwards. An 
MOI of 0.04 was chosen for use in subsequent experiments. 
 
 
 
 
Figure 3.2. vWR RK13 dilution curve.  Luminescent signals achieved from RK13 cell lysates 
infected with vWR RK13 at 4.0x10
6 
pfu/ml. Cells were tranfected using a dual luciferase
®
 
reporter assay with ILR#p238 and ILR#p240 each at 300 ng/well.  Values are normalised to 
renilla as well- to- well transfection control and given as mean luminescence in relative light 
units of n=2 triplicates. Viral dilutions are given as MOI.  
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Subsequent to insufficient signal using 10 μl of a pooled MCV preparation, the 
experimental method was altered to include the use of a greater volume of virus (50 
µl/well). The second preparation of MCV, pooled from a greater number of lesions, was 
centrifuged at 10,000 rpm in 1.5 ml non-sterile PCR tubes on two occasions. The 
supernatant was transferred to new tubes after each centrifugation in order to minimise 
the amount of debris in the sample. Consequently 50 μl of this optimal MCV 
preparation was used per well in subsequent experiments, which provided both an 
uncontaminated infection and sufficient signal from which to draw conclusions.  
 
3.2 Quantitative PCR detecting MCV mc129/ vWR A24L homolog 
It is clear that vaccinia plaque-forming units cannot be directly compared to MCV 
virion units because of the different nature of their biological activity. However, the 
PCR method described in materials and methods allows a relative quantification of 
MCV genome equivalents to VACV-WR infectious units measured in pfu/ml based on 
amplifiable genomic DNA units/molecule numbers calculated for a relatively large 
plasmid containing 25,517 bp of MCV sequence.  
 
As described in the methods section the plasmid pyMCV1-E-C has 29,760 bp. Thus, the 
molecular weight is calculated as 19.344 MDa and thus 19.344 ng of plasmid would be 
6.02 × 10
8
 mol. The actual plasmid concentration was 21 ng/μl (±1.7) and, thus, 
represented 6.5 × 10
8
 mol/μl. From this value, the molecule numbers for the pyMCV1-
E-C two-fold dilution series are calculated (Figure. 3.3d). The molecule numbers are 
then correlated to the pixel numbers of bands on a gel quantitated by ImageJ.  
 
The pfu-to-molecule ratio for vaccinia virus (mature virions) comes out as 1:31, in 
keeping with previously published ratios (Payne and Kristensson, 1982). For the same 
PCR reaction, in the figure 3.3a, lane 9, the signal (27,779 pixels) for the dilution of the 
MCV control plasmid (pyMCV1-E-C) correlates to 1.586 × 10
6
 plasmid units. The band 
in gel 3.3c (MCV PCR) with comparable pixel density (i.e., within 10%) is in lane 4 
with a pixel value of 28,726 pixels. If the 1.586 × 10
6
 mol are multiplied by the dilution 
factor (16x), the MCV aliquot of 100 µl used for genomic DNA preparation contained 
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2.5 × 10
7
 mol/genome units. If the pixel values obtained for vWR in gel b, lane 4 
(71,008), are used in the same way and related to gel a, lane 8 (67,495 pixels), after 
multiplying by the dilution factor (16x), a molecule number of 5 × 10
7
 is obtained. This 
can then be used to relate to the pfu. If WR was at 1.6 × 10
6
 pfu in 100 ml, the pfu-to-
genome unit ratio is 1:31.  
 
The PCR data can be used to calculate an MCV multiplicity of infection equivalents in 
relation to the control plasmid molecule numbers as well as in the form of pfu 
equivalents in relation to a titered vaccinia stock for comparison purposes. We 
havefound this approach to be both more reproducible and more specific than electron 
microscopy or OD quantifications of virions. 
 
 
 
Figure 3.3. PCR quantification of purified DNA. Panels a – c show two fold dilutions of 
poxviral genomic DNA purified from DNAse-treated virions (b and c) and plasmid DNA 
repurified using the HPVNA kit (a). Lane numbers at the top of the figure refer to log 2 dilutions 
from 1 to 10. Panel d tabulates the calculated molecular number for the reference plasmid 
pyMCV1- E-C (pyMC) (1,000 × by nanodrop in 10 ml of original DNA prep) and the ImageJ 
pixels for each band in gels a to c. (Sherwani et al., 2012). 
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3.3 Quantification of MCV entry into host cells and MCV infection of both 
human and animal cell lines 
In order to identify the host cell lines with maximal viral entry a panel of animal and 
human cells, namely, HEK 293, 3T3, BHK-21, BJ-1, CV-1, HaCaT, HeLa and RK13 
were transfected with ILR#p238 and ILR#p240 using the dual luciferase
®
 reporter assay 
and subsequently infected with either MCV or vWR RK13, the latter at an MOI of 0.04. 
vWR RK13 was once again used as a control that the system was functioning. All virus 
infected cell lysates were collected 16 hours p.i. and measured for luciferase activity.  
 
As predicted from previous optimisation experiments, MCV pooled from a greater 
number of lesions promoted elevation in strength of the FF signal achieved. Figure 3.4a 
illustrates that MCV-infected 293T cells emit the highest quantity of FF luminescence, 
more than double the luminescent signal of any other cell line. BHK-21 cells also 
provided high signal emission, but distribution of values about the mean was 
widespread. Results show that CV-1 consistently gave the lowest signals by a relatively 
large margin, even when compared to other animal cell lines of fibroblastic origin.  
Luminescent emissions from the 3T3 mouse fibroblast line were 2.44 fold greater than 
those from CV-1.   
 
The phRL-TK reporter plasmid provided optimal renilla luciferase expression by which 
to normalise FF readings to correct for well to well deviation within triplicates and also 
to provide a transfection comparison between different cell lines. Figure 3.4b illustrates 
the mean renilla signals achieved from the assays. There appear to be remarkable 
differences in transfectability amongst the various cell types. HEK 293T cells proved 
most easily transfected, with renilla signals averaging 16,209 RLU, whereas BJ-1 
appeared most difficult to tranfect with an average signal of 216 RLU. Correcting FF 
signals for these differences in cell transfectability allows identification of the host cells 
that underwent maximal virus entry, by calculation of the firefly readings that would be 
attained if all cell- lines were equally transfected. Figure 3.4c shows the corrected 
firefly signals. Subsequent to correction by renilla, the 3T3 cell line achieved the 
highest luminescent signal, undergoing the greatest quantity of MCV entry. The mean 
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reading from BJ-1 cells was also high, though the standard deviation was wide. 
Interestingly, cells derived from the human skin keratinocyte cell line, HaCaT, did not 
produce the greatest quantity of luminescence.    
 
Although VACV was initially used as a positive control, it also became possible to 
compare the entry capacity of MCV and VACV. A semiquantitive PCR for MCV and 
VACV infectious particle genome equivalents was conducted using a conserved 
DNAdRNA pol primer pair as described in the previous result. This allowed calculation 
of a titre for the MCV pool used in experiments (2 x 10
8 
pfu/mL).Using the calculated 
VACV titre, it became possible to compare MCV and VACV entry. Table 3.2 shows 
comparisons made between the entry capacity of the two viruses and demonstrates that 
VACV possesses a significantly greater (p<0.05) capacity to enter all cell lines except 
for HaCaT and HeLa.  
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Table 3.2. Comparisons of MCV and VACV entry 
Cell line Origin MCV 
(RLU/M
OI) 
VACV 
(RLU/MOI) 
Fold 
Difference 
T- test for equality of means 
95% Confidence Interval of 
the difference. 
P-Value 
Lower Higher 
3T3 Murine 
fibroblasts 
45.35 188727.00 4161.57 -2.80809E5 -96554.10439 0.005* 
BHK-21 Hamster 
kidney 
31.90 530544.00 16631.47 -7.00794E5 -3.60230E5 0.01* 
RK13 Rabbit kidney 22.55 261379.50 11591.11 -4.41493E5 -81221.52559 0.016* 
HEK293T Human 
embryonic 
kidney 
5.27 26340.00 4998.10 -8647.04925 -6186.41475 <0.0001* 
BJ-1 Human 
foreskin 
fibroblast 
42.25 456285.90 10799.67 -6.68191E5 -2.44296E5 0.004* 
CV-1 African green 
monkey 
kidney 
epithelial 
8.19 325660.67 39763.21 -4.20462E5 -2.30843E5 0.001* 
HaCaT Human 
keratinocytes  
20.27 268456.67 13244.04 -5.68543E5 31670.12735 0.68 
HeLa Human 
epithelial 
3.17 41668.33 13144.58 -65212.1926 -18118.13225 0.68 
 
Both viruses at an MOI =1, hence values represent Relative Light Units (RLU)/MOI. Values 
given as mean of triplicates, corrected to renilla. Independent samples t test results are shown 
with resulting p-value. Results marked * show a statistically significant (p<0.05) difference 
between entry capacity of MCV and VACV.  
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MCV isolated from human- infected skin biopsies was pooled and used to infect a panel 
of human and animal eukaryotic cells. Vaccinia virus has been used as a positive 
control. Results showed that the 3T3 cell line demonstrated maximum MCV entry. The 
present study is encouraging and the experimental approach used may prove helpful in 
the establishment of an in vitro cell culture model of MCV infection. 
 
 
 
Figure 3.4. Luminescent signals obtained from MCV entry assay. (a) Firefly (FF) signals 
achieved from eight MCV-infected cell types. Cells were infected with 50 µL MCV pool diluted 
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1:10 in PBS (MOI = 500) and transfected with 300ng/well each of reporter plasmids ILR#p238 
and ILR# p240. Values are corrected for well to well deviation in transfectability within cell line 
triplicates and are given as relative light units (RLU) as mean +/- 1 SD of triplicates. (b) Renilla 
signals achieved from the same infection/transfection assay. (c) Firefly signals normalized to 
renilla readings, correcting for differences in transfectability between cell lines. 
 
Preliminary data obtained from the entry reporter assays conducted, show that firefly 
signals for MCV entry appear substantially greater than mock, i.e. the signals are high 
in the absence of viral infection. Although accurate comparisons cannot be made 
between VACV and MCV entry, due to difficulties in titrating MCV, it is possible to 
compare entry between different cell lines.  
 
3.4 MCV drives expression of EGFP reporter in HEK293 cells 
The results illustrated in figure 3.5 show that RK13 cells, derived from rabbit kidney 
epithelium, emit the greatest quantity of luminescence.This is extremely interesting, due 
to the fact that RK13 is a rabbit kidney epithelial cell line. MCV shows GFP positive 
cells after 16 h (Figure 3.5a), whereas WR shows multiple GFP positive cells (Figure 
3.5b). Upon further incubation for another 4 days (5 days p.i.), some individual cells in 
the MCV-infected wells show medium to strong GFP signals (Figure 3.5c). At the same 
time point, the WR-infected wells show extensive plaques and cell degradation (Figure 
3.5d). Figure 3.5e shows chemiluminescence in HEK 293 cells infected with MCV and 
vWR and collected 16h post infection. The luciferase signal can be seen in vaccinia- 
infected cells (MOI 0.01 - 1) after 2 h and is seen in the MCV infected cells (MOI of 5) 
after 8 h confirming MCV entry though to a much reduced degree as compared to 
vaccinia. 
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Figure 3.5. Images of luciferase and GFP in infected/transfected cells and quantfication of 
luciferase output. Panels (a – d) show HEK 293 cells infected with MCV (a and c) and vWR (b 
and d). Inserts in c show individual GFP-positive cells. Panel e shows a histogram of luciferase 
data giving chemiluminescence in RLU. HEK 293 cells were infected with MCV or vWR at the 
indicated MOI and collected at 16 h p.i. 
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Discussion 
Determination of the optimal VACV for use as a postive control resulted in the vWR 
preparation in RK13 cells achieving the most favourable luminescent signal. The titre 
measured 4.0x10
6 
pfu/ml, giving it an MOI of 4 when 1x10
4
 cells are infected. This was 
viewed as a more desirable MOI than that of the preparation that emitted the strongest 
luminescent signal, vWR. (MOI=0.02) Prior to correction by renilla, the FF signal 
achieved from vWR was extremely low, suggesting it may not be appropriate as a 
postive control. Upon dilution of the vWR RK13 VACV preparation, MOI=0.04 was 
chosen as optimal. Dilutions after this tended to plateau in effect, with more 
concentrated dilutions providing too large a luminescent signal to provide an 
appropriate postive control. Although VACV was initially used as a control, 
semiquantitative PCR allowed this poxvirus to act as a comparator to MCV. Difficulties 
in the titration of MCV have meant that this was not previously possible. 
 
 
Determination of the optimal Renilla luciferase vector resulted in use of the phRL-TK 
reporter plasmid (ILR#238) in subsequent experiments as this expressed low to 
moderate levels of renilla luciferase which appeared to be more consistent. This 
provided a more appropriate transfection control by which to normalise firefly readings. 
 
Since vaccinia plaque-forming units cannot be directly compared to MCV virion units 
because of the different nature of their biological activity the PCR method described in 
allows a relative quantification of MCV genome equivalents to VAVC-WR infectious 
units measured in pfu/ml based on amplifiable genomic DNA units/molecule numbers 
calculated for a relatively large plasmid containing 25,517 bp of MCV sequence. The 
pfu-to molecule ratio for vaccinia virus (mature virions) comes out as 1:31, in keeping 
with previously published ratios (Postlethwaite et al., 1987). The PCR data can be used 
to calculate an MCV multiplicity of infection equivalents in relation to the control 
plasmid molecule numbers as well as in the form of pfu equivalents in relation to a 
titered vaccinia stock for comparison purposes. We have found this approach to be both 
more reproducible and more specific than electron microscopy or OD quantifications of 
virions. The biological activity of virions can be assessed using an in vitro transcription 
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reaction (Shand et al., 1976; Melquiot and Bugert, 2004). It is unclear to which exten 
the different GC content of the two virus genomes would affect the PCR product. This 
was not further investigated. 
 
Through analysis of the renilla signals achieved from different cell lysates it became 
apparant that not all cell-lines are transfected equally with reporter plasmid. For 
example, HEK 293 cells were easily transfected resulting in an extremely high mean 
renilla reading, whereas cell-lines such as 3T3 and BJ-1 were relatively poorly 
transfected. (Fig 3.4b) These discrepancies would impact on the FF signal emitted and 
consequently under-estimate viral entry. Such transfectability issues were compensated 
for by correcting firefly signals to renilla, the transfection control. Analysis of the 
corrected data (Fig 3.4c) demonstrates that cells of 3T3 lineage experienced maximum 
MCV entry, indicating that an in vitro model using this cell line may be successful. 
These results corroborate with earlier studies, the first dating back to 1967, when 
Postlethwaite and colleagues described MCV cultures using mouse embryo fibroblasts 
(Postlethwaite et al., 1978b) Notably, the host cell line derived from human 
keratinocytes, cells of the skin to which MCV may be specific, did not produce the 
strongest signal. Statistical comparisons involving mean corrected firefly signals from 
both MCV and VACV infected cell lysates demonstrated that in the majority of cases, 
viral entry is significantly different. In all but two cell lines, HaCaT and HeLa, MCV 
entry was significantly lower than that of VACV.  
 
Variability in luminescent signal is evident by wide error bar range (Figure 3.4c). This 
was most noticeable among BJ-1 and 3T3 cell lines. This may be in part due to sub-
optimal manual operation of the FLUOROstar OPTIMA. Ideally, luminescence should 
be measured immediately after the enzymatic reaction to ensure a true reading. 
However, for practical purposes, signal from four wells were read in sequence per 
measurement. The use of an injector system would guarantee an immediate 
measurement of signal, thus increasing accuracy.  
 
Although cells were seeded to number 2x10
4
/well, epithelial cell lines divide at a higher 
rate than fibroblasts. Consequently, 16 hours incubation may lead to a greater number of 
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epithelial cells to fibroblasts. This could potentially result in elevated signals from cell 
lysates of epithelial origin. In addition, routine practice in animal cell culture technique 
encourages replacement of tissue culture flasks subsequent to each cell passage. This 
ensures no sub-optimal cells remain in culture. Due to preservation of laboratory stocks, 
cells were kept in the same culture flask for ten passages. It is therefore plausible that 
incompetent cells were plated as viable, as cell viability was not taken into account 
during cell number determination. Ramifications of this may include diminished 
capacity with reference to host cell infection and transfection, thus causing variation in 
signal.   
 
In contrast to the current thinking that MCV is highly specific in both host and cell, we 
have indications that entry host-range is broad. Thus the lack of productivity in cell 
culture is not due to non-entry- or receptor issues. The virus gets into mouse (3T3), 
hamster (BHK-21), monkey (Vero) and various human cells (A549, HeLa, HaCaT) and 
drives early poxviral promoters. High specificity is unusual amongst poxviruses and we 
therefore hypothesise that MCV entry host-range is not so limited. 
 
Cells of 3T3 lineage demonstrated maximum MCV entry. The inability to grow MCV 
in cell culture has hampered biological studies using the virus and therefore 
development of therapeutic strategies. The considerable MCV entry measured in 3T3 
cells in this study is encouraging, and demonstrates that an in vitro model using this cell 
line may be successful. However, progression to late gene transcription needs to be 
investigated. Further repetition of the experiments may also confirm entry into 
alternative cell lines, e.g. BJ-1. Compared to VACV, it was found that MCV is much 
less able to enter cells, significantly so in all cell lines aside from HeLa and HaCaT.  
 
The assay depends to a significant degree on the transfectability of the cell cultures 
involved. Human keratinocytes and fibroblast cell lines are most interesting as possible 
natural hosts for MCV, but they are also hard to transfect. We found HEK 293 cells to 
be the best transfected cell line. However, while this cell line shows robust reporter 
signals, it is clearly not the type of cell MCV naturally infects. 
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Transfected plasmids with poxviral transcription signals can be transcribed by the 
poxviral transcription complex produced by transcriptionally active cores after entry. It 
is not clear whether the transcription complex is accessed inside partially uncoated 
virions, with plasmid DNA getting inside cores, or by transcription complex that is 
released into the cytoplasm. MCV infected cells produce a robust luciferase signal after 
16 h. However, GFP is only visibly expressed in a small number of individual cells, 
detectable after 5 days of incubation. Potentially, other cells may express GFP at a level 
undetectable by microscopy. The process where cores are accessible for the reporter 
plasmids may be delayed in MCV-infected cells. At the same time point, the WR 
infected wells will show extensive plaques and cell degradation.  
 
The present study has successfully optimised a reporter assay based on simultaneous 
transfection of luciferase/EGFP reporter plasmids and infection with live MCV virus. 
This method can be used to infect a series of epithelial and fibroblast type cell lines of 
human and animal origin with MCV and determine infectivity. Cells of 3T3 lineage 
demonstrated maximal virus entry. Though robust luminescent signals can be obtained 
16 hrs p.i., microscopic visualisation (using pE/L EGFP reporter) is only possible at 5 
days p.i. The use of qPCR has enabled quantification of MCV and MOI calculations 
documented for the first time and published in 2012 (Sherwani et al., 2012). 
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Chapter 4 - Seroprevalence of Molluscum contagiosum virus 
antibodies in German and UK populations 
 
Introduction 
After the eradication of smallpox, Molluscum contagiosum virus remains the principal 
poxvirus causing human disease (Chen et al., 2013). It has unique features that are 
distinct from otherpoxvirus genera pathogenic for humans such as othropoxviruses 
(OPV), including smallpox and monkeypox (Buller, 1991). MCV shares the highest 
level of amino acid similarity and unique proteins with parapoxviruses such as ORF and 
Milkers nodules (Delhon et al. 2004). MCV exclusively infects the human skin 
(Postlethwaite, 1970). The infection occurs worldwide and in all racial groups 
(Birthistle and Carrington, 1997). MC is most common in young children and teenagers. 
MCV infection in immunocompromised patients results in more numerous and 
extensive lesions, some of which may be giant (Buckley and Smith, 1999).
 
 
The true prevalence of MC has probably been underestimated because of the generally 
benign clinical manifestation and rare complications. Since it is a non-notifiable disease 
clinical cases are often neglected and underreported. Development of assays which 
could assist in seroprevalence studies has been hampered by unsuccessful attempts to 
cultivate MCV in vitro and by the lack of standardized serodiagnostic tools (Burnett and 
Neva, 1966; Burnett and Sutton, 1968; Buller et al., 1995; Fife et al., 1996). Few 
studies have addressed questions of incidence trends or burden of infection. 
 
In the first known MCV antibody study in 1953, Mitchell found three out of 14 MC 
patients had complement-fixing antibodies to an antigen prepared from human MC 
lesions (Mitchell, 1953). Mitchell suggested that it was likely that in a larger proportion 
of patients absorption of small amounts of soluble antigen caused the activation of the 
antibody-forming mechanism. However, the amount of circulating complement-fixing 
antibody was too low to be detectable. Incidents which cause vascular congestion, such 
as irritation or bacterial infection of a lesion, would cause absorption of larger amounts 
of antigen and the subsequent production of detectable antibody. Mitchell also stated 
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that the formation of antibody, as a secondary response, would lead to rapid 
disappearance of lesions as is commonly observed clinically as a sequel to secondary 
infection.  
 
Shirodaria et al. used MCV cryostat sections in an immunofluorescence study of MCV 
antibodies, reporting IgM only in MCV patients and IgG antibody responses in 16.7% 
of healthy control subjects (n=30) (Shirodaria et al., 1979). They also reported a higher 
incidence of anticellular IgM antibodies in molluscum sections in comparison to 
sections with warts or psoriasis. 
 
A study conducted by a Swiss group compared the pattern of dermatoses in different 
age groups within the pediatric population referred to Aargau Hospital in Switzerland, a 
hospital associated dermatology department, between 1998 to 2001 (Wenk and Itin, 
2003). A prospective analysis was conducted using the data files of patients seen 
(outpatients and inpatients) in the department of dermatology dusring this period. The 
patients (n=1105) were grouped by age into four categories: infants (less than 2 years 
old), preschool children (3–5 years old), school children (6–11 years old), and 
adolescents (12–15 years old). The prevalence of MC was found to be highest in school 
children (10.6%) and was also found to be frequent in pre-school children (6.9%) as 
well. The ratio of females with MC was slightly higher (5.2%) than males (4.5%). The 
study suggested a lower frequency compared to general prevalence in literature due to 
an underreporting of cases. 
 
A study by Reynolds et al. was unique in the fact that it used population based estimates 
to describe the trends in incidence and epidemiology of MC in the United States among 
American Indian and Alaska Native populations reported between 2001-2005 (Reynolds 
et al., 2009). Based on outpatient visit rates, it was found that the MC-associated 
outpatient visits for American Indian and Alaska native persons for 2001-2005 was 
20.15/10000, which was comparable to the rate for the general US population of 
22/10000. American Indian and Alaskan native children in the age groups of 1-4 years 
had the highest incidence (77.12%) which was more than twice that for children in the 
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age group of 5-14 year old (30.79%) (Reynolds et al., 2009). They also found that the 
incidence for infants <1 years of age was more than that for adults.  
 
So far only two seroprevalence studies using ELISA, have been reported; one by Konya 
and Thompson (Konya and Thompson, 1999) in 1999 and one by Watanabe and co -
workersin 2000 (Watanabe et al., 2000). 
 
Konya and co-workers described in 1992 a virion based enzyme linked immunosorbent 
assay (Konya et al., 1992). MCV virions were isolated from human lesion material. The 
antigen was extracted from pooled lesions of different genotypes with epidermal protein 
extract used as a control. MCV virions were isolated from human lesion material and 
plated for ELISA assay. ELISA plates were batch-coated with purified MCV-1 virion 
proteins (5 ug/ml), with no further details on how they were purified. Their 1999 
serological survey of a healthy Australian population (n=357), MCV infected patients 
(n=35) out of which 24 were HIV-1 negative and 11 were HIV-1 infected individuals, 
revealed a overall seroprevalence of 23%, with 77% prevalence among HIV negative 
MCV patients and, and 91% among HIV positive MCV patients. This was perceived as 
a high seroprevalance, likely to be an overestimate due to a lack of specificity of the 
antigen purified from human biopsy material considering variation of MCV antigen 
from different biopsies and patients and skin protein background.  
 
The basis for the development of recombinant antigen ELISAs was laid down with the 
sequencing of the viral genome in 1996 (Senkevich et al., 1996). Based on MCV 
sequence information then available, in 1998 Watanabe et al. identified two 
immunodominant proteins of 70 and 34 kD and mapped them to the ORFs mc133L 
(vaccinia virus homolog A27L) and mc084L (vaccinia virus homolog H3L), 
respectively using a Cowpox expression system (Watanabe et al. 1998). The proteins 
are homologues of vaccinia virus proteins H3L and A27L, and major antigenic peptides 
of the virion particle (Senkevich et al., 1996; Watanabe et al., 1998). 
 
The first MCV ELISA based on a recombinant protein was reported in 2000 by 
Watanabe and co-workerswho used the Sendai virus expression system and an N-
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terminal truncation of MCV virion protein MC133 (Watanabe et al., 2000). They 
presented seroepidemiological data in a representative Japanese population of 508 
subjects with and without clinical MCV infection. MCV specific antibodies were found 
in 58% (7/12) patients with molluscum contagiosum, 6% (7/108) healthy controls, 9% 
of patients with atopic dermatitis (7/76) and 18% of patients with systemic lupus 
erythematosus (7/39). Of the HIV positive patients with MCV only 14% (1/7) were 
seropositive compared to 2% (5/266) patients who were HIV positive but MCV 
negative. The low antibody detection rate in patients with clinical disease and the 
generally low seroprevalence in comparison to the Australian study indicates that the 
Watanabe ELISA may be underestimating MCV prevalence and that MC133 may not 
be the best choice of antigen for an MCV ELISA. Their claim of MC133 being a 
superior antigen to MC084 was not supported by data.  
 
The objective of this study was to use MC084 which is a MCV surface viral protein 
which is a part of the entry complex of the virion and develop highly sensitive 
recombinant MCV ELISA using water soluble and highly antigenic truncations of 
MC084L, expressed in E. coli, which are more suitable for large scale production. MCV 
ELISAs based on E. coli expressed MCV antigen testing have so far not been reported. 
Another aim of this study was also to establish seroprevalence trends in a German and a 
UK sera collection and to provide a comprehensive view of epidemiology of MC across 
different age groups in a German population; the first in any European population. 
 
In light of the information on poxviral zoonoses and smallpox vaccination also 
reviewed extensively in the introduction, we further investigated the specificity of what 
appear to be human Molluscum contagiosum antibodies, (high titre antibodies as 
determined by recombinant MC084S (V123-R230) ELISA, versus vaccinia virus in 
plaque and reporter inhibition assays (v3 recombinant VACV reporters). Using the 
same sera dilutions used in ELISA (1:100), we wanted to test whether any 
neutralization was observed over this dilution in reporter and plaque assays. Also if so, 
was the neutralisation a more common phenomenon in younger or older people? 
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Results 
4.1 Selection of antigen, cloning and purification 
4.1.1 Antigen selection 
The molluscum gene mc084 was selected as a candidate for expression and purification 
as an immunogenic peptide based on a previous study by Watanabe and co-workers 
(Senkevich et al., 1996; Watanabe et al., 1998). Amino acid sequences of the MC084 
(298 aa, 34 kD) were analysed using standard software packages to determine overall 
homology with related proteins in the GenBank and identify transmembrane regions and 
region of high hydrophilicity and high antigenicity.  
 
Two transmembrane regions predicted in the C-terminal end of the protein (Blasco and 
Moss, 1991) were excluded to avoid solubility issues in the E. coli expression system 
(Figure 4.1A). Of the remaining 230 amino acids, two subclones were defined; an N-
terminal truncation (V33-G117; 30% aa identity with VACV097) and a C-terminal 
truncation (aaV123-R230; 27% aa identity with CPXV_UK2000_K2984_106), both 
containing one region of high hydrophilicity in the Kyte–Doolittle plot (Figure 4.1B) 
(Kyte and Doolittle, 1982), which were further analysed for subcloning. 
 
An open unlimited NCBI BLASTN search was used to compare the truncated amino 
acid sequences of mc084 to Genbank sequences (nr). MC084V5 (aa33-117) showed the 
highest overall amino acid identity with vaccinia virus protein VACV097 (H3L) of 
30%, with no significant homologies detected using NCBI BLAST 2 algorithm between 
the MCVs most antigenic motif (GGNIRNDDKYTH) and its corresponding sequence 
in vaccinia virus.  
 
MC084S (aa123-230) showed the highest overall amino acid identity with the cowpox 
virus IMV heparin binding protein (CPXV_UK2000_K2984_106) of 27%, with no 
significant homologies detected using NCBI BLAST 2 algorithm between the MCV 
most antigenic motif (NELRGREYGASLR) and its corresponding sequence in cowpox 
virus. A similar homology of 30% was found with the agmatine deiminase enzyme of 
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Listeria monocytogenes.  MC133 and MC084 share an overall level of homology to 
orthopoxvirus homologs of between 27% (MC084) and 30% (MC133), making MC084 
potentially the more MCV specific antigen.  
  
 
 
Figure 4.1. Bioinformatics for MC084. (A) Transmembrane plot (TMHMM Server v. 2.0) of 
mc084 amino acids 1-318; (B) Hydropathy plot of MC084 protein with predicted high 
hydrophilic / antigenic regions indicated by black boxes. The full length ORF (MC084 1-318; 
predicted molecular weight 34.2 kD; shown on top) was cloned into vRB12 using specific 
primers tailed with restriction enzyme sites BamHI-HindIII and C-terminal StrepII epitope tag. 
The resulting plasmid p319 was sequenced and the recombinant vaccinia virus v319 isolated on 
BSC-1 cells using the plaqueless mutant system. N- and C-terminal (in yellow) truncations were 
subcloned from the original full length MCV gene into pGEX-2TK for overexpression in E. coli 
BL21 (RIL
+
). TMHMM was used to determine transmembrane regionswhereas the Kyte 
Doolittle plotwas used to identify hydrophilic regions with predicted high antigenicity. 
 
 
 
  
123 
 
4.1.2 Cloning of mc084 
The C-terminal truncation of MC084 (V123-R230, predicted MW 14 kD), comprising 
107aa, has the lowest homology to orthopoxvirus proteins and contains a region of high 
antigenicity (218-NELRGREYGASLR-230) with no significant homology to vaccinia/ 
cowpox virus. The C-terminal truncation of MC084 (V123-R230) was subcloned into 
the pGEX-2TK vector (Figure 4.2A) with a Strep II tag and in frame with glutathione S-
transferase separated by a thrombin kinase site (Figure 4.2B), and due to the high GC 
content, overexpressed as a GST fusion protein in codon optimized E. coli (BL21 RIL
+
). 
 
The GST fusion protein was identified with an apparent molecular weight (MW) similar 
to the predicted MW of 40 kD in IPTG induced cultures (Figure 4.3A). 
 
 
Figure 4.2. MC084-pGEX 2TK construct. (A) Schematic of recombinant plasmid p332 with 
a MC084 specific insert of 107 amino acids (V123-R230); predicted molecular weight 14 kD. 
(B) Schematic of fusion protein of GST (green), followed by Thrombin cleavage site (red), 
MC084 V123-R230 (grey), and strep II tag (blue); predicted antigenic site (black). 
 
4.1.3 Purification of recombinant MC084 protein 
The protein was protease cleaved and the C-terminal truncation of MC084 with an 
apparent MW of 14 kD was further purified using a Superdex S200 column via FPLC 
(Figure 4.3B). The Strep II tag was identified in Western Blot in both the fusion protein 
and the cleaved MC084 (V123-R230)-Strep II truncation (Figures 4.3C and 4.3D). 
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Figure 4.3. Protein purification. Characterisation of overexpressed recombinant fusion 
protein GST-MC084S and FPLC purified recombinant MC084S protein by SDS-PAGE and 
Western Blot. M: Molecular weight markers expressed in kDa. (A)  Overexpressed 40kDa 
recombinant GST-MC084S fusion protein separated in a 4-12% Bis-Tris gel. (B) FPLC purified 
14kDa protein separated in a 15% Bis-Arylamide gel. Both gels were stained with Coomassie 
Brilliant Blue R-250. (C) GST-MC084S fusion protein after transfer to nitrocellulose (D) FPLC 
purified MC084S. The membranes were probed with Strep MAB-Classic HRP conjugate (IBA-
lifesciences).  Arrow heads indicate the locations of proteins. 
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4.2 Antigen specificity and comparisons  
4.2.1 Antigen specificity 
The antigenicity of MC084S (aa123-230) was determined by direct binding ELISA.The 
strong reactivity of C-MC084S towards high titre human serum sample referred to as 
HDV0901071 antibodies belonging to a seven year old male was determined through C-
MC084S ELISA. Antigen antibody immune complex equilibrium was achieved at a 
concentration of 4 μg/ml (Figure 4.4A). Antigen and antibody (serum HD V0901071) 
binding specificity was further ascertained by competitive inhibition ELISA using 
protein inhibitors that are abundantly present in human serum such as bovine serum 
albumin (BSA) and human immunoglobulin-G (IgG). A maximum of 80% inhibition of 
anti-serum antibodies with MC084S as inhibitor was observed whereas inhibition 
observed with BSA and human IgG was negligible (Figure 4.4B). 
 
 
 
Figure 4.4.  Antigen specificity.  High titre antibodies from a representative high titre serum 
HD V0901071 (1:100) used to check (A) binding affinity to MC084 (V123-R230) protein 
antigen coated in increasing concentration (0-6 μg/ml) and (B) cross reactivity (% inhibition) 
with MC084S, BSA or human IgG in a 96 well plate. Each value represents mean of three 
independent assays. 
 
4.2.2 Antigen comparisons 
The N-terminal truncation of MC084 i.e. MC084v5 (aa33-117), C-terminal truncation 
of MC084 i.e. MC084S (aa123-230), N-terminal truncation of MC133 i.e. MC133S 
(aa1-370) and GST were prepared and compared as uncleaved fusion proteins on a GST 
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affinity plate to compare antigen affinity and seroreactivities (Figure 4.5). MC084 C-
terminal has a slight advantage over MC084 N-terminal and performs similar to 
MC133. The relative absorbances of sixteen individual sera were the same against all 
antigens tested with only minimal differences in absorbance.  
 
 
Figure 4.5. Antigen comparisons. Comparison of relative antigen affinities of MC084v5 (aa1-
117), MC084S (aa123-230) and MC133S (aa1-370) expressed as GST fusion proteins and GST 
coated on an anti GST coated plate against a selection of high and low titre sera (n=16) from a 
representative healthy German population. The horizontal bar within each group represents the 
median absorbance measurement. 
 
On comparing the two truncations of MC084, the N-terminal truncation of MC084 i.e. 
MC084v5 (aa33-117) showed reduced reactivity against the sixteen sera samples with a 
lower median absorbance measurement of 0.805 in comparison to the C-terminal 
truncation of MC084 i.e. MC084S (aa123-230), which had a slightly higher median 
absorbance measurement 1.00. In direct antigen comparison there was no significant 
difference between absorbance measurments of truncations of MC084 and MC133 
(median absorbance 1.05), and no serum showed prevalent reactivity against one or 
another of the antigen used. Purified GST antigen showed hardly any reactivity against 
the sixteen sera samples (median absorbance 0.023). 
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4.2.3 Strep II tag interference 
To rule out strep II epitope tag interference in the binding of serum antibodies against 
MC084S (aa123-230), we tested high titre human serum antibodies alone as well as 
after incubation overnight with GST-MC133S fusion protein on glutathione sepharose 
beads. After overnight incubation at 4˚C, the serum was collected and used in ELISA. 
Commercially available Strep antibodies (Classic Strep MAB) were used either alone or 
after overnight incubation under similar conditions as mentioned above and served as 
positive and negative controls for this assay (Figure 4.6).  
 
 
Figure 4.6.Strep interference. ELISA plate was coated with MC084S (aa123-230). Control 
and overnight treated sera of human (HD V0901071) alone as well as treated overnight with 
strep tagged Glutathione sepharose bead bound fusion protein GST-MC133S. Anti-strep 
antibodies alone as well as treated overnight served as positive and negative controls 
respectively.  
 
It is clear from the assay that the Strep II tag did not interfere with the binding of MC084S 
specific serum antibodies with MC084S (aa123-230) epitope. 
 
 
 
Human serum Anti-strep Abs 
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4.3 ELISA Sensitivity and cut-off  
4.3.1 ELISA sensitivity 
MC084S (aa123-230) ELISA specificity and sensitivity were established on the basis of 
twelve sera samples from MCV patients. Ten were collected at the School of 
Dermatology, Skin Institute New Delhi and two were collected in the South-western 
UK (Bath and Cardiff). To establish sensitivity a panel of these 12 sera samples from 
patients with known and clinically active MCV was first screened in comparison to sera 
from 0-1 year old individuals from the neonatal screening program of the Heidelberg 
University Clinics. In the group of sera from patients with diagnosed Molluscum 
contagiosum (n=12), the ELISA gave high absorbance for all (median δODU 1.5), with 
the most recent sample from Cardiff (CF2012-1) exhibiting the highest binding (Figure 
4.7). The control group of seventeen neonates from the Heidelberg University Clinics 
showed low reactivity with a mean δODU of 0.1 as shown in Figure 4, with one outlier 
(0.61 δODU).  The confidence interval for the difference between positive and negative 
control groups was highly significant (Figure 4.7). Sensitivity was 100% for MC 
patients.  
 
Figure 4.7. ELISA sensitivity. Absorbance plot of twelve sera from patients clinically 
diagnosed with MCV (India n=10; UK n=2); control group of 0-1 year old individuals (n=17).   
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4.3.2 ELISA cut-off 
The cut-off for ELISA was calculated based on 66 sera from infants seen in the neonatal 
unit aged 0-1 years. The mean of δODU readings was 0.12043 and the SD was 0.08300. 
In comparison the mean δODU for 12 MCV infected patients was 1.57 and the S.D. 
0.571. The infant group was used to define negativity with the upper limit being the 
mean δODU plus 3 S.D. (i.e. 0.36). Assuming that these values are indicative of a 
negative response to the recombinant protein, we defined a positive antibody response 
as being a value greater than mean plus 3 SDs i.e. δODU 0.36. Two more outliers were 
identified in this group (δODU 0.36 and 0.359) which led to an alternative cut-off 
calculation based in inclusion or exclusion of the outliers (Table 4.2). The MCV status 
of these subjects (aged 2 months, 9 months and 11months) could not be determined. 
Inter-well, intra-assay and inter-assay variability was found to be 3%, 5.25% and 6.72 
% respectively. 
 
4.3.3 Sera specificity confirmation by microscopy 
4.3.3.1 Typical staining pattern with MCV positive serum (CF2012-1) 
An example for specific reactivity human in MCV infected tissue section obtained from 
the Heidelberg University Dermatology Unit was tested with high titre serum from a 
MCV positive UK patient CF2012-1 is demonstrated in Figure 4.8. The section shows a 
dome-shaped contour with cup shaped lesions with central invagination, representing a 
typical MCV lesion consisting of two inverted lobules of hyperplastic squamous 
epithelium (red arrows) with several sub-lobules. The MC lesion shows acanthosis with 
the appearance of intraepidermal lobules with enlarged basophilic nuclei filled with 
cellular as well as MC Henderson Patterson bodies (black arrows). Intraepidermal 
lobules are separated by septa consisting of compressed dermis (dotted arrow). MCV 
inclusion bodies stain strongly golden-brown with the human polyclonal serum 
CF2012-1 taken from a patient with clinical MCV infection. The stain is confined to 
areas where MCV cores, mature and released virus particles would be expected. In a 
number of tissue sections stained, the pattern was repeatable and sensitive to tissue 
preparation. Interestingly, the debris areas filled with mature MCV particles and lipid 
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debris are also sensitive to removal by xylene/ethanol treatment of paraffin sections. 
The areas most consistently stained are the suprabasal and spinous layers.  
 
 
 
Figure 4.8. MCV infected tissue stained with MC positive human serum. Microscopy (4x) 
of a Molluscum contagiosum lesion section (17315/11) stained with MC patient positive serum 
(CF2012-1) and haematoxylin-eosin counterstain (upper left hand corner). Three insets 
showing details at various magnifications [inset 1-(10x), inset 2-(20x) and inset 3-(20x)].  
 
4.3.3.2 Typical staining pattern with MCV negative serum 
As an example for specific reactivity of serum from an unifected individual in infected 
skin, a MCV infected human tissue section obtained from the Heidelberg University 
Dermatology Unit was tested with control serum from a 32 year old female with no 
prior history of molluscum contagiosum as demonstrated in Figure 4.9. The section 
shows a multi-lobular section of an MCV lesion consisting of lobules of hyperplastic 
squamous epithelium. Staining patterns consistent with typical haematoxylin-eosin 
staining show blue staining of nuclei of cells and pink-red of eosinophilic structures 
over the entire lesion. There is a clear absence of golden-brown staining pattern in the 
lesion. 
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Figure 4.9. MC infected tissue stained with control human serum. Microscopy (4x) of a 
Molluscum contagiosum lesion section (12710/12) stained with control human serum from an 
individual with no history of MC infection and haematoxylin-eosin counterstain. Two insets 
showing details at a similar magnification [inset 1-(10x) and inset 2-(10x)].  
 
4.3.3.3 Staining patterns with high and low titre sera in MCV biopsy sections 
ELISA specificity was established by using human MCV infected tissue sections 
obtained from the Heidelberg University Dermatology Unit which were tested with high 
and low titre sera as determined from the MC084S (V123-R230) ELISA. A panel of 
high and low titre sera samples used to stain tissue samples are tabulated in Table 4.1.  
 
Table 4.1. High tire and low titre serum samples used in MC biopsy section staining. 
 
High Titre Sera (Positive) Low Titre Sera (Negative) 
Serial No. Serum No. Age ( years)  Sex Serial No. Serum No. Age (years)  Sex 
1. HD V0901071 7 M 1. HD V0905374 1 M 
2. HD V0905794 5 F 2. HD V000040 1 M 
3. HD V0903005 6 F 3. HD V901798 1 F 
4. HD AZ004482 47 F 4. HD V0905511 1 M 
5.  HD AZ005203 51 M 5. HD AZ005860 50 M 
 
In figure 4.10 panels 1-5 show molluscum contagiosum lesions stained with high titre 
human sera samples at various magnifications as determined by recombinant MC084S 
(V123-R230) ELISA and indicated in Table 4.1, together with a haematoxylin eosin 
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counterstain. The sections show epidermal stratification as basal, suprabasal and 
spinous layers. The molluscum lesions typically consist of hyperplastic squamous 
epithelium with several sub-lobules bearing molluscum bodies. The lesion(s) lie 
adjacent to normal appearing epidermis in panel 1, 3-5. Intraepidermal lobules are 
separated by septa consisting of compressed dermis. All sections show strong golden 
brown staining of the lesional area indicating specificity of the serum antibodies 
established through the MC084 (V123-R230) ELISA. The staining is especially strong 
in the the acanthotic intraepidermal lobules exhibiting central cellular MC bodies’ 
debris and released viral material. The skin adjacent to the MC lesions showed either no 
histological alterations or mild epidermal acanthosis. 
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Figure 4.10. MC tissue stains with high titre sera confirming ELISA specificity. Tissue 
sections from MCV positive patient biopsies stained with high titre human sera samples as 
determined by recombinant MC084S(V123-R230) ELISA. Panel 1 shows section 5911/12 
stained with HD V0901071-1A (4x), 1B (4x) and 1C (10x). Panel 2 shows section 7633/11 
stained with HD V0905794-2A (4x), 2B (10x) and 2C (10x). Panel 3 shows section 19858/11 
stained with HD V0903005-3A (4x), 3B (10x) and 3C (20x). Panel 4 shows section 17314/11 
stained with HD AZ005203-4A (4x), 4B (10x) and 4C (20x). Panel 5 shows section 12877/11 
stained with HD AZ004482-5A (4x), 5B (10x) and 5C (20x). (Haematoxylin-eosin counterstain). 
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In contrast, Figure 4.11 panels 1-5 show various magnifications of molluscum 
contagiosum lesions stained with low titre human sera samples as indicated in table 4.1 
together with a haematoxylin eosin counterstain. Again, the molluscum lesions typically 
consist of hyperplastic squamous epithelium with several sub-lobules separated by 
compressed dermis and bearing molluscum bodies. The lesion(s) lie adjacent to normal 
appearing epidermis in panel 1-2 and 4-5. All sections show either no staining or mild 
golden brown staining of the lesional area. It can be inferred that the sera used for 
staining these sections have either no MC084S (V123-R230) specific antibodies or very 
low titres, as already established by the MC084S (V123-R230) ELISA. The skin 
adjacent to the MC lesions showed either no histological alterations or mild epidermal 
acanthosis. 
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Figure 4.11. Molluscum contagiosum tissue stains with low titre sera confirming ELISA 
specificity. Tissue sections from MCV positive patient biopsies stained with low titre human 
sera samples as determined by recombinant MC084S(V123-R230) ELISA. Panel 1 shows 
section 10624/12 stained with HD V0905374-1A (2x) and 1B (10x). Panel 2 shows section 
12712/12 stained with HDV000040-2A (2x) and 2B (10x). Panel 3 shows section 12720/12 
stained with AZ005860-3A (4x) and 3B (20x). Panel 4 shows section 63541/12 stained with HD 
V901798-4A (2x) and 4B (10x). Panel 5 shows section 10195/12 stained with HD V0905511-5A 
(4x) and 5B (10x). (Haematoxylin-eosin counterstain). 
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4.3.3.4 Staining patterns with high titre versus low titre sera in biopsy sections 
from same patient series 
To further demonstrate the difference in tissue staining with high and low titre sera, 
tissue sections obtained from the same patient series, were stained with a panel of five 
sera each. In figure 4.12 panel 1A, 1B and 2A,2B showtwo tissue sections stained with 
a high (HD V0901071, HD V0903005) and in figure 4.12 panel 1C, 1D and 2C, 2D 
show two tissue sections stained with low titre sera (HDV0900471, HDV0900040) at 
two magnifications (4x and 10x). Sections in panel 1 belong to a single patient series 
whereas sections in panel 2 belong to another patient series.  
 
 
Figure 4.12. Serum specificities in tissue stains. Tissue sections from MCV positive patient 
biopsies stained with high titre human sera HD V0901071-1A (4x) and 1B (10x), HD 
V0903005-2A (4x) and 2B (10x) and low titre human sera HD V0900471-1C (4x), 1D (10x) and 
HD V0900040-2C (4x) and 2D (10x). (Haematoxylin-eosin counterstain). 
 
Reactivity of high titre sera are shown on the left (Figure 4.12 panel 1A, B/ transverse 
section-perpendicular to level skin and 2A, B/ plane section-parallel to level skin). High 
titre sera show strong MC084 specific staining of cellular debris and MC bodies 
extruded from and in the centre of lesions, as well as infected cells in lobules extruding 
infectious virus into the centre of the lesion and upwards. Molluscum rich lipid debris 
areas are well preserved in these lesions. There is much weaker staining with low titre 
sera (same lesions in transverse and plane sections; figure 4.12 panel 1C, D and 2C, D).   
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4.3.3.5 Confirmation of antigen specificity in HaCaTs expressing vMC084 by 
immunofluorescence 
To further establish antigen specificity we also infected human HaCaT keratinocytes 
with a vaccinia virus expressing full length mc084 (v319; aa 1 to 318) as shown in 
Figure 4.13. Infected keratinocytes were immune stained with the high titre serum HD 
V0901071 (Figure 4.13 A – 60x). Virus infected cells show a vesicular stain similar to 
an endosomal/lysosomal pattern. Infected keratinocytes were similarly immune stained 
with the low titre serum HD V0900040 and showed no reactivity (Figure 4.13 B – 60x). 
Uninfected cells (Figure 4.13 C – 60x) show no background signal, indicating the 
human polyclonal serum does not recognize keratinocyte antigens in cultured HaCaT 
cells. 
 
 
 
Figure 4.13. HaCaT Immunofluorescence. (A) HaCaT cell culture infected with 
recombinant vaccinia virus expressing MC084S (v319). Reactivity of high titre human 
serum HDV0901071 and secondary antibody Alexafluor 488 (Green) goat anti-human 
IgG (H+L). (B) HaCaT cell culture infected with recombinant vaccinia virus expressing 
MC084S (v319). Reactivity of low titre human serum HDV0900040 and secondary 
antibody Alexafluor 488 (Green) goat anti-human IgG (H+L). (C) Mock infected cells. 
Reactivity of high titre human serum HDV0901071 and secondary antibody Alexafluor 
488 (Green) goat anti-human IgG (H+L).  Nuclei are stained with DAPI (Hoechst) and 
shown in blue. Samples were analysed for fluorescence emission properties by using 
confocal scanning laser microscopy Leica TCS SP2 AOBS. 
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4.4 ELISA population studies 
4.4.1 German population studies 
Sera from 522 individuals aged 2 months to 101 years were collected at University 
Hospital Heidelberg, Germany, between 2007-2011.  The study has ethical approval for 
the use of German tissues and sera (Ethikvotum S-091/2011 Hautklinik Heidelberg). 
They were tested for the presence of anti-MC084S (aa123-230) antibodies (Figure 
4.14). Subjects are divided into groups on the basis of age: 0-1 years (n=66), 2-5 years 
(n=52), 6-10 years (n=47), 11-20 years (n=72), 21-40 years (n=52), 41-50 years 
(n=119), 51-60 years (n=62) and >60 years (n=52) (Figure 4.14A).  The reactivity in 
infants was significantly lower than in other groups. Based on the minimum cut-off 
value of δODU 0.36, 159 (30.5%) sera of the 522 sera from a representative healthy 
German population tested positive in the MC084S (123-230) ELISA. Positive antibody 
responses in the age groups were as follows: 4.5% (n=3) 0-1 year olds, 25% (n=13) in 
2-5 year olds, 23.4% (n=11) in 6-10 year olds, 12.5% (n=9) in 11-20 year olds, 13.5% 
(n=7) in 21-40 year olds, 51.26%  (n=61) in 41-50 year olds, 51.61%  (n=32) in 51-60 
year olds and 44.2% (n=23) in >60 year olds (Figure 4.14B and 4.14C). Results are 
tabulated in Table 4.2. 
 
Also based on the cut-off value of δODU 0.28, 199 (38.12%) sera of the 522 sera from a 
representative healthy German population tested positive in the MC084S (123-230) 
ELISA. Positive antibody responses in the age groups (Table 4.2) were as follows: 4.5% 
(n=3) 0-1 year olds, 36.5% (n=19) in 2-5year olds, 34% (n=16) in 6-10 year olds, 22.2% 
(n=16) in 11-20 year olds, 19.2% (n=10) in 21-40 year olds, 54.6%  (n=65) in 41-50 
year olds, 54.83%  (n=34) in 51-60 year olds and 69.23% (n=36) in >60 year olds 
(Figure 4.14D and 4.14E).  
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Figure 4.14.  Seroprevalence in a German population. Distribution of anti-MC084S 
antibodies in a German population tested by direct binding ELISA (A) Serological responses to 
MCV antigen MC084 in a German population (n=522; ages 0-101 years) expressed as the 
δODU value of an individual serum sample. The horizontal bar within each group represents 
the median absorbance measurement. (B) Serological responses to MCV antigen MC084 in a 
German population (n=522; ages 0-101 years) expressed as the δODU value of an individual 
serum sample after a cut-off of 0.36. The horizontal bar within each group represents the 
median absorbance measurement. (C) Percent seropositivities in different age groups after cut–
off of 0.36 (i) 0-1years (4.5%), (ii) 2-5 years (25%), (iii) 6-10 years (23.4%), 11-20 years 
(12.5%), 21-40 years (13.5%), 41-50 years (51.26 years), 51-60 years (51.61%) and  >60 years 
(44.2%). (D) Serological responses to MCV antigen MC084 in a German population (n=522; 
ages 0-101 years) expressed as the δODU value of an individual serum sample after a cut-off of 
0.28. The horizontal bar within each group represents the median absorbance measurement. (E) 
Percent seropositivities in different age groups after cut–off of 0.36 (i) 0-1years (4.5%), (ii) 2-5 
years (36.5%), (iii) 6-10 years (34%), 11-20 years (22.2%), 21-40 years (19.2%), 41-50 years 
(54.6%), 51-60 years (54.83%) and  >60 years (69.23%). 
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Table 4.2. Summary of seroprevalences in German and UK populations 
 
Age Group Total sera Cut-off= 
Mean+3*SD 
(0-1yr+outlier) 
0.36 
Cut-off= 
Mean+2*SD 
(0-1yr+outlier) 
0.28 
Positive Sera Positive Sera 
German Sera 
0-1 66 3 (4.5%) 3 (4.5%) 
2-5 52 13 (25%) 19 (36.5%) 
6-10 47 11 (23.4%) 16 (34)% 
11-20 72 9 (12.5%) 16 (22.2%) 
21-40 52 7 (13.5%) 10 (19.2%) 
41-50 119 61 (51.26%) 65 (54.6%) 
50-60 62 32 (51.61%) 34 (54.83%) 
>60 52 23 (44.2%) 36 (69.23%) 
 522 
Seropositivity in healthy subjects 
159 (30.45 %) 
Seropositivity in healthy 
subjects 
 199 (38.12%) 
Psoriasis 5 1 (20%) 1 (20%) 
SLE* 19 2 (10.5%) 4 (21.05%) 
Autoimm† 20 2 (10%) 2 (10%) 
UK Sera 
Healthy 
Controls 
50 12 (24%) 14 (28%) 
PPMS# 49 10 (20.4%) 13 (26.53%) 
RRMS╬ 50 6 (10%) 11 (22%) 
Total 149 28 (18.7%) 38 (25.5%) 
20-40 years 79 16 (20.2%) 21 (26.58%) 
>40 years 70 11 (15.71%) 16 (22.85%) 
Total 149 27 (18.1%) 37 (24.83%) 
 
Values reflect the prevalence of MCV seropositivity in members of a German and UK population 
comprising of different groups based on age and disease diagnosis. 
 
*
 SLE – Systemic Lupus Erythematosus 
†
 Autoimm. – General autoimmune conditions 
#
  PPMS – Primary progressive multiple sclerosis 
╬
 RRMS – Relapsing remitting multiple sclerosis 
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Analysis of data was also done after only considering sera from 289 individuals aged 2 
months to 40 years (median age 21 years) from the same sera collection tested for the 
presence of anti-MC084S (aa123-230) antibodies. The reactivity in infants was 
significantly lower than in other groups. Based on the minimum cut-off value of δODU 
0.36, 43 (14.87%) sera of the 289 sera from a representative healthy German population 
tested positive in the MC084S (123-230) ELISA.  
 
4.4.1.1 Statistical analysis using Anova in German population before cut-off: 
A one way anova was used for detection of variances and differences between the 
different groups divided on the basis of age (Figure 4.14A) (Table 4.3). From the Anova 
results for the German sera before cut-off the test statistic (F value) for anti-MC084S 
antibodies amongst the eight different groups divided on the basis of age differed 
significantly F (1.431, 0.086) = 16.676, p=0.000 (Table 4.4). Using the Tukey test for 
further post hoc analysis, it was possible to determine the most statistically relevant 
differences between age groups before a cut-off as shown in Appendix I. 
 
Table 4.3. One way Anova for German population before cut-off 
 
 
N Mean Std. Deviation 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
0 - 1 year 66 .131553 .1045174 .105859 .157247 
2 - 5 year 52 .299317 .3736997 .195279 .403356 
6 - 10 years 47 .278372 .3171693 .185248 .371497 
11 - 20 years 72 .206757 .1807952 .164272 .249242 
21 - 40 years 52 .218635 .1364325 .180652 .256618 
41 - 50 years 119 .482466 .3435129 .420108 .544825 
51 - 60 years 62 .498734 .3720875 .404241 .593226 
>61 years 52 .556632 .4199750 .354210 .759053 
Total 522 .332305 .3241976 .303499 .361111 
 
Table 4.4. Anova analysis of German titres before cut-off. 
 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 10.017 7 1.431 16.676 .000 
Within Groups 41.274 481 .086   
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 Sum of Squares Df Mean Square F Sig. 
Between Groups 10.017 7 1.431 16.676 .000 
Within Groups 41.274 481 .086   
Total 51.291 488    
 
4.4.1.2  Statistical analysis using Anova in German population after cut-off 0.36 
After cut-off the mean difference for the 0-1 year age group was 0.80 with 95% 
confidence interval of 0.10-0.80 (Figure 4.14C) (Table 4.5). The mean difference for the 
2-5 year age group was 0.30 with 95% confidence interval of 0.50-1.10. The mean 
difference for the 6-10 year age group was 0.70  with 95% confidence interval of 0.40 -
1.000. The mean difference for the 11-20 year age group was 0.60 with 95% confidence 
interval of 0.50-0.70. The mean difference for the 21-40 year age group was 0.50 with 
95% confidence interval of 0.40-0.60. The mean difference for the 41-50 year age group 
was 0.80 with 95% confidence interval of 0.72-0.831. The mean difference for the 51-
60 year age group was 0.821 with 95% confidence interval of 0.743 -0.90. Finally, the 
mean difference for the group comprising of >61 year olds was 0.834 with 95% 
confidence interval of 0.711-0.80 (Table 4.5).  
  
A one way anova was used for detection of variances and differences between the 
different groups divided on the basis of age stratification. After a cut-off of 0.36, the 
variance or mean square deviation between groups was 0.212 whereas the variance 
within groups was 0.072. The test statistic (F value) was 2.950 and the significance was 
found to be is 0.006 (Table 4.6). Further post hoc analysis was done using Tukey test to 
identify and measure statistically significant difference between groups of data as pairs 
shown in Appendix 3.  
 
In conclusion the one way anova for the detection of variances and differences between 
the different groups of a German population divided on the basis of age and a cut-off 
value of 0.36 yielded a test statistic (F value) for anti-MC084S antibodies amongst the 
eight different groups as F (2.950), p=0.006 which was a significant result but less than 
that calculated before cut-off.  
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Table 4.5. One way Anova for German population after cut-off 0.36  
 
 
N Mean Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
0 - 1 year 3 .446833 .1417395 .094733 .798934 
2 - 5 year 13 .774962 .4873230 .480475 1.069448 
6 - 10 years 11 .670000 .4680104 .355586 .984414 
11 - 20 years 9 .565222 .1447487 .453958 .676486 
21 - 40 years 7 .493000 .1154913 .386188 .599812 
41 - 50 years 61 .774779 .2225712 .717776 .831782 
51 - 60 years 32 .821469 .2163133 .743479 .899458 
>61 years 23 .834678 .2249314 .737411 .931946 
      
Total 159 .755152 .2795715 .711361 .798942 
 
Table 4.6.  Anova analysis of German titres after cut-off 0.36 
 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1.485 7 .212 2.950 .006 
Within Groups 10.864 151 .072   
Total 12.349 158    
 
4.4.1.3 Statistical analysis using Anova in German population after cut-off 0.28: 
A one way anova was used for detection of variances and differences between the 
different groups divided on the basis of age stratification (Table 4.7). After a cut-off of 
0.28 (Figure 4.14D), the variance or mean square deviation between groups was 0.333 
whereas the variance within groups was 0.084. The test statistic (F value) was 3.973 and 
the significance was found to be is 0.000 (Table 4.8). Further post hoc analysis was 
done using Tukey test to identify and measure statistically significant difference 
between groups of data as pairs (Appendix 2). 
 
Similarly when a one way anova was used for detection of variances and differences 
between the different groups in a German population divided on the basis of age and 
with a cut-off of 0.28, the test statistic (F value) for anti-MC084S antibodies amongst 
the eight different groups was found to be highly significant F (3.973), p=0.000. This 
significance was found to be more than that obtained using a cut-off of 0.36. 
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Table 4.7.One way Anova for German population after cut-off 0.28  
 
N Mean Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
0 - 1 year 3 .446833 .1417395 .094733 .798934 
2 - 5 year 19 .630447 .4541187 .411569 .849326 
6 - 10 years 16 .556406 .4200983 .332552 .780261 
11 - 20 years 16 .483750 .1850200 .385160 .582340 
21 - 40 years 10 .448050 .1189933 .362927 .533173 
41 - 50 years 65 .746854 .2419522 .686901 .806807 
51 - 60 years 34 .791294 .2428502 .706560 .876029 
>61 years 36 .650778 .3058595 .547290 .754266 
Total 199 .669947 .3043301 .627404 .712490 
 
Table 4.8. Anova analysis of German titres at cut-off 0.28 
 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2.331 7 .333 3.973 .000 
Within Groups 16.007 191 .084   
Total 18.338 198    
 
The findings summarized in Table 4.2, include alternative results based on different cut-
off calculations. Our main reference is a cut-off calculated as three standard deviations 
of an average from postnatal screening of 0 to 1 year old German newborns and babies. 
In this group three outliers were observed. As it was not possible to determine the MCV 
status of these subjects (aged 2 months, 9 months and 11months) they could not be 
excluded. The calculation of cut-off as Mean + 2×SD or Mean + 3×SD has a significant 
effect on the cut-off values which are 0.28 or 0.36 respectively. 0.36 has been taken as 
the most accurate cut-off for data analysis. 
 
4.4.2 German patient population 
Sera samples from 44 German patients with dermatological conditions such as such as 
Systemic lupus erythematosus (n=19), Psoriasis (n=5) and general autoimmune 
conditions (n=20) including patients with Autoimmune haemolytic anaemia, 
Autoimmune cerebilitis and Autoimmune hepatitis were collected at University 
Hospital Heidelberg, Germany, between 2007-2011 from frozen ‘patient sera’ on the 
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basis of clinical examinations and tested for the presence of anti-MC084S (aa123-230) 
antibodies (Figure 4.15).  
 
The sera were divided into groups on the basis of diagnosis as: Psoriasis (n=5), 
Systemic lupus erythematosus (SLE) (n=19) and Autoimmune conditions (n=20) 
(Figure 14.15). Based on the minimum cut-off value of δODU 0.36, positive antibody 
responses in MC084S (123-230) ELISA were as follows; 20% (n=1) in patients with 
Psoriasis, 10.5% (n=2) in patients with SLE and 10% (n=2) in patients with various 
autoimmune conditions, with an overall seroprevalence of 11.36% (Table 4.2). In 
addition, using a cut-off value of δODU 0.28, seroprevalences in the same patient 
groups were found to be 20% (n=1) in patients with Psoriasis, 21.05% (n=4) in patients 
with SLE and 10% (n=2) in patients with various autoimmune conditions with an 
overall seroprevalence of 16% (Table 4.2).  
 
 
Figure 4.15. Serorectivity amongst different patient groups. (A) Patients with Systemic lupus 
erythematosus (n=19), (B) Patients with Psoriasis (n=5) and (C) Patients with General 
autoimmune conditions including Autoimmune haemolytic anaemia, Autoimmune cerebilitis and 
Autoimmune hepatitis (n=20). 
 
Thus the patients with Psoriasis and SLE had similar rates of MC antibody 
seroprevalence whereas patients suffering from autoimmune diseases had a 
seroprevalence rate which was half of the above rates. MCV seroprevalence is above 
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the average rate in skin specific autoimmune conditions, but similar in general 
autoimmune conditions. 
 
4.4.3 UK population studies 
4.4.3.1 UK population studies on basis of disease 
Sera samples (n=149) from a UK population (aged 21-69 years) which had been 
collected as part of a study on Multiple sclerosis (MS) at Cardiff University entitled 'An 
Epidemiological study of Multiple sclerosis and other neuroinflammatory 
demyelinating disorders in South Wales', 05/WSE03/111 were also analysed. These 
subjects were grouped as Primary progressive multiple sclerosis (n=49), relapsing 
remitting multiple sclerosis (n=50) and healthy human/controls (n=50) (Figure 14.6A). 
Using the same calculated cut-off of δODU 0.36, the overall UK seroprevalence was 
found to be 18.7% and MCV antibodies were detected in 12 of 50 UK sera samples 
(24%) from healthy individuals. In patients with Primary progressive multiple sclerosis 
seroprevalence was 20.4% (n=10/49), as compared to 10% (n=6/50) in patients with 
relapsing remitting multiple sclerosis (Figure 14.6B and 14.6C). Using the calculated 
cut-off of δODU 0.28, the overall UK seroprevalence was found to be 25.5% and MCV 
antibodies were detected in 14 of 50 UK sera samples (28%) from healthy individuals. 
In patients with Primary progressive multiple sclerosis seroprevalence was 26.53% 
(n=113/49), as compared to 22% (n=11/50) in patients with relapsing remitting multiple 
sclerosis (Figure 14.6D and 14.6E).  
 
Before establishing a cut-off the mean difference for the PPMS group was 0.3 with 95% 
confidence interval of 0.10-0.80. The mean difference for the age group comprising of 
2-5 year olds was 0.30 with 95% confidence interval of 0.10-0.422. The mean 
difference for the RRMS age group was also 0.30 with 95% confidence interval of 0.20-
0.40. The mean difference for the healthy controls group was 0.414 with 95% 
confidence interval of 0.30-0.60. A one way anova was used for detection of variances 
and differences between the different groups divided on the basis of disease or lack of 
it.  
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As tabulated in the Table given in Appendix 7 for the statistical analysis of UK 
population before cut-off usingAnova, the test statistic (F value) for anti-MC084S 
antibodies amongst the eight different groups divided on the basis of age differed as F 
(0.197, .112) = 1.756, p=0.180. Further post-hoc analysis was done using ‘Tukey’ test 
to identify and measure statistically significant difference between pairs of data. From 
the multiple comparisons table (Appendix 7) the following conclusions can be drawn: 
Between groups PPMS and RRMS, the observed mean difference was -0.033 with 95% 
confidence interval of (-0.330-0.30) with a p value =0.963. Similarly between the 
groups PPMS and healthy controls, the observed mean difference was -0.20 with 95% 
confidence interval of (-0.50- 0.133) with a p value =0.381. Between groups RRMS and 
PPMS, the observed mean difference was 0.033 with 95% confidence interval of (-0.30- 
0.330) and a p value =0.963. Similarly between groups RRMS and healthy controls the 
observed mean difference was -0.14 with 95% confidence interval of (-0.33- 0.1) with a 
p value =0.216. Finally, between the groups healthy controls and PPMS, the observed 
mean difference was 0.20 with 95% confidence interval of (-0.133- 0.50) with a p value 
=0.381. Whereas, between the groups healthy controls and RRMS, the observed mean 
difference was 0.14 with 95% confidence interval of (-0.1- 0.33) with a p value =0.216. 
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Figure 4.16. Seroprevalence in UK population classified on the basis of disease. 
Distribution of anti-MC084S antibodies in a UK population tested by direct binding ELISA. (A) 
Serological responses to MCV antigen MC084S (V123-R230)  in UK population (n=149) 
expressed as the δODU value of an individual serum sample in different groups before cut-off 
(i) Primary progressive multiple sclerosis (PPMS; n=49), (ii) Relapsing remitting multiple 
sclerosis (RRMS; n=50) and (iii) Healthy humans  (n=50). The horizontal bar within each 
group represents the median absorbance measurement. (B) Serological responses to MCV 
antigen MC084S (V123-R230) in UK population (n=149) expressed as the δODU value of an 
individual serum sample in different groups after cut-off 0.36 (i) Primary progressive multiple 
sclerosis (PPMS; n=10), (ii) Relapsing remitting multiple sclerosis (RRMS; n=6) and (iii) 
Healthy humans  (n=12). (C) Percent positivity in individual groups for MC084S after cut-off 
0.36 (i) PPMS (20.4%), (ii) RRMS (10%) and (iii) Healthy humans (24%). (D) Serological 
responses to MCV antigen MC084S (V123-R230) in UK population (n=149) expressed as the 
δODU value of an individual serum sample in different groups after cut-off 0.28 (i) Primary 
progressive multiple sclerosis (PPMS; n=13), (ii) Relapsing remitting multiple sclerosis 
(RRMS; n=11) and (iii) Healthy humans (n=14). (C) Percent positivity in individual groups for 
MC084S after cut-off 0.28 (i) PPMS (28%), (ii) RRMS (26.53%) and (iii) Healthy humans 
(28%). 
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4.4.3.2 UK population studies on basis of age 
The 149 sera samples were also redistributed into two groups based on age i.e. 20-40 
years (n=78) and ≥41 years (n=70) (Figure 14.7A). Using the cut-off of 0.36, anti-
MC084S antibodies were detected in 20.2% (16/79) of UK sera samples from 
individuals aged 20-40 years and 15.71% (n=11/70) of UK sera samples from 
individuals aged >41 years (Figure 14.7B and 14.7C). Using a cut-off of 0.28 the 
seroprevalnce was found to be 26.58% (n=21/79) and 22.85% (n=16/70) respectively 
(Figure 14.7D and 14.7E). Since these are only two groups an independent t-test was 
performed for the two samples with unequal variance. The computed test statistic or t 
value = 2.1076 at 147 degrees of freedom, p value = 0.03 which is less than level of 
significance of 0.05. Hence a statistically significant difference exists in the age groups 
20 – 40 years and ≥ 41 years of age group.  After a cut-off of 0.36 the T value = 4.069 at 
24 degrees of freedom and p value = 0.0004. Similarly for the UK population at cut off 
0.28 the T value = 3.03 at 34 degrees of freedom and p value = 0.004 (Appendix 8). 
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Figure 4.17.  Seroprevalence in UK population grouped on the basis of age. Distribution of 
anti-MC084S antibodies in a UK population tested by direct binding ELISA. (A) Serological 
responses to MCV antigen MC084S (V123-R230)  in UK population (n=149) expressed as the 
δODU value of an individual serum sample in different groups classified on the basis of age 
before cut-off (i) 20-40 years (n=79) and (ii) >40 years (n=70). The horizontal bar within each 
group represents the median absorbance measurement. (B) Serological responses to MCV 
antigen MC084S (V123-R230) in UK population (n=149) expressed as the δODU value of an 
individual serum sample in different age groups after cut-off 0.36 (i) 20-40 years (n=16) and 
(ii) >40 years (n=11). (C) Percent positivity in individual age groups for MC084S after cut-off 
of 0.36 (i) 20-40 years (20.2%), (ii) >40 years (15.7%). (D) Serological responses to MCV 
antigen MC084S (V123-R230) in UK population (n=149) expressed as the δODU value of an 
individual serum sample in different age groups after cut-off 0.28 (i) 20-40 years (n=21) and 
(ii) >40 years (n=16).(E) Percent positivity in individual age groups for MC084S after cut-off 
of 0.28 (i) 20-40 years (20.6%), (ii) >40 years (23%). 
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4.5 Neutralising antibodies in sera samples 
4.5.1 Detection of neutralising antibodies in different sera samples using reporter 
assay 
Using the neutralisation assay developed by us in 96 well format, that uses poxviral 
reporter system v3, we conducted a preliminary study evaluating the neutralizing 
antibody (NAb) activity 24 hours post infection of HeLa cells, as a function of reduction 
of luminescent signal and hence transgene expression inhibition, in the presence of 
specific anti-MC antibodies in the sera samples tested in our MC084S (V123-230) 
ELISA (Table 4.9). 
Table .4.9. Sera samples used in neutralisation assays. 
S. No. Serum sample ID Serum type Age (years) Sex 
1.  HDV0905794 High titre 5 F 
2.  HDV0901772 High titre 5 F 
3.  HDV0905796 High titre 2 M 
4.  HDV0903090 High titre  2 M 
5.  HD V0903005 High titre 6 F 
6. HD V0905374 High titre 1 M 
7.  HD V0904696 High titre 4 M 
8.  HDV0901071 High titre 7 M 
9.  HD AZ003970 High titre 47 F 
10. HD AZ003735 High titre 56 M 
11. HD AZ005203 High titre 51 M 
12. HD AZ004482 High titre 47 F 
13. HD AZ005347 High titre 56 M 
14. HD AZ003746 High titre 48 F 
15. HD AZ003749 High titre 45 F 
17. HD V0900040 Low titre 1 M 
18. HD V0900471 Low titre 16 M 
19. HD V0901798 Low titre 1 F 
20. HD V0900223 Low titre 2 M 
21. HD AZ005860 Low titre 50 M 
22. HD AZ005914 Low titre 47 F 
23. HD AZ006064 Low titre 45 M 
24. HD AZ007182 Low titre 57 M 
25.  HD AZ007363 Low titre 51 F 
C1 CF2012-1 MCV positive 27 M 
C2 VV8191 Anti-vaccinia Rabbit serum   
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High titre sera samples from  individuals aged <30 years showed little to no inhibition 
and neutralising antibody responses at sera dilutions varying from 1:3 to 1:9 (Figure 
14.18A). High titre sera samples from individuals aged >30 years showed neutalising 
antibody responses at sera dilutions varying from 1:3 to 1:243 (Figure 14.18B) with sera 
numbers 11, 14 and 15 showing reporter inhibition (Figure 14.18B). Low titre sera 
samples fromindividuals aged <30 years showed neglegible inhibition with measurable 
neutalising antibody responses at sera dilutions of 1:3 (Figure 14.18C). Finally, low titre 
sera samples from individuals aged >30 years showed neutalising antibody responses at 
sera dilutions varying from 1:3 to 1:81 with reporter onserved in sera numbers 22-24 
(Figure 14.18D). On comparing the neutralisation titres of sera in the reporter assay it 
was found that a low prevalence of neutralising antibodies with no reporter inhibition 
was observed in the groups consisting of individuals <30 years of age ranging from a 
dilution of 1:3 to a maximum of 1:9 which may be considered non-specific 
 
However, in the groups consisting of individuals >30 years of age, a high reporter 
inhibition is observed due to neutralising antibodies, ranging from a low dilution of 1:3 
(considered non-specific) to a maximum of 1:243. This group consists of individuals 
who would have definitely received the smallpox vaccine and may therefore exhibit a 
basal titre of VACV specific antibodies as is exhibited by sera samples 11, 14 and 15. 
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Figure 4.18. Neutralising antibodies as determined by reporter assay. Neutralising antibody 
titres determined as luminescence using reporter assay for high and low titre sera samples 
differentiated on the basis of age. (A) High titre sera samples (1-8 and C1) from individuals 
<30 years of age. (B) High titre sera samples (9-15) from individuals 30 years of age. (C) Low 
titre sera samples (16-20) from individuals <30 years of age. (D) Low titre sera samples (21-
25) and C2 from individuals >30 years of age. Each value is the arithmetic mean of three 
independent assays. 
 
4.5.2 Detection of neutralising antibodies in different sera samples using plaque 
reduction neutralisation tests 
Plaque reduction neutralisation assays were conducted for all of the above mentioned 
sera samples to obtain MCV neutralising antibody titres required for replication 
inhibition.Plaque reduction was assessed three days post infection. Figure 14.19 shows 
the results from the PRNT using ELISA defined low and high titre sera samples. Wells 
from the plaque reduction neutralisation test corresponding to neutralising serum titre in 
reporter assay displayed by the bars in histogram (Figure 14.19). Maximum virus 
infection was observed in control wells without serum and the anti-vaccinia rabbit 
polyclonal was included as a positive control. Comparison of the NAb titres between 
the high titre and sera samples from individuals aged <30 years show that sera samples 
3,4,5,7 and 8 show low levels of neutralising Abs at a dilution of 1:3 whereas sera 
samples 1,2 and 6 show slightly higher Nab levels at a dilution of 1:9. Compared to the 
previous group, NAb levels in the group consisting of high titre sera samples from 
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individuals aged >30 years are slightly elevated, with sera samples 9-13 showing 
antibodies in a dilution range of 1:27 and samples 14-15 showing Nabs in a dilution 
range of 1:81. Results with low titre sera samples as determined by recombinant MC084 
ELISA were also analysed after division on the basis of age. For the sera samples from 
individuals aged <30 years it was found that samples 16, 17, 19 and 21 showed 
detectable levels of neutralising antibodies in wells with serum dilutions of 1:3. No 
neutralising activity was evident in samples 18 and 19 with plaque formation even at the 
lowest dilution levels. In the group consisting of samples from individuals aged >30 
years the neutralising antibody activity was evident for samples 22-24 in a dilution of 
1:3 and at a higher dilution of 1:9 in sera sample 25.  
 
 
Figure 4.19. PRNT-Neutralising antibody titres. NAb titres(A) determined using plaque 
reduction neutralisation test three days post infection for high and low titre sera samples 
differentiated on the basis of age as high titre sera samples (1-8) and <30 years of age, high 
titre sera samples (9-15) and individuals >30 years of age, low titre sera samples (16-20) and 
<30 years of age, low titre sera samples (21-25) and >30 years of age and controls C1 and C2. 
Each value is the arithmetic mean of three independent assays. 
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Discussion 
We describe here for the first time a seroepidemiological study of MCV in Europe, the 
largest survey reported so far (n=715) and the first MCV ELISA based on viral antigen 
expressed in E. coli.   
 
The selection of antigen was both based on a previous study by Watanabe et al. and 
independent analysis of the amino acid sequences of candidate MCV proteins. 
Watanabe had previously identified MC084 and MC133 as two major antigenic virion 
particle proteins of MCV (Watanabe et al., 1998).They offered no data for their 
decision to establish an ELISA on mc133 antigen, other than that it performed better 
than mc084 in their assays.  
 
Previously reported MCV ELISAs used antigen from human lesion material (Konya and 
Thompson, 1999) or Sendai virus (Watanabe et al., 1998) expressed full length MC133, 
raising issues with background skin antigens and posttranslational antigen processing. 
To improve water solubility and provide an expression platform more suitable for 
commercial production of a MCV ELISA we decided to compare antigen prepared from 
truncated MC084 and MC133 and expressed in E. coli.  
 
On the basis of previous work by Watanabe et al. and our own homology analyses we 
chose a C-terminal truncation of MC084 (V123-R230), upstream of A238-Q298 
previously found non-reactive in ELISA by Watanabe, as our candidate ELISA 
(Watanabe et al,. 2000) antigen. Our choice of antigen minimizes the possibility of 
cross reactivity with vaccinia virus specific antibodies, exclude the membrane spanning 
domains of mc084, but include a possible major antigenic site, identified by 
hydrophilicity plotting (MC084 N218-R230).  
 
Using a C-terminal truncation of MCV ORF mc084 as an antigen, we were able to 
establish an ELISA both sensitive (100%, n=12) and specific, with low inter- and intra-
assay variability.This is in comparison to the lower sensitivities of 77% and 58%, in the 
ELISAs reported by Konya et al. (Konya and Thompson, 1999) and Watanabe 
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(Watanabe et al., 2000), respectively. Our experiments determining specificity in MCV 
tissue sections also compare well to data shown in Konya et al. (Konya and Thompson, 
1999), while Watanabe only showed specificity in an immunoblot using recombinant 
protein (Watanabe et al., 2000). 
 
Our homology studies indicate that both mc084 and mc133 share amino acid 
homologies with vaccinia virus proteins H3L and A27L. We studied truncated versions 
of the proteins, N-and C-terminal halves separately, and found that homologies vary 
between 27% - 30% amino acid identities, with the C-terminal part of mc084 sharing 
the lowest homology with vaccinia H3L of 27% amino acid identity. We consequently 
chose MC084 (aa123-230) as our candidate ELISA antigen to minimize possible cross 
reactivity with vaccinia virus specific antibodies. Interestingly, Watanabe had tested a 
peptide (aa238-298) further downstream of the C-terminal of our truncation, well into 
the transmembrane domain (TMHH prediction), which showed no reactivity with 
human sera at all.  
 
The C-terminal truncation of mc084 chosen by us (aa123-230) exclude the membrane 
spanning domains of mc084, but include a possible major antigenic site, identified by 
hydrophilicity plotting (Kyte–Doolittle): NELRGREYGASLR (mc084 amino acids 
218-230). 
 
Also, while Watanabe chose mc133 expressed using a Sendai virus expression system 
in hen eggs using the infected allantoic fluid (Watanabe et al., 2000), we decided to 
express mc084 and mc133 protein truncation excluding membrane spanning domains in 
E. coli to provide an expression platform more suitable for commercial production of a 
MCV ELISA. 
 
 
Both N- and C-truncations of mc084 and the N-terminal truncation of mc133 were 
expressed as fusion proteins with GST and purified using a glutathione sepharose beads. 
All truncations tested were water soluble. On the relative merits of mc084 and mc133 as 
suitable antigens for detection of MCV antibodies, we made a direct comparison, using 
a high titre serum from a patient with active MCV infection. In this assay the mc084 C-
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terminus performed slightly but not significantly better than mc084 N-terminus and was 
similar to mc133. 
 
The C-terminal MC084S (aa123-230) truncation without GST was further purified 
using FPLC on a Sephadex 200 column, resulting in a sufficiently pure protein for 
ELISA studies. The antigen load for plating was optimized and in vitro specificity 
shown in an inhibitor titration assay. A strep tag was used for detection of recombinant 
antigen in western blots. The tag did not interfere with ELISA results in a serum study 
of 149 serum samples.  
 
A stringent cut-off was determined as mean ODU plus three standard deviations, using 
a serum sample collection of Heidelberg university clinics neonates up to 1 year of age, 
assuming a minimal exposure to MCV in this age group. We have specifically looked at 
sera from newborns and babies from 0-1 years after birth, where under hygienic 
conditions, the exposure and incidence to MC should be the lowest. Surprisingly despite 
this, serum samples from a 2 month, a 7 month and a 9 month old subject showed 
significant reactivity in ELISA, indicating a possible exposure and active infections. 
This would be considered rare. However a study has reported a case of vertically 
transmitted molluscum contagiosum viral infection in which the maternal infection was 
clinically documented before vaginal delivery (Luke and Silverberg, 2010). Also a 
clinical case of a female patient with DOCK8 deficiency presenting extensive clinical 
MC from birth and eventually dying in her early teens was evidenced by Dr. Bugert. 
Also the greatest likelihood of infection with MC in babies is from transmission from 
immediate family members. However a confirmation of diagnosed clinical Molluscum 
contagiosum in these three cases could not be made as this was a study with an 
anonymised sera collection for which no clinical data was available apart from age and 
sex. For the purposes of the cut-off calculations we have presented cut-offs calculated 
with and without these outlying sera results. The respective cut-offs of 0.36 and 0.28, 
result in a significant difference of overall seroprevalence of 30.45 to 38.12 percent in 
the German population or 18.7 to 25.5% in the UK population. 
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In direct antigen comparison there was no significant difference between truncations of 
mc084 and mc133 and no serum showed prevalent reactivity against one or another of 
the antigen used. Also the difference in reactivity between the MC084S (aa123-230) or 
MC084S-GST with sera samples was negligible. A strep tag was used for detection of 
recombinant antigen in western blots. The tag did not interfere with ELISA results as 
established by our strep interference assay confirming no cross-reactivity between 
MC084S (aa123-230) specific serum antibodies and strep tag.  
 
To determine sensitivity of our ELISA, we were able to collect 12 sera from patients 
with ongoing clinical MCV. All sera showed significant reactivity in comparison to a 
control group of healthy individuals. The serum with the highest absorbance value was 
collected form a British patient (CF2012-1) with acute molluscum contagiosum and 
frozen immediately with little handling. This was higher than the Watanabe study, 
where only 7 of 12 young children with clinical MC showed substantial reactivity in the 
mc133 ELISA, indicating that their ELISA may be underestimating the true 
seroprevalnce (Watanabe et al., 2000).
 
 
The same serum (CF2012-1) was used to determine specificity of MC antibodies using 
MCV infected human skin tissue samples. This and a series of other high titre sera 
reacted positively with the expected tissue distribution in clinical lesions: stratum 
spinosum up to egress in debrisomes. There was a significant difference between high 
and low titre sera in tissue reactivity. With the ELISA thus validated as highly sensitive 
and specific we proceeded to look at larger population to determine seroprevalnece. We 
also infected human HaCaT keratinocytes with a vaccinia virus expressing full length 
mc084 (v319). Infected keratinocytes were immune stained with the same high titre 
serum HDV0901071. Virus infected cells show a vesicular stain similar to an 
endosomal/lysosomal pattern. Uninfected cells show no background signal, indicating 
the human polyclonal does not recognize keratinocyte antigens in cultured HaCaT cells.  
 
Antibody cross reactivity between MCV and VACV was never reported and is in fact 
not observed as documented in publications on MCV serology (Agromayor et al.,2002). 
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Also amino acid homology studies do not indicate a potential for cross reactivity using 
C-terminal mc084, as mentioned before. 
 
Information on the epidemiology of zoonotic poxviruses especially those belonging to 
the genera OPV is still too poor to enable us to clearly understand and estimate the 
chances of zoonoses in humans. A recent review sheds light on aspects of the host range 
of some poxviruses being broader than initially thought (Essbauer et al., 2010). 
Presently the two most studied OPV infections responsible for zoonoses are monkeypox 
virus and cowpoxvirus (CPXV).  
 
Of these monkeypox infection is rare with no case reports outside of Africa and 
America. Cowpoxvirus is the most likely natural source of zoonoses amongst European 
populations with cats being the main mode of transmission. The literature points to 
more than 400 cases of CPXV infections described for domestic cats (Essbauer et al., 
2010; Bennett et al., 1986; Bennett et al.1989; Hinrichs et al., 1999; Brown et al., 1989; 
Baxby, 1994; Pfeffer et al., 2002), but it is estimated that many infections are not 
recognized by veterinarians and/or owners. The real incidence of CPXV in cats may be 
reflected by serological data. One study gives a variation of 0 up to 16% in cats with 
antibodies against CPXV (OPV, respectively) reported from England, Norway, Austria, 
Germany and Finland (Juncker-Voss et al., 2004). The variation is seasonal, with an 
accumulation of CPXV infections in late summer and autumn (Bennett et al., 1986; 
Pfeffer et al., 2002). Cats as predators are exposed to CPXV while hunting rodents 
which serve as a reservoir for CPXV (Pfeffer et al., 2002).  
 
Human CPXV cases are mainly caused by direct contact to ‘cuddly’ cats (Baxby, 1994). 
It is suspected that the cowpox virus infections in humans maybe more common than 
thought due to the lack of an adequate immune status of the population because of the 
abrogated but cross-protective smallpox vaccination in the 1980s (Essbauer et al., 
2010). However currently there is a lack of published data giving true incidence and 
serology in human populations rather than most studies which are reports of cases in 
isolated populations.  Hence it would be difficult to estimate the contribution of 
neutralizing antibodies in our study due to zoonotic poxviral infections. 
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Looking at an age stratified grouping of 522 sera from healthy German individuals, we 
observed lowest δODU in the youngest age group, increasing to the highest mean in 1-5 
year olds, then falling to lower values in higher age groups of 20-40 year olds. This is 
perfectly reflected in the literature with respect to these various age groups. It is also in 
agreement with data published by Konya and Thompson, using a virion particle ELISA, 
the lowest mean δODU in their youngest subjects (˂6 years), where they consider it to 
be representative of maternally acquired antibodies (Konya and Thompson, 1999). 
Another study from the Netherlands found that the childhood from of MC was common, 
with a cumulative incidence of 17% by age 15 (Koning et al., 1994). However after cut-
off of 0.36 the seroprevalences in the age groups of 41-50 years and over are 
significantly higher; with rates in the 41-50 years and 50 to 60 years strictly comparable 
(51.26% and 51.61% respectively) and then showing a slight decrease in >60 year olds 
(44.2%). These results may also be somewhat affected by sera numbers within each 
individual group however it would not have been possible to increase or reduce sera 
samples tested without creating bias in the final result. The study by Konya and 
Thompson also reported an increase in seropositivity rate with age to a final high rate of 
39% in those ≥50 years old.  
 
From the statistical analysis using Anova,  results for the German sera before cut-off, 
the test statistic (F value) for anti-MC084S antibodies amongst the eight different 
groups divided on the basis of age differed significantly F (1.431, .086) = 16.676, 
p=0.000. However from the statistical analysis using Anova calculations for the German 
sera after cut-off 0.36,  the test statistic (F value) for anti-MC084S antibodies amongst 
the eight different groups divided on the basis of age, differed statistically as F (0.212, 
0.072) = 2.950, p=0.006. The F values in both cases were significant. The Tukey test 
was used for further post hoc analysis before and after cut-off was established 
(Appendix) however the statistical significances between groups before cut-off are 
much greater than after cut-off. These differences may be attributed to difference in 
group sizes.  
 
In a serum collection from a UK MS study, the sera from healthy individuals revealed a 
lower overall seroprevalence of 18.7%, as compared to 30.45% in the German 
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population using the cut-off calculated with outliers.  This may be explained by the fact 
that the UK sera collection (n=149) consisted largely of patients with multiple sclerosis 
(n=99) who may exhibit altered antibody profiles due to disease. 
 
For the UK population divided on the basis of disease, post-hoc analysis done by using 
Tukey test, found no statistically significant differences between Healthy controls, 
PPMS and RRMS before or after cut-off calculations. After redistribution of the UK 
data set on the basis of age and performing an independent t-test with unequal variance 
a p value was calculated as 0.03 which is less than level of significance of 0.05. Hence a 
statistically significant difference exists in the titres in the age groups 20-40 years and 
≥41 years of age group.  After a cut-off of 0.36 the p value was found to be highly 
significant as 0 .0004. Similarly after a cut off of 0.28 the calculated p value = 0.004 
was highly significant. 
 
This is the largest seroprevalences study conducted in European populations. The 
findings of our serological survey are higher than those reported for an 
immunofluorescence study of MCV antibodies in Northern Ireland and two previous 
ELISA studies in Australia and Japan even though different antigen and expression 
systems were used (Shirodaria et al., 1979; Konya and Thompson, 1999; Watanabe et 
al., 2000). Importantly, considering the MC seroprevalence of 14.8% in 0-40 year olds 
in our German population is a threefold increase over the reported incidence of MC in a 
comparable Swiss population of 4.9% (Wenk and Itin, 2003) supporting the notion, that 
MC is a underreported infection.  
 
We find an overall seropositivity in a general German population of 30.45%, depending 
on cut-off 0.36 and 18.7%  in the UK as compared to 16.7% in Ireland (n=30; IgG 
responses) (Mitchell, 1953),  23% in an Australian population (Konya and Thompson, 
1999) and 6% in a Japanese survey (Watanabe et al., 2000). Whereas the German 
seroprevalence is higher than previously published seroprevalences, the UK 
seroprevalence is and slightly lower than the Australian seroprevalences. The calculated 
seroprevalence of anti-MC084S (123-230) antibodies in 0-40 year olds in the German 
population is found to be much lower i.e. 14.8% with a cut-off of 0.36. However with 
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the same stringent cut-off, the overall German seroprevalence rate was calculated to be 
higher, because of the clear trend of higher antibody titres in a large group of people in 
the age groups consisting of >40 years; a population which has definitely received the 
smallpox vaccine and is most likely to exhibit some neutralising antibody titres as 
previously published (Liu et al., 2012).  
 
The age profile determined using the MC084 ELISA correspond well with our 
understanding of the natural history of MCV infections, with low exposure of very 
young children and a high prevalence among toddlers and kindergarten aged children, 
where MCV smear infections is most likely to be transmitted among larger numbers of 
children. Our data confirm previously reported findings of stronger antibody responses, 
mostly in the 2-10 age group, with waning immunity as the population reaches 
adulthood. This would suggest very little reexposures boosting immunity up to 40 year 
of age.  
 
An MC incidence study based on outpatient visits in American Indian and Alaska 
Native populations also notes a relatively high incidence amongst 1-4 year olds 
(Reynolds et al., 2009). Other studies measuring age-related health care utilization for 
MC also suggest that the overall numbers of MC associated visits were highest among 
2-5 year olds (Molino et al., 2004; Dohil et al., 2006). A Swiss study (Wenk and Itin, 
2003) also found high prevalence of MC in pre-school children (6.9%) and school 
children (10.6%). Increased utilization of childcare leading to a lowering in age of 
socialization outside the immediate household may be contributory factors this 
increased MC incidence in pre-school children.  
 
In contrast to Konya et al. (Konya and Thompson, 1999), who report a very high 
seropositivity rate in their 0-6 year old population of 31%, explaining this with maternal 
antibodies, our data do not indicate a high seropositivity rate in very young children. 
Seroprevalence with the mc084 (V123-R230)  ELISA is below 5% in 0-1 year olds and 
only increases in the age group of 2-5 year olds, not exceeding 25%.   
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Watanabe et al. explained their low overall seropositivity (n=108, 6%) in healthy 
subjects (Watanabe et al., 2000) in comparison to the prior Australian study (n=357; 
23%) (Konya and Thompson, 1999)with their mc133 ELISA failing to pick up sera with 
mc084 antibodies as shown in immunoblots, indicating that mc133 may not be the best 
choice of antigen underestimating seroprevalence.  
 
The objective of this study was to develop a convenient and specific ELISA based on 
recombinant viral antigen by expression of selected molluscum contagiosum open 
reading frame in E. coli as a strep tagged protein. The virion surface protein, with 
serodiagnostic utility was identified, expressed and incorporated into an ELISA that 
offers the prospect of examination of seroprevalence of antibodies against MCV in 
subjects with and without clinical Molluscum contagiosum infection. 
 
This solves the problem of finding sufficient MC antigen for ELISAs as established by 
Konya et al., and circumvents the problem of standardization in eukaryotic expression 
systems as established by Watanabe et al. Due to outliers in our cut-off control group, 
we propose a possible seroprevalence in Europe of about 30% in healthy populations 
with lower seroprevalences of 14.7% in the age groups of 0-40 years with a clear 
increase in those aged >40 years. 
 
On comparison of data comprising of healthy 0-40 year olds the seroprevalences are 
lower (14.8% in Germans) than the Australian survey (n=357; 23%) (Konya and 
Thompson, 1999) based on a MCV virion particle ELISA which may have 
overestimated seroprevalence due to lack of antigen specificity. Our data indicates a 
seroprevalence higher than found in the Japanese survey (n=108, 6%) (Watanabe et al., 
2000). However they used MC133 which may be an inferior antigen for maximum 
sensitivity, and they expressed their antigen in embryonated chicken eggs and monkey 
cells, where host specific posttranslational modifications may be an issue. 
 
 
We have only looked at very small groups of patients with specific clinical diagnoses 
other than MC. Of interest may be the fact that all patient groups comprising of general 
autoimme conditions and skin conditions, psoriasis and SLE seem to show a lower than 
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average seroprevealence of MC. The seroprevalence in German patients with SLE is 
lower (10.9%) than that reported by Watanabe and group (57%) in their study 
(Watanabe et al., 2000) which was described to be a result of hyperimmunity or 
hypergammaglobulinemia. In MS patients, who are mostly under therapeutic immune 
suppression we observe a lower than average seroprevalence, which may be due to 
suppression of immune cells involved in antibody production.  This data is necessarily 
weak due to lack of numbers. Also the seropositivity in patients with primary 
progressive seroprevalence is almost twice that in patients with relapsing remitting 
multiple sclerosis.  
 
This is the first seroepidemiological study of MCV in Europe, the largest survey 
reported so far (n=715) and the first MCV ELISA based on surface viral antigen 
involved in the viral entry complex expressed in E. coli.In summary, we propose 
MC084 (V123-R230) is a suitable antigen for MCV serological surveys when expresse 
in E. coli.  It includes a probable highly antigenic site at amino acid position N219-
R230. Our study suggests that Molluscum contagiosum is strikingly common in the UK 
and Germany, especially in children under 5 years of age as is well documented in 
literature but also, as was apparent in the German population, in the older community 
comprising of individuals >40 years of age. The assay allows further investigations into 
the seroprevalence of MCV in other geographical areas, including the US, China, Japan 
and Australia.  
 
The reporter assay described in chapter 3 is based on the inhibition of infection 
introduced in cells by a recombinant v3 virus that carries a firefly luciferase gene with 
the resulting inhibition of transgene expression. Quantitative analysis of the assay 
allows measurement of a luminescent signal in relative light units which is directly 
proportional to transgene expression. We conducted neutralisation assays based on a 
working range of 22-1800 pfu/30,000 cells and an optimum pfu of 400 for 
reproducibility and sensitivity established by a group using a similar vaccinia virus 
neutralisation assay (Liu et al., 2012). It was found that sera from individuals of 
different age groups had different levels of non-specific reporter inhibition at different 
dilutions. Comparison of the neutralisation titres obtained by the two assays, i.e. 
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reporter assay and plaque reduction neutralisation test, indicated a high correlation 
between the two (near identical results for 15 sera samples), with a slight enhanced 
sensitivity of the reporter assay in results for 7 seven sera samples (samples 3, 8, 11, 14, 
20 and C1), compared to PRNT for 5 sera samples (samples1, 2, 4, 6 and 25). These 
differences may be due to the differences in protocols followed. A low prevalence of 
neutralising antibodies with no reporter inhibition was observed in the groups consisting 
of individuals <30 years of age ranging from a dilution of 1:3 to a maximum of 1:9 
which may be considered non-specific 
 
In the groups consisting of individuals >30 years of age, a high reporter inhibition is 
observed due to neutralising antibodies, ranging from a low dilution of 1:3 (considered 
non-specific) to a maximum of 1:243. This group consists of individuals who would 
have definitely received the smallpox vaccine and may therefore exhibit a basal titre of 
VACV specific antibodies as is exhibited by sera samples 11, 14 and 15. The levels of 
neutralising antibodies amongst the two different groups sorted on the basis of high/low 
titres established by ELISA are somewhat different. Within the group consisting of low 
titre, sera samples antibody titres are in the range of 1:3 (sample 21) or 1: 27 (samples 
22-24) and one serum sample (25) shows a higher prevalence of NAbs at a dilution of 
1:81. In the group consisting of high titre sera samples, the neutralising antibody titres 
are found to me much higher with detectable titres at dilutions ranging from 1:27 
(samples 9, 10, 12 and 13), 1:81 (samples 11 and 15) to as high as 1:243 (sample 14). 
The levels of neutralising antibodies amongst the two different groups sorted on the 
bases of high/low titres established by ELISA are almost comparable, with the 
exception of two samples (sample 3 and 8) which show greater neutralising activity. 
 
We consider readings at dilutions of 1:3 and 1:9 to be non-specific in reporter assay and 
PRNT as they are not observed to the same levels. A likely explanation for higher 
neutralising antibody titres in sera samples of individuals >30 years may be that since 
these individuals would have received the small pox vaccine they would retain some 
residual immunity to vaccinia. It is well known that serological tests such as ELISA and 
PRNT for orthopoxvirus species may not be virus species specific due to high levels of 
cross-antigenicity amongst species of the genus (Liu et al., 2012).However, from the 
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reporter assay we found no neutralization in serum dilutions over 1:100 i.e. the same 
dilution used in our recombinant ELISA in those aged <30 years. This clearly indicates 
no cross-reactivity between MCV and VACV neutralising antibodies. There is a 
possibility that some sera from individuals aged >30 years may have neutralising 
antibodies against MCV as well as exhibiting a low affinity for vaccinia. Although not 
clearly understood, the higher MCV seroprevalence we observed in the over 30, 
vaccinated populations, could be a booster affect on the immunity of these individuals 
either through exposure to MCV, VACV or other poxviruses. Also, if this is the case 
then the booster effect may function in both ways i.e. MCV exposure boosts anti-VACV 
antibodies or vice versa.This may have implications for a role of MC when smallpox is 
endemic. 
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Chapter 5 - MC084 and MC133 Monoclonal Antibodies 
Introduction 
Vaccinia virus which is the representative virus of the genus orthopoxvirus is a well 
studied virus for which a number of valuable antigen (ELISA) and antibody reagents are 
available. Apart from interest in the virus on account of its use in the eradication of 
smallpox and various vaccine delivery systems, the ease of reagent generation and 
availability has been one of the major reasons for the thorough investigation of this 
virus and its mechanisms of action. On the other hand compared to other well known 
poxviruses, Molluscum contagiosum has failed to garner sustained interest from a 
clinical perspective due to the benign nature of the disease but has also suffered from 
dearth of interest from a research perspective due to the lack of a conventional cell 
culture system or animal models.The severe lack of reagents has greatly impacted our 
understanding of the virus in general and also the true nature and extent of the disease in 
particular. One of the main aims that I hoped to address with this study was to develop 
MCV gene specific reagents which would contribute to further investigation of the 
MCV.  
 
It would be extremely interesting to be able to detect and visualise Molluscum 
contagiosum at the site of the infection. Molecular detection assays could possibly 
provide more specific and rapid detection which could be a useful supplement to 
diagnosis on basis of physical examination alone, especially in patients showing 
complicated and unclear presentation. Nucleic acid-based techniques rely on detection 
of specific DNA sequences in the pathogen genome. The methods typically consist of 
sample extraction, a PCR amplification step and a product analysis step. The techniques 
are highly specific but generally time consuming and confined to a dedicated research 
laboratory environment. Pathogen detection using specific antibodies offers the 
potential for more rapid analysis than nucleic acid-based techniques due to limited 
sample preparation. Also an antibody based system would allow other disease related 
investigations such as a more specific sandwich ELISA. Currently no monoclonal 
antibodies specific for Molluscum contagiosum virus exist.  
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Monoclonal antibodies (mAb) specific to cell-surface antigens have systematically 
provided a means of identification and characterisation of the structure and function of 
many integral membrane proteins. The fast advances in molecular biology cloning have 
allowed the isolation of novel genes encoding specific membrane proteins. However, in 
the case of molluscum contagiosum research, the initial characterization of these novel 
gene products has been greatly hampered by the lack of specific antibodies. Currently 
most poxviral antibodies which are available recognize mostly VACV proteins that are 
involved in virion assembly or/and are major antigens in smallpox vaccine. These 
antibodies are useful for tracking distinct steps in virion assembly and for studying the 
B cell epitopes in smallpox vaccine. 
 
Thus the development of monoclonal antibodies raised against specific MCV surface 
proteins would greatly contribute to the investigation and understanding of the disease. 
It would help us to identify the distribution of MC proteins MC084 and MC133 in 
infected skin biopsy material as well as potentially contribute to the development of a 
more accurate and specific assays such as a sandwich ELISA which would enable more 
thorough and accurate screening of sera samples. 
 
The aim of the work presented in this chapter was the production and screening of novel 
monoclonal antibodies (mAbs) against specific MCV virion surface proteins MC084 
and MC133 by immunizing mice with purified MC084S (aa123-230) characterised in 
Chapter 4 and due to time constraints against the fusion protein MC133S-GST (aa1-
370), as possible reagents for future implementation in skin biopsy staining, 
development of routine serological reagents and development of a possible sandwich 
ELISA.  
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Results 
5.1 Selection of antigen, cloning and purification 
The two candidate immunogenic peptides selected for the purpose of production of 
MCV specific monoclonal reagents were MC084 and MC133, both of which are 
homologues of proteins which are part of the virus particle entry complex in VACV. 
 
5.1.1 Antigen selection – MC084 
The selection, purification and characterisation of the recombinant C-terminal 
truncation of molluscum surface protein MC084, used for monoclonal antibody 
production i.e. MC084S (V123-230), has been extensively discussed in Chapter 4 and to 
avoid repetition will not be discussed here. 
 
5.1.2 Antigen selection – MC133 
The molluscum gene mc133 was selected as a candidate for expression and purification 
as an immunogenic peptide based on a previous study by Watanabe and co-workers 
where they identified MCV proteins capable of recognition by the humoral immune 
system of molluscum patients (Senkevich et al., 1996; Watanabe et al., 1998). This was 
done by screening 12 sera from molluscum contagiosum patients with a library of 
molluscum contagiosum transferred into cowpox expression system (Watanabe et al., 
1998). A 70 kD recombinant protein was detected by immunoblotting and mapped to 
the open reading frame MC133L.  Consensus sites were also determined between 
MC133 and homologs in vaccinia and variola (Watanabe et al., 1998). MC133 is an 
IMV membrane associated type A inclusion protein. Amino acid sequences of the 
MC133 (aa1-546), calculated molecular weight 61.5 kD) were analysed using standard 
software packages to determine overall homology with related proteins in the GenBank 
and identify transmembrane regions and region of high hydrophilicity and high 
antigenicity.  
 
Of the 546 amino acids in total, two subclones were defined; an N-terminal truncation 
(aa1-370; calculated molecular weight 40.5 kD) and a C-terminal truncation (aa 371-
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546; calculated molecular weight 20.6 kD) (Figure 5.1A), both containing one region of 
high hydrophilicity in the Kyte–Doolittle plot (Figure 5.1B) (Kyte and Doolittle, 1982), 
which were further analysed for subcloning. 
 
An open unlimited NCBI BLASTN search was used to compare the truncated amino 
acid sequences of mc133 to Genbank sequences (nr). Compared to the N-terminal 
mc133S (aa1-370), the C-terminal mc133v5 (aa371-546) showed the highest overall 
amino acid identity with vaccinia virus protein A27L and variola virus protein A30L. 
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Figure 5.1. Bioinformatics of MC133. (A) Transmembrane plot (TMHMM Server v. 2.0) of 
mc133 amino acids 1-546 with the two most antigenic regions indicated by black boxes. (B) 
Hydropathy plot of MC133 protein with predicted high hydrophilic / antigenic regions indicated 
by black arrows in the corresponding transmembrane plot. The full length ORF (MC133; aa1-
546; predicted molecular weight 61.5 kD; shown on top) was cloned into vRB12 using specific 
primers tailed with restriction enzyme sites EcoRI-HindIII and C-terminal Flag StrepII epitope 
tag. The resulting plasmid p343 was sequenced and the recombinant vaccinia virus v343 
isolated on BSC-1 cells using the plaqueless mutant system. N-terminal (in yellow) and C-
terminal (in white) truncations were subcloned from the original full length MCV gene into 
pGEX-2TK for overexpression in E. coli BL21 (RIL
+
). TMHMM was used to determine 
transmembrane regionswhereas the Kyte Doolittle plotwas used to identify hydrophilic regions 
with predicted high antigenicity. 
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5.1.2.1  Cloning of mc133 
The N-terminal truncation of mc133 (M1-N370, predicted MW 40.5 kD), comprising 
370 aa, has the lowest homology to orthopoxvirus proteins and contains a region of high 
antigenicity with no significant homology to vaccinia/cowpox virus. The N-terminal 
truncation MC133 (M1-N370) was then subcloned into the pGEX-2TK vector (Figure 
5.2A) with a Strep II tag and in frame with glutathione S-transferase separated by a 
thrombin kinase site (Figure 5.2B) and overexpressed as a GST fusion protein in codon 
optimized E. coli (BL21 RIL
+
).   
 
The GST fusion protein was identified with an apparent molecular weight (MW) similar 
to the predicted MW of 66.5 kD in (40.5+26 kD) IPTG induced cultures (Figure 5.2B). 
 
 
Figure 5.2. pGEX 2TK-mc133 (M1-N370) construct and fusion protein. (A) Schematic of 
recombinant plasmid p334 with a MC133 specific insert of 370 amino acids (M123-N370); 
predicted molecular weight approx. 40.5 kD. Vector NTI (vNTI) was used to produce virtual 
molecules and schematic diagrams of constructs prior to molecular cloning (InforMax, Inc). 
(B) Schematic of fusion protein of GST (green) followed by Thrombin cleavage site (red), 
MC133 (M123-N370) (grey), and strep II tag (blue); predicted antigenic site (black).  
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5.1.2.2 Purification of antigen 
The recombinant GST fusion N-terminal truncation of MC133 was obtained in 
overexpressed bacterial lysate and purified over glutathione sepharose beads using a 
batch purification method. The eluted fusion protein was visualised using the Strep II 
tag for detection in Western Blot of the fusion protein GST-MC133 (M1-N370)-StrepII  
using a an anti-strep antibody i.e Strep MAB-Classic HRP conjugate (Figure 5.3). 
 
Figure 5.3. Characterisation of GST-MC133S(M1-N370). Characterisation of overexpressed 
recombinant fusion protein GST-MC133S (M1-N370) in Western Blot. Proteins were separated 
on a 4-12% Bis-Tris gel and after transfer to nitrocellulose overexpressed 66 kD recombinant 
GST-MC133S fusion protein is seen. Spectra BR: Molecular weight marker expressed in kD. 
The membrane was probed with Strep MAB-Classic HRP conjugate (IBA-lifesciences).   
 
5.2 Hybridoma production 
5.2.1 Production of MC084S (123-230) antibody producing hybridomas and 
hybridoma yield following fusion  
In this study we used the previously characterised MC084S (123-230) (Chapter4) as an 
immunogen for the production of specific mouse mAbs. The amino acid sequence of 
MC084S, was evaluated for regions of high hydrophilicity/ high antigenicity, making it 
an ideal candidate for immunising mice. All animal immunisations and hybridoma 
fusions were carried out with the help of individuals in the Morgan Lab. Initially three 
BALB/c mice (1R, 1L and 1B) were immunised with MC084S (123-230) according to 
the protocol in materials and methods. Unfortunately each splenocyte fusion from the 
three mice immunised with MC084S (123-230), suffered from fungal and mycoplasma 
contamination within the first week of fusion, which was the result of large scale 
contamination of shared CO2 incubators and hoods in the cell culture lab used for the 
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procedures. This was confirmed visually and by PCR testing for mycoplasma. Further 
to this two other BALB/c mice (2R and 2L) were immunised with MC084S following 
the same protocol. These mice were sacrificed sequentially based on the highest 
peritoneal Ab titre of the mouse sera, assessed by ELISA experiments described 
previously and from the splenocyte fusions fully cloned antibody-producing cell lines 
were obtained. The hybridomas were selected on the basis of a positive reaction with 
MC084S coated microtitre ELISA wells. All cell lines were found to produce IgG-
isotype antibodies. Mouse 2R generated 9 clones while Mouse 2LR produced 6 clones, 
respectively (Table 5.1).  
 
Table 5.1. Summary of hybridoma yield following fusion for mice immunised with MC084S 
 
Mouse Total 
hybridomas 
Single 
clones  
% single 
clones 
Original positive 
hybridomas 
Subcloned 
2R 9 3 33.33% 2 1 
2L 6 2 30% 1 1 
      
 
5.2.2 Production of MC133 (M1-N370) antibody producing hybridomas and 
hybridoma yield following fusion  
Similarily we used the fusion protein MC133S-GST (M1-N370) characterised in 
previous result (Figure 5.3), as an immunogen for the production of specific monoclonal 
antibodies mAbs. The amino acid sequence of MC133S was evaluated for regions of 
high hydrophilicity/high antigenicity. A region of high hydrophilicity was confirmed 
and thus this was considered an ideal immunogen. Three BALB/c mice (1R, 1L and 1B) 
were immunised with MC133S (M1-N370) according to the protocol in materials and 
methods. These mice were sacrificed sequentially based on the highest peritoneal Ab 
titre of the mouse sera, assessed by ELISA experiments described previously and from 
the splenocyte fusions of fully cloned antibody-producing cell lines were obtained. 
Antibody-containing culture supernatants from the mAb producing clones were tested 
and hybridomas were selected on the basis of negative screening by comparing 
reactions with MC133S-GST, vMC133 (v343) and GST coated microtitre ELISA wells. 
In the end clones showing strongest reactivity against MC133S-GST and vMC133 and 
no reactivity with GST were selected and found to produce IgG-isotype antibodies. 
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Mouse 1L generated 6 clones, while Mouse 1R and 1B produced 2 and 3 clones, 
respectively (Table 5.2).  
 
Table 5.2. Summary of hybridoma yield following fusion for mice immunised with MC133S 
 
Mouse Total 
hybridomas 
Single 
clones  
% single 
clones 
Original positive 
hybridomas 
Subcloned 
1R 6 2 33.33% 2 2 
1L 12 6 50% 3 1 
1B 7 3 43% 2 1 
      
 
5.2.3 Specificity of hybridoma supernatants for mouse and human 
Hybridomas from MC084 fusions were initially screened using ELISA as described in 
2.9.5. However, Mouse 2L produced six hybridomas that responded to the the ELISA 
and mouse 2R produced nine. These further screened for positive single clones and the 
positive hybridomas were subcloned by limiting dilution as described in materials and 
methods. The specificity of one of these clones i.e. MC084-(6-2, 11-A-2, 11-D-2, 6C) or 
MC084-6C has been investigated in 5.3. The yield from MC133 immunised mice 
spleens were higher (1R-6, 1L-12, 1B-7) perhaps due to the fusion with a larger GST 
fusion protein for immunization in comparison to the peptide alone. To rule out 
hybridomas against GST, the hybridomas from MC133 fusions were also screened 
using ELISA with three proteins GST, MC133S and v343. Mouse 2L produced six 
hybridomas that responded to the ELISA screening and mouse 2R produced nine. These 
further screened for positive single clones and the positive hybridomas were subcloned 
by limiting dilution as described in materials and methods. Due to time constraints the 
positive single clones for the producing MC133S (M1-N370) hybridomas have been 
screened using ELISA and are yet to be fully characterised. 
 
5.3 Characterisation of MC084 (V123-R230) monoclonal (6-2, 11-A-2, 
11-D-2, 6C) or MC084-6C 
5.3.1 Specificity of MC084 (V123-R230) monoclonal MC084-6C for antigen 
TheMC084 (V123-R230) monoclonal (6-2, 11-A-2, 11-D-2, 6C) which shall hence 
forth be referred to as MC084-6Cfor simplicity, was characterised for specificity for 
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antigen used in immunisation protocol.  A 4-12% Bis-Tris gel was run with lanes 1 and 
2 loaded with the 14 kD purified MC084S (V123-R230) peptide; lanes 3 and 4 loaded 
with the 40 kD fusion protein GST-MC084S (V123-R230); lane 5 with 26 kD GST 
alone and lane 6 with 66 kD fusion protein GST-MC133S (M1-N370). The gel was 
transferred to nitrocellulose and the western blot stained with MC084S-6C and an 
ImmunoPure
®
 secondary goat anti-mouse IgG antibody and visualised using the 
Supersignal WestPico chemiluminescent kit (Figure 5.4). 
 
 
 
Figure 5.4. Characterizationof MC084 (V123-R230) monoclonal MC084S-6C. Page Ruler: 
Molecular weight marker expressed in kD. Lanes 1&2: Purified 14kD recombinant MC084S 
(V123-R230), Lanes 3&4: MC084S-GST fusion protein (60.5 kD), Lane 5 GST protein (26kD) 
andLane 6:MC133S-GST fusion protein by SDS-PAGE and Western Blot. The membrane was 
probed with ImmunoPure
®
 antibody 2º goat anti-mouse IgG (Pierce). Detection using 
SuperSignal
TM
 WestPico Chemiluminescent Substrate (Pierce). 
 
5.3.2 Antigenicity and specificity of MC084 (V123-R230) monoclonal MC084-6C 
Mice were sacrificed 2-3 days after final intraperitoneal immunisation and bled to 
collect sera by cardiac puncture. Serum from a normal healthy non-immunised mouse 
was also collected that served as control. Immune serum against MC084 antigen 
showed a high titer of at least >12400 when tested by direct binding ELISA (Figure 
5.5A). Serum from healthy mouse (control) exhibited no binding with MC084 antigen.  
Antigen-antibody binding in direct binding ELISA was confirmed by inhibition ELISA. 
In this assay serum was incubated with increasing amounts of inhibitor (MC084) for 
four hours at 37ºC or overnight at 4ºC. Immune complexe(s) formation increased with 
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increase in inhibitor concentration (0.1-10 μg/ml). Instead of directly using sera as in 
direct binding ELISA, these sera was treated overnight with inhibitors and coated on 
ELISA plates. The remaining steps were identical to direct binding ELISA. Maximum 
inhibition (83.4%) was achieved with highest the concentration (10 μg/ml) of inhibitor 
i.e. MC084S (V123-R230) (Figure 5.5B). Fifty percent inhibition was achieved at 2 
μg/ml of inhibitor (Figure 5.5B). This shows that immunised mouse serum antibodies 
exhibited high specificity and affinity towards immunogen (MC084S (V123-R230)).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5.5. Immune serum antigenicity and specificity of MC084 (mouse-2R). (A) Direct 
binding ELISAs were performed with serial dilution of immune sera (■) and sera from non-
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immunised healthy BALB/c mice (control) (▲) against immunogen MC084 (V123-R230). (B) 
Inhibition ELISAs were performed with immune (■) and control (▲) sera against MC084. 
MC084S (V123-R230) was used as an inhibitor with increasing concentrations (0.01-10 μg/ml) 
Microtitre plates were coated with immunogen MC084S (V123-R230) (4 μg/ml). 
  
Characterisation of monoclonal antibody MC084-6C was done using ELISA assays. 
Increasing concentrations (0-20 μg/ml) of antigen MC084S (V123-R230) was coated on 
ELISA plates and MC084 monoclonal antibody supernatant was used to perform direct 
binding ELISA. Antigen-antibody binding is found to increase with increase in 
concentration of antigen (Figure 5.6A). Antigen MC084S (V123-R230) and antibody 
(MC084-6C mAb) binding equilibrium was achieved at an antigen concentration of 3 
μg/ml. Antigen antibody antigenicity was confirmed by a more sensitive inhibition 
ELISA (Figure 5.6B).  A high inhibition of 93% was detected with 10 μg/ml of inhibitor 
(MC084). Fifty percent inhibition was achieved at 1 μg/ml. 
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Figure 5.6. Antigenicity and specificity of MC084 (V123-R230) monoclonal antibody 
MC084-6C by direct binding and inhibition ELISA. (A) Direct binding ELISAs were 
performed  for MC084 monoclonal antibodies (MC084-6C) against increasing concentration 
(0-20 μg/ml) of immunogen MC084. (B) Inhibition ELISAs were performed for monoclonal 
MC084-6C. MC084 was used as an inhibitor with increasing concentrations (0.01-10 μg/ml) 
Microtitre plates were coated with immunogen MC084 (4 μg/ml). 
 
 
 
 
 
 
 A 
B 
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5.3.3 Specificity determined by Molluscum contagiosum tissue staining with 
MC084-6C  
5.3.3.1 Specificity determined by Molluscum contagiosumparaffin section staining with 
MC084-6C  
The MC084 (V123-R230) clone designated MC084-6C, was further characterised for 
specificity by tissue staining. MC biopsy tissue sections consisting of infected skin were 
stained with the MC084 monoclonal i.e.MC084-6C (Figure 5.7 panels 1-3 and 5). MC 
positive patient serum CF2012-1 (Figure 5.7 Panel 4) was used as positive control and 
normal human epidermal skin (Figure 5.7 panel 5) as a negative control.  
 
Panels 1-4 show molluscum contagiosum lesions with typical pattern of staining at 
various magnifications counterstained with haematoxylin eosin. Figure 5.7-1A shows a 
MC section (4x) with concentrated golden brown stain in areas. Figure 5.7-1B (10x) 
shows a small area of the same section (not pictured in Figure 5.7-1A) with 
concentrated golden brown stain in basal layers of the cup shaped lesion as show by 
solid arrows. Figure 5.7-1C inset higher magnification (20x) of central crater containing 
cell and viral debris and showing strong golden brown staining (dotted arrows). Figure 
5.7-2A shows a lesion with typical molluscum contagiosum histology (4x). Figure 5.7-
2B shows an inverted lesion with clear epidermal stratification as basal, suprabasal and 
spinous layers (10x). The majority of brown stain is observed in the spinous layers 
(dotted arrows) surrounding the central crater. Figure 5.7-2C inset; cell and viral debris 
filled crater with staining shown by arrows (20x). Figure 5.7-3A shows a molluscum 
lesion with staining around central waxy plug where viral material has been washed 
away (10x). Figure 5.7-3B shows the same lesion at the same magnification (10x) with 
the viral plug intact and stained golden brown. Figure 5.7-3C shows the same follicular 
infundibulum at a higher magnification (20x).  
 
Figure 5.7-4A shows MC section with intraepidermal lobules stained with MCV 
positive patient serum CF2012-1 (4x). Figure 5.7-4B is an area in the same lesion 
shown by dotted box in previous panel (10x). Figure 5.7-4C is a magnification (20x) of 
the area shown in panel A in solid box showing the cell debris and MC bodies filled 
crater. Figure 5.7-5A shows normal skin section showing no staining with MC084-6C 
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(4x). Figures 5.7-5B and 5C show different areas of normal epidermis (arrows) with no 
apparent staining with the monoclonal antibody (both 10x). 
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Figure 5.7. MC084S (V123-R230) monoclonal antibody MC084S-6C specificity in MC 
tissue stains. Tissue sections from MCV positive patient biopsies stained with MC084S (V123-
R230) monoclonal MC084S-6C showing specific golden brown stain in lesions (Panel 1-4). 
Panel 1 shows section 10245/11-1A (4x), 1B (10x) and 1C (20x). Panel 2 shows section 
12229/12-2A (4x), 2B (10x) and 2C (20x).Panel 3 shows section 19517/11-3A (10x), 3B (10x) 
and 3C (20x). Panel 4 shows section 18894/11 stained with positive control MC positive serum 
CF2012-1-4A (10x), 4B (10x) and 4C (20x) and showing positive golden brown staining. Panel 
5 shows negative control normal human epidermal skin stained with MC084-6C- 5A (4x), 5B 
(10x) and 5C (10x) and showing no golden brown staining. (Haematoxylin-eosin counterstain). 
 
5.3.3.2 Specificity determined by Molluscum contagiosum frozen biopsy section (HD91) 
staining with MC084-6C  
The MC084 (V123-R230) monoclonal antibody MC084-6C, was further characterised 
for specificity by immune histology. MC frozen sections from an old collection 
belonging to Dr. Bugert from 1991 were stained with the MC084 monoclonal i.e. 
MC084-6C (Figure 5.8). Due to the age of these frozen biopsy sections and fluctuation 
in storage temperature the sections did not show clear histology. However when stained 
with MC084-6C and a secondary Alexa Fluor 488 (Green) chicken anti-mouse IgG 
(H+L) antibody (1:1000) the section showed clear distribution of an apple green stain in 
the cup shaped lesion. It was possible to distinguish the lesion into a central crater filled 
with viral debris containing cells (Figure 5.8A, solid arrow) and the surrounding 
epidermal basal membrane (Figure 5.8A, dotted white arrow). Figure 5.8B shows 
immunofluorescent (blue filter) staining of the nuclei concentrated in and around the 
central lesional crater (solid white arrows). Some blue staining is also visible in the 
basal layer surrounding the central crater (dotted white arrow).  
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Figure 5.8. Immunofluorescent specificity of MC084S-6C monoclonals in MC frozen tissue 
sections. (A) Reactivity ofMolluscum contagiosum biopsy freeze cuts (HD 91) withMC084S 
(V123-R230) monoclonal MC084-6 (neat) in and around central virus plug and the surrounding 
epidermis. (B) Blue staining of nuclei with DAPI mostly in central crater of MC lesion. 
Secondary antibody Alexa Fluor 488 (Green) chicken anti-mouse IgG (H+L) (1:1000). Nuclei 
are stained with DAPI and shown in blue. Sample was analysed for fluorescence emission 
properties by using an Olympia BX51 (A) green filter and (B) blue filter. 
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5.3.4 Specificity determined by immunofluorescent staining of viral mc084 with 
MC084-6C 
5.3.4.1 Binding specificity of MC084-6C for viral mc084 expressed in BSC-1 cells 
To establish monoclonal MC084-6C specificity for antigen we infected African green 
monkey kidney epithelial cells with a vaccinia virus expressing full length mc084 
(v319; aa 1 to 318). These were fixed and stained with MC084-6C (1:50). Most cells on 
the coverslip (Figure 5.9A) showed binding of expressed viral MC084 with the 
monoclonal antibody MC084-6C. Figure 5.9B shows some uninfected cells with blue 
DAPI stained nuclei (solid white arrows) but no apple green indicating no expression of 
MC084.  Figure 5.9C shows strep control. 
 
 
 
Figure 5.9. Determination of specificity of MC084S-6C for vMC084 in BSC-1s. 
Immunofluorescent detection of recombinant vaccinia virus expressed MC084S (v319) in BSC-1 
cell culture with MC084-6C. (A&B) Reactivity of MC084S (V123-R230) monoclonal MC084-6 
expressed in hybridoma supernatant (1:50) with MC084 (10x) and secondary antibody Alexa 
Fluor 488 (Green) chicken anti-mouse IgG (H+L) (1:1000). (C) Reactivity of Classic Strep 
MAB (1:100) with MC084S. Nuclei are stained with DAPI and shown in blue (solid white 
arrows).  Coverslips were analysed for fluorescence emission properties by using an Olympia 
BX51.  
 
5.3.4.2 Binding specificity of MC084-6C for vmc084 expressed in HaCaT cells 
To further establish monoclonal MC084-6C specificity for antigen we infected human 
keratinocytes with a vaccinia virus expressing full length mc084 (v319; aa 1 to 318) and 
stained with MC084-6C (1:50). Fewer keratinocytes were infected compared to 
uninfected cells as evidenced by an apple green stain. Single infected cells  shown by 
solid white arrows indicating binding of monoclonal MC084-6C with expressed viral 
MC084 shown in Figure 5.10, Panels A and B (10x). Figure 5.10C shows a higher 
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magnification (20x) of two keratinocytes with large DAPI stained nuclei surrounded by 
viral MC084 stained an apple green (solid white arrows). It is also apparent that the 
MC084 is produced outside of the nucleus in an endosomal pattern. Figure 5.10D shows 
the strep antibody control (1:100) (10x) in cells indicated by solid white arrows.  
 
 
Figure 5.10. Determination of specificity of MC084S-6C for vMC084in HaCaTs. 
Immunofluorescent detection of recombinant vaccinia virus expressed MC084S (v319) in 
HaCaT cell culture with MC084-6C. (A and B) Reactivity of MC084S (V123-R230) monoclonal 
MC084-6 expressed in hybridoma supernatant (1:50) with MC084 (10x) and secondary 
antibody Alexa Fluor 488 (Green) chicken anti-mouse IgG (H+L) (1:1000). (C) Higher 
magnification (20x) of two cells showing staining of nuclei and reactivity with MC084-6C in 
endosomes. (D) Reactivity of Classic Strep MAB (1:100) with MC084S. Nuclei are stained with 
DAPI and shown in blue. Samples were analysed for fluorescence emission properties by using 
an Olympia BX51.  
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Discussion 
We developed monoclonal antibodies against MCV recombinant surface proteins 
MC084 and MC133 truncations i.e. MC084S (V123-R230) and MC133S (M1-N370). 
BALB/c mice were immunised with the purified MC084S peptide and GST-MC133 
fusion protein according to immunization protocol as discussed in materials and 
methods. The mice were sacrificed sequentially and the splenocytes were fused with 
SP2/0 cells to achieve hybridoma fusion. These hybridomas were ELISA screened and 
subcloned as described in materials and methods. The percentage of hybridomas 
obtained from MC133 fusions was greater than that for MC084 fusions. This may be the 
result of the nature (fusion protein) and size of protein (40 kD) used for MC133 
immunisation. Of the two original positive MC084 hybridomas which were subcloned, 
the clone (6-2, 11-A-2, 11-D-2, 6C) or MC084-6C was further investigated.  
 
Polyclonal antibodies isolated from immune sera of experimental animal after final 
boost showed MC084 recombinant viral protein as highly immunogenic and induced 
high titre anti-MC084 antibodies. After several routine screens of clones, we 
successfully selected MC084-6C clone that was further characterised by western blot 
for specificity for immunogen. The antibodies showed reactivity with 14 kD peptide 
used in immunisation as well as the 40 kD GST-MC084S fusion protein but no binding 
with GST (26 kD) alone or with GST-MC133 fusion protein. The specificity and 
immune-reactivity were also ascertained by direct binding and inhibition ELISAs. The 
results revealed high affinity of MC084-6C for the immunogen, MC084S (V123-230), 
suggesting that the monoclonal antibodies are immunogen specific and possibly 
recognise the most antigenic motif (GGNIRNDDKYTH) of MC084 protein.  
 
Specificity of MC084-6C was determined in Molluscum contagiosum infected tissue 
biopsies by clear golden brown staining confirming reactivity of the monoclonal with 
the MC084 in sections (Figure 5.7 panels 1-3). Thee staining pattern of tissues stained 
with MC084-6C, show the concentration of golden brown stain in the basal, suprabasal 
layers as well as the central crater indicating MC084-6C specificity and possible 
abundance and aggregation of MC084 in these layers. Immunofluorescent staining of 
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frozen MC biopsy sections with the monoclonal MC084-6C showed clear staining of 
the MC lesion with concentration of green signal in the central crater probably filled 
withviral and cell debris as well as the surrounding basal epidermal layer. Blue coloured 
nuclei stained with DAPI were visible in the lesion, particularly concentrated in the 
centre of the lesion. 
 
Monoclonal MC084-6C specificity for antigen was further investigated by 
immunofluorescent staining of different cells infected by a vaccinia virus expressing 
full size mc084 (v319; aa 1 to 318) constructed earlier as a part of my project and 
described in the materials and methods. The African green monkey kidney epithelial 
cells infected with the vaccinia virus v319 stained positive and showed strong apple 
green signal in a pattern resembling virus factories. Infected cells showed a blue DAPI 
stained nucleus. Similarly infected keratinocyes (HaCaTs) showed an apple green stain 
which was found to surround the DAPI stained nucleus in and endosomal pattern.  
 
In summary, we have developed and screened hybridomas producing monoclonal 
antibodies against MC084S (V123-R230 and MC133S (M1-N370). From these the 
monoclonal antibodies produced by hybridoma designated as MC084-6C producing 
mAbs against MC084S have been characterised and these seem to work very well in 
recombinant vaccinia controls and in human MCV infected tissues.  These monoclonal 
antibodies are unique reagents and will be used in future work to test a hypothesis that 
MCV replicates in human epidermal stem cells. 
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Chapter 6 - General Discussion 
Molluscum contagiosum virus (MCV) is a significant benign, but underreported 
pathogen for children and adults, which causes a skin infection similar to warts. It 
causes molluscum contagiosum (MC) a stigmatising skin infection which severely 
impedes quality of life and may develop into chronic infections lasting 12 months and 
longer.  
 
Viral skin infections are the most common cause of GP visits in the UK, with over a 
million cases per year constituting a high burden of diseases and incurring considerable 
cost to the NHS (Schofield et al., 2011).  Meta-analysis suggests a point prevalence of 
MC in children aged 0 to 16 years of between 5.1% and 11.5% (Olsen et al., 2013). The 
lack of effective therapies is largely due to a poor understanding of the virus specific 
immune responses in the human skin. 
 
Compared to other human skin viruses it has failed to garner sustained interest from a 
research perspective due to the lack of a conventional cell culture system or animal 
model. The resulting lack of reagents has proven a major obstacle in further 
investigation of this unique virus. My doctoral research project focuses on aspects 
relating to the lifecycle of Molluscum contagiosum virus and the human immune 
response to it. In light of the fact that MCV research has suffered from the absence of 
reagents enabling its further investigation, the major aim of this PhD project was to 
develop and design valuable MCV gene specific reagents to enable this work. 
 
As outlined in the introduction and chapter 3, the MCV lifecycle starts upon entry of the 
virus particle into human epidermal cells or more specifically differentiating 
keratinocytes. Although the seat of replication is still to be investigated and 
substantiated, popular belief is that it may be epidermal stem cells. Another challenge to 
any investigations is that infections of epithelial type cells in vitro are non-productive 
but do produce early gene products.  The lack of a cell culture system also contributes to 
this dilemma. Since the first step of any viral lifecycle is entry, so in order to determine 
whether MCV has entered cells, we have developed a couple of a GFP and luciferase 
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based reporter assays detailed in chapter 3 of my work. Also due to the fact that MCV 
cannot be titrated, we developed a qPCR correlating MCV genome units with genome 
units of its surrogate virus which is titratable i.e. vaccinia virus. Although these are 
different viruses but this has enabled quantification of MCV and MOI calculations 
which can be used together with a reporter assay.Some of the findings during the course 
of this study were quite unexpected. When we infected a range of cells with MCV using 
our reporter assay (Sherwani et al., 2012) we found rather unexpectedly that MCV is 
not limited to infecting keratinocytes (HaCaT) or even to human cells. So the lack of 
productivity in cell culture is not due to non-entry- or receptor issues as the live virus 
gets into mouse (3T3), hamster (BHK-21), monkey (Vero) and various human cells 
(A549, HeLa, HaCaT) and drives early poxviral promoters. 
 
To enter cells,the Molluscum contagiosum virus uses homologs of a cell fusion complex 
identified in vaccinia virus; these are the MCV genes mc084 and mc133 both of which I 
have mostly worked with.  Because of their role in entry these proteins are located on 
the surface of the virion particle, so human antibodies versus MCV are raised against 
mc084 and mc133. We have expressed mc084 and mc133 in prokaryotic and eukaryotic 
expression systems and then purified the antigens to test human patient serum samples 
for the presence of polyclonal antibodies in Chapter 4. We have used the reporter assay 
to determine whether these antibodies can neutralize a MCV infection in vitro and 
whether there is cross reactivity with orthopoxviruses. We have compared parts of 
MC084 and MC133 for suitability as antigens and identified why the C-terminal 
domain of a MC084 peptide selected by Watanabe et al., failed to show reactivity with 
sera samples of Molluscum positive patients in an ELISA. This was because the peptide 
used was a part of the transmembrane region of that protein.  
 
In a serosurvey using mc084 antigen in an ELISA format versus serum collections from 
Heidelberg and Cardiff, we found that MC is very common in Germany, especially in 
children under 5 years of age. This is the first such study in Europe (In print; PLOS 
ONE PONE-D-13-44356R1). Our numbers are higher than previous Australian and 
Japanese studies, but this may be due to the use of different antigens.  
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We have used the most stringent cut-off conditions as we have specifically looked at 
sera from new-borns and toddlers from 0-1 years after birth, where due to the least 
exposure to MC due to hygienic conditions, the incidence should be the lowest. But 
Molluscum contagiosum (MC) seems to be strikingly common in general populations 
and we have despite this, found evidence for MCV infections in very young children, 
basically new-borns, and a few months after birth. Because our serum sample 
collections were anonymized, we could not follow up on this clinically with more 
sample information. However though rare the occurrence of such infections in new-
borns is not unheard of as proved by a case of a DOCK8 deficient patient as previously 
observed by my supervisor Dr. Bugert at the NIH, who had extensive MC (Figure 1.5C) 
from birth, and eventually died from the condition as a teenager.  
 
Another interesting case was a patient in our collection that we could follow up 
clinically during the course of this PhD in collaboration with a Bath dermatologist; the 
patient suffers from a haematological cancer and has a documented chronic severe and 
incurable case of MCsince 2008. It is known that MC thrives in immunesuppressed 
hosts, but is well controlled in immune competent individuals (Bugert and Darai, 1997). 
A recent study has shown MCV actually induces a massive immune response in 
immune competent hosts (Vermi et al., 2011). 
 
We have further investigated the specificity of what appear to be human MC antibodies 
versus vaccinia virus in plaque and reporter inhibition assays using the recombinant 
VACV reporters and found no neutralization in serum dilutions over 1:100 i.e. the same 
dilution used in our recombinant ELISA in those aged <30 years. This clearly indicates 
no cross-reactivity between MCV and VACV antibodies.Three sera samples from 
individuals aged >30 years whose ages in fact range from 45-51 years, showed 
neutralisation which can only be explained as the result of vaccinia antibodies acquired 
through small pox vaccination.Although not clearly understood, the higher MCV 
seroprevalence we observed in the over 40, vaccinated populations, could be a booster 
effect on the immunity of these individuals either through exposure to MCV, VACV or 
other poxviruses. Also, if this is the case then the booster effect may function in both 
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ways i.e. MCV exposure boosts anti-VACV neutralising antibodies or vice versa.This 
may have implications for a role of MC when smallpox is endemic. 
 
As discussed in Chapter 5, we have also raised monoclonal antibodies against mc084 
and 133. Whereas the monoclonal raised against mc133 have been screened and are yet 
to be properly characterised, monoclonal antibodies specific for the antigen MC084S 
(V123-R230) have been characterised. We have tested MC084-6C and theseseem to 
work very well in recombinant vaccinia controls and in human MCV infected tissues.  
They will be used in helping to determine the MCV host cell in the epidermis. 
 
Future work emanating from this research project includes the possible development of 
a capture ELISA using our characterised mAbs and immunogenic peptide for more 
seroprevalence studies focussing on different geographical areas. Also, the possible 
identification of the host cell, by monoclonal detection of the virus in infected skinand 
testing the stem cell hypothesis using our reporter assays and in skin models.The 
peptides characterised in this study could also lead to the development of novel reagents 
to detect and characterize T cells in the blood of healthy and MCV infected patients, 
and investigate the virus specific immune responses by immunehistocytochemistry in 
sections of MCV skin lesions. 
 
As part of Dr. Bugerts poxvirus group I have also been involved in some of the other 
work of the group that could be used to address MCV issues. We used the reporter assay 
to test antiviral compounds and found that Laura Farleighs (another PhD student in the 
group) ddBCNAs, active against vaccinia virus, also inhibit MCV (part of IBSc Niamh 
Blythe). I was also involved in a single gene study on mc162, specifically a 
recombinant of vaccinia virus v354 made by Asif Nizam, which induces class e 
endosomes in a range of eukaryotic cells, through binding of ESCRT pathway proteins, 
and possibly inducing EGFR overexpression in tissue studies. This could explain in part 
the proliferative nature of MC. We have a new collaboration with a HPV group in 
Novara, Italy, with a raft system who will help by testing the monoclonals in a MCV 
raft infection model. We will provide lentiviral expression vectors for MCV single gene 
studies on proliferation and they will provide more virus and sera with clinical data,as 
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well as test candidate antiviral compounds in clinical studies (ethical permissions have 
recently been obtained). 
 
In summary as part of my PhD project, I carried out the largest survey yet of serum 
antibodies directed against the surface virion protein MC084 in European populations. I 
was able to show for the first time an unexpectedly high seroprevalence of MCV in 
Europe, and a very early onset in children. I have also produced a number of novel 
reagents, including monoclonal antibodies specific for MCV virion proteins MC084 and 
MC133and established a luciferase reporter assay to efficiently evaluate MCV in panels 
of potential host cells in vitro.  
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Appendix-1- Before cut off 
Statistics analysis of German Population 
 
N Mean Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
0 - 1 year 66 .131553 .1045174 .105859 .157247 
2 - 5 year 52 .299317 .3736997 .195279 .403356 
6 - 10 years 47 .278372 .3171693 .185248 .371497 
11 - 20 years 72 .206757 .1807952 .164272 .249242 
21 - 40 years 52 .218635 .1364325 .180652 .256618 
41 - 50 years 119 .482466 .3435129 .420108 .544825 
51 - 60 years 62 .498734 .3720875 .404241 .593226 
>61 years 52 .556632 .4199750 .354210 .759053 
Total 489 .332305 .3241976 .303499 .361111 
 
ANOVA 
German titres before cut off 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 10.017 7 1.431 16.676 .000 
Within Groups 41.274 481 .086   
Total 51.291 488    
 
Multiple Comparisons 
German titres before cut off 
Tukey HSD 
(I) German age 
groups 
(J) German age 
groups 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.1677643* .0543168 .044 -.333122 -.002407 
6 - 10 years -.1468193 .0559094 .149 -.317025 .023387 
11 - 20 years -.0752039 .0499192 .804 -.227174 .076766 
21 - 40 years -.0870816 .0543168 .748 -.252439 .078276 
41 - 50 years -.3509134* .0449580 .000 -.487780 -.214047 
51 - 60 years -.3671808* .0518088 .000 -.524903 -.209458 
>61 years -.4250785* .0762653 .000 -.657255 -.192902 
*. The mean difference is significant at the 0.05 level. 
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Appendix-2- After 0.28 cut off 
 
N Mean Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
0 - 1 year 3 .446833 .1417395 .094733 .798934 
2 - 5 year 19 .630447 .4541187 .411569 .849326 
6 - 10 years 16 .556406 .4200983 .332552 .780261 
11 - 20 years 16 .483750 .1850200 .385160 .582340 
21 - 40 years 10 .448050 .1189933 .362927 .533173 
41 - 50 years 65 .746854 .2419522 .686901 .806807 
51 - 60 years 34 .791294 .2428502 .706560 .876029 
>61 years 36 .650778 .3058595 .547290 .754266 
Total 199 .669947 .3043301 .627404 .712490 
 
ANOVA 
German titres at 0.28 cut off 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 2.331 7 .333 3.973 .000 
Within Groups 16.007 191 .084   
Total 18.338 198    
 
Multiple Comparisons 
German titres at 0.28 cut off 
Tukey HSD 
(I) German age 
groups 
(J) German age 
groups 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.1836140 .1798533 .971 -.734836 .367608 
6 - 10 years -.1095729 .1821380 .999 -.667797 .448652 
11 - 20 years -.0369167 .1821380 1.000 -.595141 .521308 
21 - 40 years -.0012167 .1905704 1.000 -.585285 .582852 
41 - 50 years -.3000205 .1709549 .651 -.823970 .223929 
51 - 60 years -.3444608 .1743593 .501 -.878845 .189923 
>61 years -.2039444 .1739662 .939 -.737124 .329235 
*. The mean difference is significant at the 0.05 level. 
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Appendix-3- After 3.6 cut off 
 
N Mean Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
0 - 1 year 3 .446833 .1417395 .094733 .798934 
2 - 5 year 13 .774962 .4873230 .480475 1.069448 
6 - 10 years 11 .670000 .4680104 .355586 .984414 
11 - 20 years 9 .565222 .1447487 .453958 .676486 
21 - 40 years 7 .493000 .1154913 .386188 .599812 
41 - 50 years 61 .774779 .2225712 .717776 .831782 
51 - 60 years 32 .821469 .2163133 .743479 .899458 
>61 years 23 .834678 .2249314 .737411 .931946 
Total 159 .755152 .2795715 .711361 .798942 
 
ANOVA 
German titres at 0.36 cut off 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 1.485 7 .212 2.950 .006 
Within Groups 10.864 151 .072   
Total 12.349 158    
 
Multiple Comparisons 
German titres at 0.36 cut off 
Tukey HSD 
(I) German age 
groups 
(J) German age 
groups 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.3281282 .1718031 .546 -.856235 .199978 
6 - 10 years -.2231667 .1747071 .906 -.760199 .313866 
11 - 20 years -.1183889 .1788184 .998 -.668059 .431282 
21 - 40 years -.0461667 .1850946 1.000 -.615130 .522796 
41 - 50 years -.3279454 .1586236 .441 -.815539 .159648 
51 - 60 years -.3746354 .1619578 .293 -.872478 .123207 
>61 years -.3878449 .1646514 .271 -.893968 .118278 
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Appendix-4- Multiple comparisons – Before cut off 
Multiple Comparisons 
German titres before cut off 
Tukey HSD 
(I) German age 
groups 
(J) German age 
groups 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.1677643* .0543168 .044 -.333122 -.002407 
6 - 10 years -.1468193 .0559094 .149 -.317025 .023387 
11 - 20 years -.0752039 .0499192 .804 -.227174 .076766 
21 - 40 years -.0870816 .0543168 .748 -.252439 .078276 
41 - 50 years -.3509134* .0449580 .000 -.487780 -.214047 
51 - 60 years -.3671808* .0518088 .000 -.524903 -.209458 
>61 years -.4250785* .0762653 .000 -.657255 -.192902 
2 - 5 year 0 - 1 year .1677643* .0543168 .044 .002407 .333122 
6 - 10 years .0209450 .0589567 1.000 -.158538 .200428 
11 - 20 years .0925604 .0533101 .663 -.069733 .254853 
21 - 40 years .0806827 .0574486 .855 -.094209 .255575 
41 - 50 years -.1831491* .0486956 .005 -.331394 -.034904 
51 - 60 years -.1994166* .0550835 .008 -.367108 -.031725 
>61 years -.2573143* .0785267 .025 -.496375 -.018254 
6 - 10 years 0 - 1 year .1468193 .0559094 .149 -.023387 .317025 
2 - 5 year -.0209450 .0589567 1.000 -.200428 .158538 
11 - 20 years .0716154 .0549319 .897 -.095615 .238846 
21 - 40 years .0597377 .0589567 .972 -.119745 .239221 
41 - 50 years -.2040940* .0504659 .002 -.357728 -.050460 
51 - 60 years -.2203615* .0566546 .003 -.392836 -.047887 
>61 years -.2782592* .0796366 .012 -.520699 -.035820 
11 - 20 years 0 - 1 year .0752039 .0499192 .804 -.076766 .227174 
2 - 5 year -.0925604 .0533101 .663 -.254853 .069733 
6 - 10 years -.0716154 .0549319 .897 -.238846 .095615 
21 - 40 years -.0118777 .0533101 1.000 -.174171 .150415 
41 - 50 years -.2757094* .0437364 .000 -.408857 -.142562 
51 - 60 years -.2919769* .0507524 .000 -.446484 -.137470 
>61 years -.3498746* .0755517 .000 -.579878 -.119871 
21 - 40 years 0 - 1 year .0870816 .0543168 .748 -.078276 .252439 
2 - 5 year -.0806827 .0574486 .855 -.255575 .094209 
6 - 10 years -.0597377 .0589567 .972 -.239221 .119745 
11 - 20 years .0118777 .0533101 1.000 -.150415 .174171 
41 - 50 years -.2638318* .0486956 .000 -.412077 -.115587 
51 - 60 years -.2800993* .0550835 .000 -.447791 -.112407 
>61 years -.3379970* .0785267 .001 -.577057 -.098937 
41 - 50 years 0 - 1 year .3509134* .0449580 .000 .214047 .48778 
2 - 5 year .1831491* .0486956 .005 .034904 .331394 
6 - 10 years .2040940* .0504659 .002 .050460 .357728 
11 - 20 years .2757094* .0437364 .000 .142562 .408857 
21 - 40 years .2638318* .0486956 .000 .115587 .412077 
51 - 60 years -.0162675 .0458814 1.000 -.155945 .123410 
>61 years -.0741652 .0723695 .971 -.294481 .146151 
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51 - 60 years 0 - 1 year .3671808* .0518088 .000 .209458 .524903 
2 - 5 year .1994166* .0550835 .008 .031725 .367108 
6 - 10 years .2203615* .0566546 .003 .047887 .392836 
11 - 20 years .2919769* .0507524 .000 .137470 .446484 
21 - 40 years .2800993* .0550835 .000 .112407 .447791 
41 - 50 years .0162675 .0458814 1.000 -.123410 .155945 
>61 years -.0578977 .0768133 .995 -.291742 .175947 
>61 years 0 - 1 year .4250785* .0762653 .000 .192902 .657255 
2 - 5 year .2573143* .0785267 .025 .018254 .496375 
6 - 10 years .2782592* .0796366 .012 .035820 .520699 
11 - 20 years .3498746* .0755517 .000 .119871 .579878 
21 - 40 years .3379970* .0785267 .001 .098937 .577057 
41 - 50 years .0741652 .0723695 .971 -.146151 .294481 
51 - 60 years .0578977 .0768133 .995 -.175947 .291742 
*. The mean difference is significant at the 0.05 level. 
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Appendix-5- Multiple comparisons after 0.28 cut off 
Multiple Comparisons 
German titres at 0.28 cut off 
Tukey HSD 
(I) German age 
groups 
(J) German age 
groups 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.1836140 .1798533 .971 -.734836 .367608 
6 - 10 years -.1095729 .1821380 .999 -.667797 .448652 
11 - 20 years -.0369167 .1821380 1.000 -.595141 .521308 
21 - 40 years -.0012167 .1905704 1.000 -.585285 .582852 
41 - 50 years -.3000205 .1709549 .651 -.823970 .223929 
51 - 60 years -.3444608 .1743593 .501 -.878845 .189923 
>61 years -.2039444 .1739662 .939 -.737124 .329235 
2 - 5 year 0 - 1 year .1836140 .1798533 .971 -.367608 .734836 
6 - 10 years .0740411 .0982294 .995 -.227017 .375099 
11 - 20 years .1466974 .0982294 .810 -.154360 .447755 
21 - 40 years .1823974 .1131010 .742 -.164240 .529034 
41 - 50 years -.1164065 .0755006 .784 -.347804 .114991 
51 - 60 years -.1608467 .0829213 .525 -.414988 .093294 
>61 years -.0203304 .0820914 1.000 -.271928 .231267 
6 - 10 years 0 - 1 year .1095729 .1821380 .999 -.448652 .667797 
2 - 5 year -.0740411 .0982294 .995 -.375099 .227017 
11 - 20 years .0726563 .1023527 .997 -.241039 .386351 
21 - 40 years .1083563 .1167001 .983 -.249311 .466024 
41 - 50 years -.1904476 .0807924 .269 -.438063 .057168 
51 - 60 years -.2348879 .0877667 .136 -.503879 .034103 
>61 years -.0943715 .0869831 .959 -.360961 .172218 
11 - 20 years 0 - 1 year .0369167 .1821380 1.000 -.521308 .595141 
2 - 5 year -.1466974 .0982294 .810 -.447755 .154360 
6 - 10 years -.0726563 .1023527 .997 -.386351 .241039 
21 - 40 years .0357000 .1167001 1.000 -.321967 .393367 
41 - 50 years -.2631038* .0807924 .029 -.510720 -.015488 
51 - 60 years -.3075441* .0877667 .013 -.576535 -.038553 
>61 years -.1670278 .0869831 .539 -.433617 .099562 
21 - 40 years 0 - 1 year .0012167 .1905704 1.000 -.582852 .585285 
2 - 5 year -.1823974 .1131010 .742 -.529034 .164240 
6 - 10 years -.1083563 .1167001 .983 -.466024 .249311 
11 - 20 years -.0357000 .1167001 1.000 -.393367 .321967 
41 - 50 years -.2988038 .0983373 .054 -.600192 .002585 
51 - 60 years -.3432441* .1041433 .025 -.662427 -.024061 
>61 years -.2027278 .1034837 .512 -.519889 .114434 
41 - 50 years 0 - 1 year .3000205 .1709549 .651 -.223929 .823970 
2 - 5 year .1164065 .0755006 .784 -.114991 .347804 
6 - 10 years .1904476 .0807924 .269 -.057168 .438063 
11 - 20 years .2631038* .0807924 .029 .015488 .510720 
21 - 40 years .2988038 .0983373 .054 -.002585 .600192 
51 - 60 years -.0444403 .0612725 .996 -.232231 .143350 
>61 years .0960761 .0601447 .751 -.088258 .280410 
51 - 60 years 0 - 1 year .3444608 .1743593 .501 -.189923 .878845 
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2 - 5 year .1608467 .0829213 .525 -.093294 .414988 
6 - 10 years .2348879 .0877667 .136 -.034103 .503879 
11 - 20 years .3075441* .0877667 .013 .038553 .576535 
21 - 40 years .3432441* .1041433 .025 .024061 .662427 
41 - 50 years .0444403 .0612725 .996 -.143350 .232231 
>61 years .1405163 .0692313 .465 -.071667 .352700 
>61 years 0 - 1 year .2039444 .1739662 .939 -.329235 .737124 
2 - 5 year .0203304 .0820914 1.000 -.231267 .271928 
6 - 10 years .0943715 .0869831 .959 -.172218 .360961 
11 - 20 years .1670278 .0869831 .539 -.099562 .433617 
21 - 40 years .2027278 .1034837 .512 -.114434 .519889 
41 - 50 years -.0960761 .0601447 .751 -.280410 .088258 
51 - 60 years -.1405163 .0692313 .465 -.352700 .071667 
*. The mean difference is significant at the 0.05 level. 
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Appendix-6- Multiple comparisons – After 0.36 cut off 
Multiple Comparisons 
German titres at 0.36 cut off 
Tukey HSD 
(I) German age groups 
(J) German age 
groups 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0 - 1 year 2 - 5 year -.3281282 .1718031 .546 -.856235 .199978 
6 - 10 years -.2231667 .1747071 .906 -.760199 .313866 
11 - 20 years -.1183889 .1788184 .998 -.668059 .431282 
21 - 40 years -.0461667 .1850946 1.000 -.615130 .522796 
41 - 50 years -.3279454 .1586236 .441 -.815539 .159648 
51 - 60 years -.3746354 .1619578 .293 -.872478 .123207 
>61 years -.3878449 .1646514 .271 -.893968 .118278 
2 - 5 year 0 - 1 year .3281282 .1718031 .546 -.199978 .856235 
6 - 10 years .1049615 .1098857 .980 -.232816 .442739 
11 - 20 years .2097393 .1163113 .619 -.147790 .567269 
21 - 40 years .2819615 .1257470 .333 -.104573 .668496 
41 - 50 years .0001828 .0819375 1.000 -.251685 .252051 
51 - 60 years -.0465072 .0882192 .999 -.317684 .224670 
>61 years -.0597167 .0930720 .998 -.345811 .226378 
6 - 10 years 0 - 1 year .2231667 .1747071 .906 -.313866 .760199 
2 - 5 year -.1049615 .1098857 .980 -.442739 .232816 
11 - 20 years .1047778 .1205593 .988 -.265810 .475366 
21 - 40 years .1770000 .1296864 .872 -.221643 .575643 
41 - 50 years -.1047787 .0878635 .933 -.374863 .165305 
51 - 60 years -.1514688 .0937489 .740 -.439644 .136706 
>61 years -.1646783 .0983292 .703 -.466933 .137576 
11 - 20 years 0 - 1 year .1183889 .1788184 .998 -.431282 .668059 
2 - 5 year -.2097393 .1163113 .619 -.567269 .147790 
6 - 10 years -.1047778 .1205593 .988 -.475366 .265810 
21 - 40 years .0722222 .1351740 .999 -.343290 .487734 
41 - 50 years -.2095565 .0957781 .365 -.503969 .084856 
51 - 60 years -.2562465 .1012043 .190 -.567339 .054846 
>61 years -.2694560 .1054613 .181 -.593634 .054722 
21 - 40 years 0 - 1 year .0461667 .1850946 1.000 -.522796 .615130 
2 - 5 year -.2819615 .1257470 .333 -.668496 .104573 
6 - 10 years -.1770000 .1296864 .872 -.575643 .221643 
11 - 20 years -.0722222 .1351740 .999 -.487734 .343290 
41 - 50 years -.2817787 .1070395 .153 -.610808 .047250 
51 - 60 years -.3284687 .1119210 .073 -.672503 .015566 
>61 years -.3416783 .1157847 .070 -.697589 .014233 
41 - 50 years 0 - 1 year .3279454 .1586236 .441 -.159648 .815539 
2 - 5 year -.0001828 .0819375 1.000 -.252051 .251685 
6 - 10 years .1047787 .0878635 .933 -.165305 .374863 
11 - 20 years .2095565 .0957781 .365 -.084856 .503969 
21 - 40 years .2817787 .1070395 .153 -.047250 .610808 
51 - 60 years -.0466901 .0585470 .993 -.226658 .133278 
>61 years -.0598996 .0656318 .984 -.261645 .141846 
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51 - 60 years 0 - 1 year .3746354 .1619578 .293 -.123207 .872478 
2 - 5 year .0465072 .0882192 .999 -.224670 .317684 
6 - 10 years .1514688 .0937489 .740 -.136706 .439644 
11 - 20 years .2562465 .1012043 .190 -.054846 .567339 
21 - 40 years .3284687 .1119210 .073 -.015566 .672503 
41 - 50 years .0466901 .0585470 .993 -.133278 .226658 
>61 years -.0132095 .0733240 1.000 -.238600 .212181 
>61 years 0 - 1 year .3878449 .1646514 .271 -.118278 .893968 
2 - 5 year .0597167 .0930720 .998 -.226378 .345811 
6 - 10 years .1646783 .0983292 .703 -.137576 .466933 
11 - 20 years .2694560 .1054613 .181 -.054722 .593634 
21 - 40 years .3416783 .1157847 .070 -.014233 .697589 
41 - 50 years .0598996 .0656318 .984 -.141846 .261645 
51 - 60 years .0132095 .0733240 1.000 -.212181 .238600 
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Appendix-7- Statistical analysis of UK population grouped on basis of 
disease   
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
PPMS 49 .246167 .2292621 .0764207 .069940 .422393 
RRMS 50 .278703 .2466215 .0405443 .196475 .360930 
Healthy 50 .414303 .4307495 .0749839 .261566 .567040 
Total 149 .331639 .3385956 .0380950 .255798 .407481 
 
ANOVA 
UK Population 
 Sum of Squares Df Mean Square F Sig. 
Between Groups .395 2 .197 1.756 .180 
Within Groups 8.548 76 .112   
Total 8.942 78    
 
Multiple Comparisons 
UK Population 
Tukey HSD 
(I) Age Group (J) Age Group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
PPMS RRMS -.0325360 .1246437 .963 -.330494 .265422 
Healthy -.1681364 .1261130 .381 -.469607 .133334 
RRMS PPMS .0325360 .1246437 .963 -.265422 .330494 
Healthy -.1356003 .0802980 .216 -.327551 .056350 
Healthy PPMS .1681364 .1261130 .381 -.133334 .469607 
RRMS .1356003 .0802980 .216 -.056350 .327551 
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Appendix-8 - Statistical analysis of UK population grouped on basis of age – 
Independent t-test 
 UK age groups before cut off N Mean Std. Deviation 
UK titre before cut off 20 - 40 years 79 .331639 .3385956 
>40 years 70 .239207 .1803878 
 
Since these are only two groups we performed independent t test for two samples with 
unequal variance. The compute test statistic or t value = 2.1076 at 147 degrees of 
freedom, p value = 0.03 which is less than level of significance of 0.05. Hence 
statistically significant difference exists in the titres in the age groups 20 – 40 and more 
than 40 years of age group.  
 
Similarly for the UK population at cut off 0.28 
 T value = 3.03 at 34 degrees of freedom and p value = 0.004 
 
And for UK population at cut off 0.36 
 T value = 4.069 at 24 degrees of freedom and p value = .0004 
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 Chapter 8 
 New Method for the Assessment of Molluscum 
Contagiosum Virus Infectivity 
 Subuhi  Sherwani ,  Niamh  Blythe ,  Laura  Farleigh , 
and  Joachim  J.  Bugert  
 Abstract 
 Molluscum contagiosum virus (MCV), a poxvirus pathogenic for humans, replicates well in human skin 
in vivo, but not in vitro in standard monolayer cell cultures. In order to determine the nature of the replica-
tion de fi ciency in vitro, the MCV infection process in standard culture has to be studied step by step. The 
method described in this chapter uses luciferase and GFP reporter constructs to measure poxviral mRNA 
transcription activity in cells in standard culture infected with known quantities of MCV or vaccinia virus. 
Brie fl y, MCV isolated from human tissue specimen is quantitated by PCR and used to infect human HEK293 
cells, selected for ease of transfection. The cells are subsequently transfected with a reporter plasmid encod-
ing  fi re fl y luciferase gene under the control of a synthetic early/late poxviral promoter and a control plasmid 
encoding a renilla luciferase reporter under the control of a eukaryotic promoter. After 16 h, cells are har-
vested and tested for expression of luciferase. MCV genome units are quantitated by PCR targeting a 
genome area conserved between MCV and vaccinia virus. Using a GFP reporter plasmid, this method can 
be further used to infect a series of epithelial and  fi broblast-type cell lines of human and animal origin to 
microscopically visualize MCV-infected cells, to assess late promoter activation, and, using these parameters, 
to optimize MCV infectivity and gene expression in more complex eukaryotic cell culture models. 
 Key words:  Molluscum contagiosum virus ,  Luciferase reporter construct ,  Eukaryotic cells ,  Infection , 
 Transfection ,  Quantitative PCR 
 
 Molluscum contagiosum virus (MCV) does not produce a 
quanti fi able cytopathic effect and does not produce viral progeny 
in infected standard cell cultures. But small amounts of viral mRNA 
and protein expression can be detected indicating that MCV virions 
are transcriptionally active  ( 1– 3 ) . Many investigators have observed 
 1.  Introduction
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that poxvirus transcription complexes can drive luciferase reporters 
under the control of poxviral promoters in plasmids in poxvirus-
infected cells. A recent paper uses this as a method to diagnose 
orthopoxvirus infections  ( 4 ) . 
 In the assay described in this chapter, the same principle is 
used. We introduce a luciferase reporter expression in trans as a 
new surrogate marker of infectivity and gene expression for MCV. 
To compare the infectivity of MCV with other poxviruses ( 11 ), the 
number of virions must be determined. Quantitation by EM or 
OD300 can be used  ( 5 ) , but requires relatively large amounts of 
gradient puri fi ed virons. However, currently, MCV can only be 
isolated from clinical specimens and thus is dif fi cult to obtain 
amounts suf fi cient for gradient puri fi cation  ( 5 ) . PCR is an alterna-
tive method of quantitation of smaller amounts of poxviruses from 
clinical specimens, which is both reliable and highly speci fi c for 
individual poxviruses. The method described in this chapter uses a 
novel PCR target in an area with signi fi cant DNA homology 
(~65%) between MCV and vaccinia virus strain WR (VACV-WR). 
The MCV gene is mc129R, which is homologous to the VAVWR144 
(also called A24R gene encoding RPO132, the large subunit of the 
DNA-dependent RNA polymerase). The method provides a means 
to quantitate poxviral genome units in the same virus preparations 
used to compare transcriptional activity and infectivity of MCV 
and VACV-WR. 
 
  1.  OPTIMEM, stored at 4°C. 
  2.  Plasmids described in Subheading  2.3 (see Note 1). 
  3.  Lipofectamine 2000, stored at 4°C until used. 
  4.  Human HEK 293 cells (ATCC CRL1573) (see Note 2). 
  5.  Dulbecco’s modi fi ed Eagle medium: DMEM, high glucose 
with glutamine, stored at 4°C until  used. 
  6.  Fetal calf serum: FCS, stored in aliquots at −70°C until used. 
  7.  Cell growth medium: DMEM with 10% FCS. 
 
  1.  Dual Luciferase Assay Substrate (lyophilized) stored at −20°C 
for up to 6 months reconstituted. 
  2.  10 ml Luciferase Assay Buffer II, stored in a 1-ml aliquots at 
−20°C for up to 6 months until used. 
  3.  Stop and Glo Substrate (50×) stored at −20°C. 
 2.  Materials
 2.1.  MCV Luciferase 
Reporter Assay
 2.1.1.  Infection–
Transfection 
of Cell Cultures
 2.1.2.  Luciferase Assay 
(The Dual-Luciferase ® 
Reporter Assay System 
from Promega)
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  4.  10 ml of Stop & Glo Buffer, stored in a 1-ml aliquots at −20°C 
for up to 6 months until used. 
  5.  30 ml of Passive Lysis Buffer (5×) stored at −20°C, then diluted 
to 1× using sterile water, and kept at 4°C until used. 
  6.  Clear  fi lm plate protectors (to prevent evaporation from 
wells). 
  7.  FLUOStar Luminometer. 
  1.  Primers outlined in Table  1 suspended in injection-grade 
water to a  fi nal concentration of 100 pmol/ m l and stored at 
−20°C. 
  2.  MCV isolated from human skin biopsy material as described 
previously  ( 5 ) and kept in 100- m l aliquots frozen at −70°C in 
PBS (see Note 3). 
  3.  VACV-WR, vaccinia virus, strain WR (kind gift of B. Moss) 
was prepared and puri fi ed from infected HeLa cells, titrated in 
BSC-1 cells, and kept in 100- m l aliquots frozen at −70°C in 
PBS (see Note 3). 
  4.  DNAse at 1 mg/ml. 
  5.  DNAse/BamHI buffer: 78  m l water, 2  m l DNAse, 20  m l 10× 
BamHI buffer from New England Biolabs. 
  6.  High Pure viral nucleic acid (HPVNA) kit (e.g., Roche). 
  7.  Nanodrop-Spectrophotometer. 
 2.2.  MCV and VACV 
Quantitative PCR 
Assay
 Table 1 
 MCV–VACV quantitative PCR assay primers 
 Primer ID  Primer sequence (nhb) 
 Primer 
length 
 Product size (nucleotide 
position), GenBank Acc. # 
 Mcv129 
1-2F149275 
 5 ¢ -CC G CACTA C 
TC C TGGATGCAGAA-3 ¢ 
 23  576 bp (149,275–149,850), 
U60315 
 Mcv129 
1-3R149850 
 5 ¢ -CTG G ATGTC
 G GAGAA G GTCATG-3 ¢ 
 22 
 VACV-WR 
1-2F132482 
 5 ¢ -CC T CACTA T 
TC A TGGATGCAGAA-3 ¢  ( 3 ) 
 23  573 bp (132,482–122,054), 
AY243312 
 VACV-WR 
1-3R133054 
 5 ¢ -CTG A ATGTC 
A GAGAA T GTCATG-3 ¢  ( 3 ) 
 22 
 nhb nonhomologous bases underlined (number of mismatches) 
 Primers were designed using BLAST2 (NCBI:  http://blast.ncbi.nlm.nih.gov/ ) alignment of MCV (GenBank accession 
# U60315) and VACV-WR (GenBank accession # AY243312) genome sequences and Vector NTI vs. 4.0, 1994–1996 
InforMax Inc. 
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  8.  ImageJ (Wayne Rasband (wayne@codon.nih.gov) Research 
Services Branch, National Institute of Mental Health, Bethesda, 
Maryland, USA). 
  9.  Injection-grade water. 
  10.  AmpliTaq 360 polymerase (5 U/ m l). 
  11.  dNTP (0.2 mM). 
  12.  10× PCR buffer. 
  13.  2% Agarose gel. 
  14.  Ethidium bromide solution: 10 mg/ml stock solution in 
demineralized water and used at 20  m l per 200 ml. 
  1.  PCR control plasmid . The complete MCV-1 genome was 
cloned  ( 6 ) and sequenced  ( 7,  8 ) and the redundant MCV 
genome fragment library of MCV type 1 was submitted to 
 2.3.  Plasmids 
( See Fig.  1 )
 Fig. 1.  Plasmid constructs. VectorNTI drawings for the recombinant plasmids ( a ) pyMCV1-EcoRI-fragment C (pyMCV1-E-C; 
available from ATCC molecular section), ( b ) phRG-TK (Promega; Internal lab reference number p238), ( c ) pRB21-pE/L-FF 
luciferase (p240), and ( d ) pRB21-pE/L-EGFP-SFX (p300). 
 
1398 New Method for the Assessment of Molluscum Contagiosum Virus Infectivity 
ATCC for safekeeping in 2003 and 2008. For the quantitative 
PCR assay, the genomic MCV-1  Eco RI fragment C (25,516 bp) 
cloned into bacterial plasmid vectorp pACYC184 was used as a 
MCV target control (pyMCV1-E-C, see Fig.  1a ). 
  2.  Transfection control plasmid . Plasmid phRG-TK (Promega 
GenBank accession number AF362545: 4,045 bp), expressing 
renilla luciferase under the control of the herpes simplex virus 
TK gene promoter. In this protocol, this plasmid is called p238 
and used as plasmid transfection control (p238 Promega; see 
Fig.  1b ). 
  3.  Poxviral luciferase reporter plasmid . The coding sequence of 
 fi re fl y luciferase ( Photinus pyralis GenBank accession number 
M15077) was ampli fi ed with a modi fi ed Kozak sequence by 
PCR and ligated into the pRB21 donor plasmid (kind gift of 
B. Moss  ( 9,  10 ) ) using the EcoRI and HindIII restriction sites 
in the donor plasmid multiple cloning site, resulting in the 
pRB21-E-Koz-Fire fl y luciferase-H (also called pRB21-pE/L-FF 
luciferase) construct of 7,178 bp with the internal lab designa-
tion p240 (p240, see Fig.  1c ). 
  4.  Poxviral EGFP reporter plasmid . The coding sequence of EGFP 
was ampli fi ed from a commercially available plasmid with a 
modi fi ed Kozak sequence by PCR and ligated into the pRB21 
donor plasmid using the EcoRI and NheI restriction sites in 
the donor plasmid multiple cloning site, resulting in the 
pRB21-E-Koz-EGFP-X- fl ag-strepII-N construct (also called 
pRB21-pE/L-EGFP-SFX) of 6,333 bp with the internal lab 
designation p300 (p300, see Fig.  1d ). 
 
  1.  Prepare enough 12-well plates containing HEK 293 cells in 
growth media to allow for infection/transfection in triplicate 
for each experimental condition (including a mock that will be 
transfected but not infected, as well as wells that will be har-
vested at 16 h and wells that will be continued to be incubated 
for days) (see Note 4). 
  2.  Thaw virus aliquots, sonicate, and keep on ice. 
  3.  Thaw plasmid DNA and keep on ice. 
  4.  Bring OptiMEM and Lipofectamine 2000 to room tempera-
ture (RT). 
  5.  Prepare transfection mixes by adding a dilution of 2  m l of 
Lipofectamine 2000 in 50  m l of OptiMEM to a dilution of 
0.3  m g of each plasmid DNA (p240 FF reporter and p238 
 3.  Methods
 3.1.  Infection–
Transfection: 
Luciferase Assay
 3.1.1.  Infection/
Transfection
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transfection control plasmid, p300 EGFP reporter) in 50  m l of 
OptiMEM. Mix gently for 15 min at RT in the dark to allow 
formation of transfection complexes. 
  6.  Remove growth media from HEK293 cells and put 100  m l of 
transfection mix in each well. 
  7.  Combine 100  m l each of ice-cold virus in PBS and 100  m l of 
transfection mix at RT and transfer the mixture into appropri-
ate wells of HEK293 cells (see Note 5). 
  8.  Incubate for 16 h at 37°C in 5% CO 2 atmosphere (see Note 6). 
  1.  At 16 h post infection (p.i.), inspect cells transfected with the 
GFP reporter plasmid using live cell microscopy. Document 
GFP-positive cells noting that MCV does not show GFP-
positive cells after 16 h, whereas WR shows multiple GFP-
positive cells. 
  2.  Upon further incubation for another 4 days (5 days p.i.), some 
individual cells in the MCV-infected wells will show medium 
to strong GFP signals (see Note 7). At the same time point, 
the WR-infected wells will show extensive plaques and cell 
degradation (see Fig.  2a–d ). 
  3.  For luciferase assay, at 16 h p.i., wash adherent cells in wells 
once with PBS and add 100  m l of 1× passive lysis buffer to each 
well (see Note 8). 
 3.1.2.  Microscopy 
and Collection of Cells 
for Luciferase Assay
 Fig. 2.  Images of luciferase and GFP in infected/transfected cells and quanti fi cation of luciferase output.  Panels ( a – d ) show 
HEK 293 cells infected with MCV ( a and  c ), and vWR ( b and  d ). Inserts in  c show individual GFP-positive cells.  Panel  e 
shows a histogram of luciferase data giving chemiluminescence in RLU. HEK 293 cells were infected with MCV or vWR at 
the indicated moi, and collected at 16 h  p.i. 
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  4.  Cover the 12-well plate with clear  fi lm plate protectors to stop 
evaporation and incubate with agitation on a belly-dancer at 
RT for  15 min. Plates are then frozen at −20°C for at least 
15 min or stored overnight or for up to 2 weeks before 
assayed. 
  5.  Cell lysates are tested for luciferase activity by adding 100  m l 
Dual Luciferase Assay Substrate to each well (see Note 9). 
  6.  Luciferase activity is then measured in a FLUOStar 
Luminometer. 
  7.  Data is compiled in a Microsoft EXCEL  fi le and evaluated 
using standard statistical protocols (average, standard devia-
tion, Student’s  P test). A typical result is shown in Fig.  2e 
(see Notes 6, 10, and 11). 
  1.  Incubate equal volumes of freshly thawed virions (100- m l ali-
quot) in 100  m l DNAse/BamHI buffer for 30 min at 37°C. 
  2.  Extract viral genomic DNA using a HPVNA kit following the 
manufacturer’s instructions. The control plasmid pyMCV1-E-
C (see Fig.  1a ) is prepared using the same procedure. 
  3.  Determine the DNA concentration of the control plasmid 
using a Nanodrop-Spectrophotometer or a similar device. 
  4.  Calculate molecule numbers using the average molecular 
weight of DNA molecules and Avogadro’s number 
(6.02 × 10 23 per mole). The molecular weight of a plasmid (in 
Daltons) can be estimated as MW of a double-stranded DNA 
molecule ( http://www.epibio.com/techapp.asp ) = (# of base 
pairs) × (650 Da/base pair). The plasmid pyMCV1-E-C has 
29,760 bp. Thus, the molecular weight is calculated as 
19.344 MDa and thus 19.344 ng of plasmid would be 
6.02 × 10 8 mol. The actual plasmid concentration was 21 ng/ m l 
(±1.7) and, thus, represented 6.5 × 10 8 mol/ m l. From this 
value, the molecule numbers for the pyMCV1-E-C twofold 
dilution series are calculated (see Fig.  3d ). The molecule 
numbers are then correlated to the pixel numbers of bands on 
a gel quantitated by ImageJ (see Fig.  3d ). 
  1.  Prepare twofold dilutions of viral genomic DNA and plasmid 
control in injection-grade water and store at −20°C. 
  2.  Prepare PCR assays as outlined in Table  2 . PCR reaction con-
ditions are included in the table. 
  3.  Visualize PCR bands by loading a 2% agarose gel with 10  m l 
from each PCR reaction and run for 1 h at 100 V (constant 
voltage). Stain with ethidium bromide, photograph with a dig-
ital unit, and export into a jpeg  fi le (see Note 13). 
  4.  To quantitate the PCR product, one can use the captured 
bands on the jpeg photograph with a series of identical gates 
 3.2.  Quantitative PCR 
Assay
 3.2.1.  Virus and DNA 
Preparation
 3.2.2.  PCR Reaction 
( see  Note 12 )
 Fig. 3.  PCR quanti fi cation of puri fi ed DNA.  Panels  a – c show twofold dilutions of poxviral genomic DNA puri fi ed from 
DNAse-treated virions ( b and  c ) and plasmid DNA repuri fi ed using the HPVNA kit ( a ). Lane numbers at the top of the  fi gure 
refer to log 2 dilutions from 1 to 10.  Panel  d tabulates the calculated molecular number for the reference plasmid pyMCV1-
E-C (pyMC) (1,000× by nanodrop in 10  m l of original DNA prep) and the ImageJ pixels for each band in gels  a to  c . ImageJ 
(Wayne Rasband (wayne@codon.nih.gov) Research Services Branch, National Institute of Mental Health, Bethesda, 
Maryland, USA) was used to quantitate pixel densities in boxes of 212 × 42 pixels. 
 Table 2 
 PCR reaction 
 Volume ( m l) 
 Primer 1-2F a (100 pmol/ m l)  0.5 
 Primer 1-3R a (100 pmol/ m l)  0.5 
 Injection-grade water  36.8 
 10× PCR buffer  5.0 
 TaKaRa dNTP (0.2 mM)  2.0 
 Template (series of twofold dilutions)  5.0 
 AmpliTaq 360 polymerase (1 unit of 5 U/ m l)  0.2 
 Total  50.0 
 PCR reaction: 2 min of denaturation at 96°C; and then 45 cycles of 
1 min at 96°C, 2 min at 55°C, and 3 min at 72°C. Block and then cool 
to 10°C
aFor MCV Primer 1-2F and Primer 1-3R, use Mcv129 1-2F149275 and 
Mcv129 1-3R149850, respectively. For WR Primer 1-2F and Primer 1-3R, 
use VACV-WR 1-2F132482 and VACV-WR 1-3R133054, respectively 
 
1438 New Method for the Assessment of Molluscum Contagiosum Virus Infectivity 
using IMAGEJ software to produce a quanti fi ed pixel output 
that can be imported into a Microsoft EXCEL  fi le. 
  5.  Plot quantitative results of digital imaging (quanti fi ed pixel 
output) of a twofold dilution series of plasmid pyMCV1-E-C 
against molecule numbers using Microsoft EXCEL software. 
  6.  Take molecule/genome equivalent numbers from the calibra-
tion plot and compare to the pixel readings obtained for 
VACV-WR. Tabulate results and evaluate using standard statis-
tical protocols (average, standard deviation, Student’s  P test). 
  7.  Results from a PCR reaction and the corresponding mole 
numbers and pixels are shown in Fig.  3d . In that  fi gure, for gel 
a, lane 9, the signal (27,779 pixels) for the dilution of the MCV 
control plasmid (pyMCV1-E-C) correlates to 1.586 × 10 6 plas-
mid units. The band in gel c (MCV PCR) with comparable 
pixel density (i.e., within 10%) is in lane 4 with a pixel value of 
28,726 pixels. If the 1.586 × 10 6 mol are multiplied by the 
dilution factor (16×), the MCV aliquot of 100  m l used for 
genomic DNA preparation contained 2.5 × 10 7 mol/genome 
units. If the pixel values obtained for vWR in gel b, lane 4 
(71,008), are used in the same way and related to gel a, lane 8 
(67,495 pixels), after multiplying by the dilution factor (16×), 
a molecule number of 5 × 10 7 is obtained. This can then be 
used to relate to the pfu. If WR was at 1.6 × 10 6 pfu in 100  m l, 
the pfu-to-genome unit ratio is 1:31  (see Notes 14–16). 
 
  1.  All plasmid DNA should be puri fi ed using 100- m g capacity 
midiprep-columns (HPVNA) and then stored in elution buffer 
at −20°C until used. 
  2.  The assay depends to a signi fi cant degree on the transfectabil-
ity of the cell cultures involved. Human keratinocytes and 
 fi broblast cell lines are most interesting as possible natural hosts 
for MCV, but they are also hard to transfect. We found HEK 
293 cells to be the best transfected cell line. However, while 
this cell line shows robust reporter signals, it is clearly not the 
type of cell MCV naturally infects. 
  3.  We prepare vaccinia virus and MCV preparations in 1 ml PBS 
and then immediately make ten 100- m l aliquots and freeze. 
The vaccinia virus stock was generated by infecting one T150 
 fl ask containing adherent HeLa cells. Harvest of the infected 
cells and resuspending them in 1 ml PBS yielded a titer of 
2 × 10 7 pfu/ml. Thus, each of the ten 100- m l aliquots of vaccinia 
virus used here contained 2 × 10 6 pfu. The 100- m l aliquot MCV 
 4.  Notes
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contained an unknown number of MCV particles, but is 
quanti fi ed using the described PCR method. 
  4.  Transfection ef fi ciency can vary considerably from cell batch to 
cell batch. Passage number (best low), cell con fl uence (best 
below 60%), and time of culture prior to experiment (best no 
longer than 24 h) are determinant factors. 
  5.  While in this protocol we transfect adherent cells, we have 
found that for some harder-to-transfect cells (e.g., human 
 fi broblasts) we can get higher transfection ef fi ciency when cells 
are in  suspension. 
  6.  The incubation time of 16 h allows for a robust signal from the 
transfection control plasmid p238, so  fi re fl y signal readings can 
be adjusted to renilla transfection ef fi ciency readings between 
experiments. 
  7.  Transfected plasmids with poxviral transcription signals can be 
transcribed by the poxviral transcription complex produced by 
transcriptionally active cores after entry. It is not clear whether 
the transcription complex is accessed inside partially uncoated 
virions, with plasmid DNA getting inside cores, or by tran-
scription complex that is released into the cytoplasm. MCV-
infected cells produce a robust luciferase signal after 16 h. 
However, GFP is only visibly expressed in a small number of 
individual cells, detectable after 5 days of incubation. Potentially, 
other cells may express GFP at a level undetectable by micros-
copy. The process where cores are accessible for the reporter 
plasmids may be delayed in MCV-infected cells. 
  8.  The samples for the luciferase assay are collected at 16 h post 
infection. This allows the control plasmid ILR#238 to get to 
the nucleus and be expressed to yield a robust control signal. 
In 293 cells, the Renilla luciferase signal can be seen in vac-
cinia-infected cells after 2 h, and is seen in the MCV signal 
after 8 h. 
  9.  If one does not have instrumentation that can add 100  m l of 
PROMEGA Dual luciferase  fi re fl y substrate one can hand, 
pipet series of four samples in a row, then load the plate, and 
read. The reading time, including the initial shake for four 
samples, is 20 s. Doing this results in a signal loss per reading 
of <1%, which is less than the sample-to-sample variation in 
triplicate samples, when compared to machine pipetting sam-
ple per sample. 
  10.  The signal from early poxviral promoters can be used as a sur-
rogate parameter of viral infectivity. 
  11.  The signal can be further dissected and used to look at early 
and late transcription activity using transfected plasmids with a 
reporter gene behind the respective promoters in isolation. 
1458 New Method for the Assessment of Molluscum Contagiosum Virus Infectivity 
  12.  The conventional PCR assay described has the problem of 
assay-to-assay variation due to agarose gel and staining arti-
facts. Future advances may be the development of a real-time 
PCR assay using molecular Taqman probes speci fi c to either 
VAVC-WR or MCV and binding in the internal section of the 
rather large PCR product  (550 bp). 
  13.  The source template of the PCR products produced can also 
be determined by XhoI digest, which cleaves the MCV prod-
uct into 227- and 349-bp subfragments but does not cleave 
the VAVC-WR PCR product. 
  14.  It is unclear to which extent the different GC content of the 
two virus genomes would affect the PCR product. This was 
not further investigated. 
  15.  It is clear that vaccinia plaque-forming units cannot be directly 
compared to MCV virion units because of the different nature 
of their biological activity. However, the PCR method 
described in Subheading  3.2 allows a relative quanti fi cation 
of MCV genome equivalents to VAVC-WR infectious units 
measured in pfu/ml based on ampli fi able genomic DNA 
units/molecule numbers calculated for a relatively large 
plasmid containing 25,517 bp of MCV sequence. As described 
in Subheading  3.2.2 ,  step 7 , the pfu-to-molecule ratio for 
vaccinia virus (mature virions) comes out as 1:31, in keeping 
with previously published ratios  ( 12 ) . The PCR data can be 
used to calculate an MCV multiplicity of infection equivalents 
in relation to the control plasmid molecule numbers as well as 
in the form of pfu equivalents in relation to a titered vaccinia 
stock for comparison purposes. We have found this approach 
to be both more reproducible and more speci fi c than electron 
microscopy or OD quanti fi cations of virions. 
  16.  The biological activity of virions can be assessed using an 
in vitro transcription reaction  ( 1,  5,  13 ) . 
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Abstract 23 
 24 
Molluscum contagiosum virus (MCV) is a significant but underreported skin pathogen for children and 25 
adults. Seroprevalence studies can help establish burden of disease. Enzyme linked immunosorbent 26 
assay (ELISA) based studies have been published for Australian and Japanese populations [1-2], and 27 
the results indicate seroprevalences between 6 and 22 percent in healthy individuals, respectively. To 28 
investigate seroprevalence in Europe, we have developed a recombinant ELISA using a truncated MCV 29 
virion surface protein MC084 (V123-R230) expressed in E. coli. The ELISA was found to be sensitive 30 
and specific, with low inter- and intra-assay variability. Sera from 289 German adults and children aged 31 
0-40 years (median age 21years) were analysed for antibodies against MC084 by direct binding ELISA. 32 
The overall seropositivity rate was found to be 14·8%. The seropositivity rate was low in children below 33 
the age of one (4·5%), peaked in children aged 2-10 years (25%), and fell again in older populations 34 
(11-40 years; 12·5%). Ten out of 33 healthy UK individuals (22%; median age 27 years) had detectable 35 
MC084 antibodies. MCV seroconversion was more common in dermatological and autoimmune 36 
disorders, than in immunocompromised patients or in patients with multiple sclerosis. Overall MCV 37 
seroprevalence is 2.1 fold higher in females than in males in a UK serum collection. German 38 
seroprevalences determined in the MC084 ELISA (14·8%) are at least three times higher than incidence 39 
of MC in a comparable Swiss population (4.9%; [3]). While results are not strictly comparable, this is 40 
lower than Australian seroprevalence in a virion based ELISA (n=357; 23%; 1999) [1], but higher than 41 
the seroprevalence reported in a Japanese study using an N-terminal truncation of MC133 (n=108, 6%; 42 
2000) [2]. We report the first large scale serological survey of MC in Europe (n=393) and the first MCV 43 
ELISA based on viral antigen expressed in E. coli.  44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
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Introduction 53 
After the eradication of smallpox, MCV is the principal poxvirus causing human disease [4-7]. MCV is 54 
classified as a member of the family Poxviridae, in its own genus Molluscipoxvirus [8]. It has unique 55 
features that are distinct from other poxviruses pathogenic for humans, including smallpox and 56 
monkeypox [9]. MCV shares the highest level of amino acid (aa) similarity and unique proteins with 57 
parapoxviruses such as Orf viruses [10].
 58 
 59 
MCV infects the human skin and Molluscum contagiosum (MC) is a sexually transmitted disease, with 60 
infections occuring worldwide [4, 11-13].Clinical infection is characterized by a variable number of 61 
papules, each forming a central crater filled with a waxy plug of cell debris mixed with a large numbers 62 
of virus particles. Histopathologically, MC causes a benign epidermal hyperproliferation, known as an 63 
acanthoma [14]. MC is most common in young children and teenagers. MC in immunocompromised 64 
patients results in more numerous and extensive lesions [15]. In immune-competent patients, lesion 65 
may persist for up to 12 months [14]. Spontaneous regression of MC lesions is commonly preceded by 66 
clinical signs of inflammation [16], indicating a vigorous immune response [17].
 67 
 68 
The true prevalence of MC has probably been underestimated because of the benign clinical 69 
manifestation and rare complications. Development of assays which could assist in seroprevalence 70 
studies has been hampered by unsuccessful attempts to cultivate MCV efficiently in vitro [18-21]. The 71 
viral genome was sequenced in 1996 [5].  72 
 73 
In the first known MCV antibody study in 1952, Mitchell found three out of 14 MC patients with 74 
complement-fixing antibody to an antigen prepared from human MC lesions [22]. Shirodaria et al. used 75 
MCV cryostat sections in an immunofluorescence study of MCV antibodies, reporting IgM class of 76 
antibodies only in MCV patients and IgG antibody responses in 16.7 % of healthy control subjects 77 
(n=30) [23]. Only two seroprevalence studies using ELISA, have been reported; one by Konya and 78 
Thompson [1] in 1999 and another by Watanabe et al. in 2000 [2]. 
 79 
 80 
Konya and coworkers described in 1992 a virion based enzyme linked immunosorbent assay [24]. MCV 81 
virions were isolated from human lesion material. The antigen was extracted from pooled lesions of 82 
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different genotypes with epidermal protein extract used as a control. Their 1999 serological survey of a 83 
healthy Australian population (n=357) revealed an overall seroprevalence of 23% and up to 77% in 84 
MCV infected HIV negative individuals [1].  85 
 86 
Based on MCV sequence information then available, in 1998 Watanabe et al. identified two 87 
immunodominant proteins of 70 and 34 kDa and mapped them to the ORFs mc133L and mc084L, 88 
respectively [25].  The proteins are homologues of vaccinia virus proteins H3L and A27L, and major 89 
antigenic peptides of the virion particle [4, 25].  90 
 91 
Using this information they developed an ELISA, based on an N-terminal truncation of MCV virion 92 
protein MC133produced in a Sendai virus expression system [2]. Their survey of a Japanese population 93 
of 508 subjects found mc133 specific antibodies only in 58% of patients with MC, and in only 6% of 94 
healthy controls (n=108).  95 
 96 
The objective of our current study was to develop a recombinant MCV ELISA using water soluble and 97 
highly antigenic truncations of MC084L expressed in E. coli and to establish seroprevalence in a 98 
German and a UK serum collection.    99 
 100 
Materials and Methods  101 
 102 
Ethics statement 103 
The study has ethical approval for the use of German tissues and sera (Ethikvotum S-091/2011 104 
Hautklinik Heidelberg. Ethical approval was given by the Heidelberg University board in charge of 105 
ethical approvals, the ‘Ethikkommission’. Ethical approval for UK samples was part of 'An 106 
Epidemiological study of Multiple sclerosis and other neuroinflammatory demyelinating disorders in 107 
South Wales', 05/WSE03/111. Ethical approval was given by the Cardiff University 'Biobank Ethics 108 
Board'.  All patients provided prospective informed consent in writing upon admission. All children’s' 109 
parents/guardians provided informed consent in writing.  Class 2 GM work was notified to HSE with the 110 
project number GM 130/10.3. 111 
 112 
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pGEX-2TK expression of truncated MCV –GST fusion proteins 113 
The plasmid pGEX-2TK was used for expression of truncated and epitope tagged MCV ORFs mc084 114 
(V33-G117V5), MC084 (V123-R230 StrepII), and MC133 (M1-N370 StrepII) in E. coli with Glutathione 115 
S-Transferase (GST) fusion protein at the N terminus. Recombinant plasmids were constructed by PCR 116 
using specific primers tailed with restriction enzyme sites (BamHI-EcoRI) and C-terminal epitope tags.  117 
 118 
Expression and purification of MC084S (V123-R230) protein 119 
pGEX 2TK GSTmc084S (ILR#332; MC084 specific insert 107 amino acids; 14 kD) was transformed into 120 
E. coli BL21 (RIL
+
).Cultures were induced with Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 121 
fractions analysed for fusion protein expression by SDS-PAGE and StrepII tag expression by western 122 
blotting. Cultures were incubated at 37ºCfor 4hrs after which the cells were harvested by centrifugation 123 
at 10,000 × g for 20 min and lysed by sonification in buffer B (8 M urea, 0.1 M NaH2PO4, 0.01 M and 124 
Tris-HCl, pH 8.0). Lysate containing the protein of interest was added to glutathione sepharose beads 125 
and GST-MC084S was bound to beads using batch purification. The fusion protein was cleaved using 126 
Precision protease at RT overnight. AKTA-FPLC of the resulting 14kD sized protein was done using 127 
size exclusion Superdex S200 column (GE Healthcare).  128 
 129 
SDS-PAGE, western transfer and immunodetection 130 
Protein preparations were separated using denaturing sodium dodecyl sulphate polyacrylamide 131 
electrophoresis (SDS-PAGE) in NuPAGE Novex 4-12% Bis-tris Gels (Life technologies) and MOPS 132 
SDS running buffer (Invitrogen). Protein bands were visualised by staining with 0.01% Coomassie 133 
Brilliant Blue R-250. For immunodetection proteins prepared by SDS-PAGE were electrotransferred 134 
onto nitrocellulose and probed with Strep MAB Classic HRP conjugate (IBA). Detection by 135 
chemiluminescence was performed using Super Signal West Pico Chemiluminescent Substrate 136 
(Thermo Scientific) according to the manufacturer’s recommendations.  137 
 138 
Human serum/ tissue samples 139 
314 serum samples and lesion material from patients with molluscum contagiosum were collected at 140 
University Hospital Heidelberg, Germany, between 2007-2011. 79 UK sera samples were collected at 141 
Cardiff University. Twelve serum samples were collected from MCV patients (10 from Dr P N Behl Skin 142 
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Institute and School of Dermatology, New Delhi, India; two from UK; aged 2-62 years) as diagnostic 143 
specimens.  144 
 145 
MCV direct binding ELISA 146 
Ninety six well Maxisorp ELISA plates (Nunc) were coated with 3 µg/ml of FPLC purified recombinant 147 
truncated MC084S (aa123-230) protein per well in 100 µl of 0.05M carbonate-bicarbonate buffer 148 
(pH9.6) and incubated  at 37ºC for 2 hours and then overnight at 4ºC. Plates were washed with PBS 149 
and blocked with 5% skim milk. Test sera, diluted 1:100 in dilution buffer, and were coated across the 150 
plate (100µl/well). The plates were incubated at 37ºC for 2h and washed ten times with PBS-T. 151 
Secondary anti-human IgG conjugated to horseradish peroxidase (GE Healthcare), diluted 1:2000 in 152 
dilution buffer was subsequently added (100µl/well). After incubation at 37ºC for 2h the plate was 153 
washed ten times with PBS-T and 100 µl of BD OptEIA™ substrate reagents (BD Biosciences) was 154 
added to each well. 50 µl of 1M H2SO4 was used to stop the enzyme reaction after 20min incubation at 155 
RT. The OD of the reaction product was read at 450nm on an FLUROSTAR OPTIMA - ELISA plate 156 
reader (BMG Labtech).  157 
 158 
Plate description 159 
42 serum samples were tested in duplicate on each plate along with a panel of four control sera 160 
consisting of two negative and two positive as well as four blanks, all in duplicate. The results were 161 
expressed as δODU (δODU =mean of duplicate wells minus mean of the blank wells). 162 
 163 
ELISA performance 164 
Plate to plate variation was monitored by comparing the control panel results between the different wells 165 
of the same plate; same sera samples run on different plates on the same day as well as on different 166 
days.  167 
 168 
Immunofluorescence and Immunohistochemistry 169 
Paraffin embedded sections were deparaffinized and rehydrated. Dako Cytomation Envision
®
+Dual Link 170 
System-HRP (DAB
+
) kit (Dako) was used as per manufacturer’s instructions. For staining of tissue with 171 
human sera, ECL Anti-human IgG (1:2000) (GE Healthcare) was used. Staining was completed with 172 
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Mayers haematoxylin and eosin counterstaining. All sections were analysed using an Olympus BX51 173 
light microscope. Vaccinia virus infected HaCaT cells were grown on glass coverslips and fixed with 3% 174 
paraformaldehyde for 10 min, followed by staining with human serum antibodies (1:100) and an anti-175 
human Alexafluor-488 secondary antibody (Invitrogen).  176 
 177 
Statistical Analysis 178 
Serological data was stratified by age or diagnosis. Statistical significance of differences between the 179 
ELISA responses of different groups was assessed by one way ANOVA. Tukey post hoc anova was 180 
used to identify and compare statistically significant means and differences of different groups. 181 
Additional information on material and methods is shown in supporting information.  182 
 183 
Results 184 
 185 
Selection of MC084 antigen, cloning and purification 186 
Amino acid sequences of MC084 (298aa, 34kD) were analysed to determine overall homology with 187 
related proteins in the GenBank and identify transmembrane regions and region of high hydrophilicity / 188 
high antigenicity. Two transmembrane regions predicted in the C-terminal end of the protein [26], were 189 
excluded to avoid solubility issues in the E. coli expression system (Figure 1A). Of the remaining amino 190 
acids, a N-terminal region (V33-G117) and a C-terminal region (aaV123-R230), both containing one 191 
region of high hydrophilicity in the Kyte–Doolittle plot (Figure 1B) [28] were further analysed for 192 
subcloning.  193 
 194 
The C-terminal truncation of mc084 (V123-R230, predicted MW 14kD), comprising 107 aa, has the 195 
lowest homology to orthopoxvirus proteins and contains a region of high antigenicity (218-196 
NELRGREYGASLR-230) with no significant homology to vaccinia/ cowpox virus. The C-terminal 197 
truncation MC084 (V123-R230) was then subcloned into the pGEX-2TK vector (Figure 2A) with a Strep 198 
II tag and in frame with glutathione S-transferase separated by a thrombin kinase site (Figure 2B) and 199 
overexpressed as a GST fusion protein in codon optimized E. coli (BL21 RIL
+
).   200 
 201 
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The GST fusion protein was identified with an apparent molecular weight (MW) similar to the predicted 202 
MW of 40 kD in IPTG induced cultures (Figure 3A) and was absent in the uninduced cultures. The 203 
protein was protease cleaved and the C-terminal truncation of MC084 with an apparent MW of 14kD 204 
was further purified via FPLC using a size exclusion Superdex S200 column (Figure 3B). The Strep II 205 
tag was identified in Western Blot in both the fusion protein and the cleaved MC084 (V123-R230)-Strep 206 
II truncation (Figures 3 C and D).  Additional data on antigen selection and optimization can be found in 207 
supporting information figures S1 and S2. 208 
 209 
ELISA sensitivity, cut-off, and specificity 210 
MC084S (V123-R230) antigen coated ELISA plates were produced as described in material and 211 
methods. Serum samples were diluted 1:100.  212 
 213 
To establish sensitivity a panel of 12 sera from patients with known and clinically active MCV was first 214 
screened in comparison to sera from 0-1 year old individuals from the neonatal screening program of 215 
the Heidelberg University Clinics. In the group of sera from patients with diagnosed Molluscum 216 
contagiosum (n=12) the ELISA gave high readings for all (median δODU 1.5), with the most recent 217 
sample from Cardiff (CF2012-1) giving the highest (Figure 4). The control group of seventeen neonates 218 
from the Heidelberg University Clinics showed low readings with a mean of 0.1 δODU as shown in 219 
Figure 4, with one outlier (0.61 δODU).  The confidence interval for the difference between positive and 220 
negative control groups was highly significant (Figure 4). Sensitivity was 100% for MC patients.  221 
 222 
The cut-off for ELISA was calculated based on 66 sera from infants seen in the neonatal unit aged 0-1 223 
years. The mean of δODU readings was 0·12043 and the SD was 0·08300. In comparison the mean 224 
δODU for 12 MCV infected patients was 0·833 and the S.D. 0·571. The infant group was used to define 225 
negativity with the upper limit being the mean δODU plus 3 SD (i.e. 0·36). Assuming that these values 226 
are indicative of a negative response to the recombinant protein, we defined a positive antibody 227 
response as being a value greater than mean plus 3 SDs i.e. δODU 0·36. Two more outliers were 228 
identified in this group (δODU 0·36 and 0·35). The MCV status of these subjects (aged 2 months, 9 229 
months and 11months) could not be determined. Inter-well, intra-assay and inter-assay variability was 230 
found to be 3%, 5·2% and 6·7 %, respectively. 231 
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In order to establish ELISA specificity, human MCV infected tissue section obtained from the Heidelberg 232 
University Dermatology Unit were tested with high and low titre sera form our serum collections 233 
(supporting information Figure S3). An example for specific reactivity (MCV positive UK patient CF2012-234 
1) is demonstrated in Figure 5. The section shows a dome-shaped contour with cup shaped lesions with 235 
central invagination, representing a typical MCV lesion consisting of two inverted lobules of hyperplastic 236 
squamous epithelium (red arrows) with several sub-lobules. The MC lesion shows acanthosis with the 237 
appearance of intraepidermal lobules with enlarged basophilic nuclei filled with cellular as well as MC 238 
bodies’ debris (black arrows). Intraepidermal lobules are separated by septa consisting of compressed 239 
dermis (dotted arrow). MCV inclusion bodies stain strongly golden-brown with the human polyclonal 240 
serum CF2012-1 taken from a patient with clinical MCV infection. The stain is confined to areas where 241 
MCV cores, mature and released virus particles would be expected. In a number of tissue sections 242 
stained, the pattern was repeatable and sensitive to tissue preparation. Interestingly, the debris areas 243 
filled with mature MCV particles and lipid debris are also sensitive to removal by xylene /ethanol 244 
treatment of paraffin sections. The areas most consistently stained are the suprabasal and spinous 245 
layers.  246 
 247 
To further establish antigen specificity we also infected human HaCaT keratinocytes with a vaccinia 248 
virus expressing full length mc084 (v319; aa 1 to 318) as shown in Figure 6. Infected keratinocytes were 249 
tested with the high titre serum HD V0901071. Virus infected cells show a vesicular stain similar to an 250 
endosomal / lysosomal pattern. Uninfected cells show no background signal, indicating the human 251 
polyclonal does not recognize keratinocyte antigens in cultured HaCaT cells. 252 
Antigen optimization and comparisons are described in supporting information.  253 
 254 
ELISA population studies 255 
Sera from 289 individuals aged 2 months to 40 years (median age 21 years) were randomly selected 256 
from frozen ‘normal control sera’ collected at the University of Heidelberg, Germany, and tested for the 257 
presence of anti-MC084S (aa123-230) antibodies (Figure 7 A). Healthy subjects are divided into groups 258 
on the basis of age: 0-1 years (n=66), 2-5 years (n=52), 6-10 years (n=47), 11-20 years (n=72) and 21-259 
40 years (n=52).  The reactivity in infants was significantly lower than in other groups. Based on the 260 
minimum cut-off value of δODU 0·36, 43 (14·8%) sera of the 289 sera from a representative healthy 261 
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German population tested positive in the MC084S (123-230) ELISA. Positive antibody responses in the 262 
age groups were as follows: 4·5% (n=3) 0-1 year olds, 25% (n=13) in 2-5year olds, 23·4% (n=11) in 5-263 
10 year olds, 12·5% (n=9) in 10-20 year olds and 13·5% (n=7) in 20-40 year olds (Figure 7 B). A one 264 
way anova was used for preference differences between the different age groups. The test statistic (F 265 
value) is 4.587 and the p value is 0.001. Further post hoc analysis was done using Tukey test to identify 266 
and measure statistically significant difference between groups of data as pairs. From the multiple 267 
comparisons it can be concluded that there is a sharp increase in positive sera responses between 0-1 268 
year olds and  2-5 year olds which are  statistically significant at p value =0.001. The differences in the 269 
sera responses between 0-1 year olds and 6-10 year olds are also statistically significant (p=0.011). 270 
Differences in sera responses between all other groups are not statistically significant. The results of the 271 
serological survey in members of the German populations are shown in Table 1. 272 
 273 
We analysed 25 patients (8-40 years of age) with dermatological conditions such as Systemic lupus 274 
erythematosus (n=10), Psoriasis (n=3) and general autoimmune conditions (n=12), including patients 275 
with Autoimmune haemolytic anaemia, Autoimmune cerebilitis and Autoimmune hepatitis diagnosed at 276 
the University of Heidelberg. The findings are summarized in Table 1. MCV seroprevalence is above the 277 
average rate in skin specific autoimmune conditions, but similar in general autoimmune conditions. 278 
 279 
79 serum samples from a UK population (aged 21-40 years; median age 27 years) were analysed which 280 
had been collected as part of a study on Multiple sclerosis (MS) at Cardiff University. These subjects 281 
were grouped as Primary progressive multiple sclerosis (n=9), relapsing remitting multiple sclerosis 282 
(n=37) and healthy humans (n=33) (Figure 8A). 283 
 284 
Using the same cut-off of 0·36, MCV antibodies were detected in 10 of 33 healthy UK serum samples 285 
(22%). In patients with primary progressive multiple sclerosis seroprevalence was 11·1% (n=1/9), as 286 
compared to 16·2% (n=6/37) in patients with relapsing remitting multiple sclerosis (Figure 8B). A one 287 
way anova was used for preference differences between the different groups. The test statistic (F value) 288 
is 1.756 and the p value is 0.180. Further post hoc analysis was done using Tukey test to identify and 289 
measure statistically significant difference between groups of data as pairs. From the multiple 290 
comparisons it can be concluded that differences in sera responses between groups are not statistically 291 
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significant. An overall gender ratio (M: F) of 1.4:1 (183:131) was found in the German serum collection, 292 
as compared to 1:2.1 (25: 54) in the UK population. The results of the serological survey in members of 293 
all UK populations are shown in Table 1.  294 
 295 
Discussion 296 
We describe here for the first time a seroepidemiological study of MCV in Europe, the largest survey 297 
reported so far (n=393) and the first MCV ELISA based on viral antigen expressed in E. coli.   298 
 299 
Previously reported MCV ELISAs used antigen from human lesion material or Sendai virus expressed 300 
N-terminal amino acid sequences of MC133, raising issues with background skin antigens and 301 
posttranslational antigen processing. To improve water solubility and provide an expression platform 302 
more suitable for commercial production of a MCV ELISA, we decided to use hydrophilic antigenic 303 
regions of MC084 expressed in E. coli. On the basis of previous work by Watanabe et al. [2] and our 304 
own homology analyses we chose a C-terminal truncation of MC084 (V123-R230), upstream of A238-305 
Q298 previously found non-reactive in ELISA by Watanabe [2], as our candidate ELISA antigen. Our 306 
choice of antigen minimizes the possibility of cross reactivity with vaccinia virus specific antibodies, 307 
exclude the membrane spanning domains of mc084, but include a possible major antigenic site, 308 
identified by hydrophilicity plotting (MC084 N218-R230).  309 
 310 
The ELISA is sensitive (100%) and specific, with low inter- and intra-assay variability. This is in 311 
comparison to the lower sensitivities of 77 and 58%, in the ELISAs reported by Konya et al. [1] and 312 
Watanabe [2], respectively. We have determined specificity in MCV tissue sections, similar to Konya et 313 
al. [1]. To determine specificity quantitatively, a collection of sera would be needed  314 
 315 
We have calculated cut-off for our ELISA to include outlier results from our neonatal control group. The 316 
MC status of the outliers could not be determined, as the data was anonymised.  317 
 318 
Any comparisons of our findings with previous ELISA results must be fundamentally flawed, because 319 
different antigen and expression systems were used. However, no other data are available, so with the 320 
above reservations, we compared the findings of our serological survey to results reported for Northern 321 
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Ireland and two previous ELISA studies in Australia and Japan [1-2, 23]. We find an overall 322 
seropositivity in a general German population of 14·7% and 22% in the UK. This correlates well with 323 
previous findings of16.7% in Ireland (n=30; IgG responses) [23], 23 % in an Australian population [1] 324 
and less so with 6 % reported in a Japanese survey [2]. 325 
 326 
The age profile determined using the MC084 ELISA correspond well with our understanding of the 327 
natural history of MCV infections, with low exposure of very young children and a high prevalence 328 
among toddlers and preschool children, where MCV smear infections is most likely to be transmitted 329 
among larger numbers of children. Our data confirm previously reported findings of stronger antibody 330 
responses in acute MC [1], mostly in the 2-10 age group [3, 29], with waning antibody levels being 331 
detectable as the population ages. This would suggest very little re-exposure in older age groups.  332 
 333 
In contrast to Konya et al. [1],  who report a very high seropositivity rate in their 0-6 year old population 334 
of 31%, explaining this with maternal antibodies, our data do not indicate a high seropositivity rate in 335 
very young children. Seroprevalence with the mc084 (V123-R230)  ELISA is below 5% in 0-1 year olds 336 
and only increases in the age group of 2-5 year olds, not exceeding 25%.  Watanabe et al. explained 337 
their low overall seropositivity (n=108, 6%) [2] in healthy subjects in comparison to the prior Australian 338 
study (n=357; 23%) [1], with their mc133 ELISA failing to pick up sera with mc084 antibodies as shown 339 
in immunoblots, indicating that mc133 may not be the best choice of antigen, underestimating 340 
seroprevalence.  341 
 342 
The findings in immunocompromised patients and patients with skin and other inflammatory disorders 343 
indicate an increased seroprevalence in skin disorders, and a decrease in generally or therapeutically 344 
immunocompromised populations, but lack statistical power because of low sample numbers. The 345 
gender ratios calculated, indicate a higher seroprevalence (2.1 fold) in females than males of in the UK 346 
serum collection, but a lower ratio in the German collection. 347 
 348 
In summary, we propose MC084 (V123-R230) is a suitable antigen for MCV serological surveys when 349 
expressed in E. coli.  It includes a probable highly antigenic site at amino acid position N219-R230. 350 
Importantly, the MC seroprevalence of 14·8% in our German population is a threefold increase over the 351 
13 
 
reported incidence of MC in a comparable Swiss population of 4·9% [3], supporting the notion, that MC 352 
is an underreported infection. The assay will allow further investigations into the seroprevalence of MCV 353 
in other geographical areas, including the US, China, Japan and Australia.  354 
 355 
Ongoing work includes possible use of a subpeptide of MC084 (N218-R230) comprising only the highly 356 
antigenic site for a capture ELISA and T cell studies, and the development of aIgMMC084 (V123-R230) 357 
ELISA. We are also in the process of investigating the MC084 (V123-R230) peptide for its potential to 358 
compete with MCV/VACV entry in a MCV/VACV reporter assay [30]. 359 
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 448 
Legends to figures 449 
 450 
Figure 1. Bioinformatics 451 
(A) Transmembrane plot (TMHMM Server v.2.0) [26] of mc084 amino acids 1-318; (B) hydropathy plot 452 
of MC084 protein with predicted high hydrophilic / antigenic regions indicated by black boxes. The full 453 
length ORF (MC084 1-318; predicted molecular weight 34.2 kD; shown on top) was cloned into vRB12 454 
using specific primers tailed with restriction enzyme sites BamHI-HindIII) and C-terminal StrepII epitope 455 
tag. The resulting plasmid p319 was sequenced and the recombinant vaccinia virus v319 isolated on 456 
BSC-1 cells using the plaqueless mutant system [27]. N- and C-terminal (in yellow) truncations were 457 
subcloned from the original full length MCV gene into pGEX-2TK for overexpression in E. coli BL21 458 
(RIL
+
). TMHMM was used to determine transmembrane regions [26] whereas the Kyte-Doolittle plot was 459 
used to identify hydrophilic regions with predicted high antigenicity [28]. 460 
 461 
Figure 2.pGEX 2TK construct 462 
(A) Schematic of recombinant plasmid p332 with a MC084 specific insert of 107 amino acids (V123-463 
R230); predicted molecular weight 14 kD (B) Schematic of fusion protein of GST (green), followed by 464 
Thrombin kinase site (red), MC084 V123-R230 (grey), and strep II tag (blue); predicted antigenic site 465 
(black)  (C) Western blot giving 40kD GST fusion protein GST-MC084S (V123-R230) detected using 466 
Strep MAB-Classic HRP conjugate (IBA-lifesciences). Vector NTI (vNTI) was used to produce virtual 467 
molecules and schematic diagrams of constructs prior to molecular cloning (InforMax, Inc) 468 
 469 
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Figure 3. Protein purification 470 
Characterisation of over expressed recombinant fusion protein GST-MC084S and FPLC purified 471 
recombinant MC084S protein by SDS-PAGE and Western Blot. M: Molecular weight markers expressed 472 
in kDa. (A)  over expressed 40kDa Recombinant GST-MC084S fusion protein separated in a 4-12% 473 
Bis-Tris gel. (B) FPLC purified 14kDa protein separated in a 15% Bis-Arylamide gel. Both gels were 474 
stained with Coomassie Brilliant Blue R-250. (C) GST-MC084S fusion protein after transfer to 475 
nitrocellulose (D) FPLC purified MC084S. The membranes were probed with Strep MAB-Classic HRP 476 
conjugate (IBA-lifesciences).  Arrow heads indicate the locations of proteins.  477 
 478 
Figure 4.Sensitivity  479 
Absorbance plot of twelve sera from patients clinically diagnosed with MCV (India n=10; UK n=2; control 480 
group of 0-1 year old individuals n=17).   481 
 482 
Figure 5. Tissue stain details 483 
Microscopy (4x) of a Molluscum contagiosum lesion section (17315/11) stained with MC patient positive 484 
serum (CF2012-1) and haematoxylin-eosin counterstain (upper left hand corner). Three insets showing 485 
details at various magnifications [inset 1-(10x), inset 2-(20x) and inset 3-(20x)].  486 
 487 
Figure 6. HaCaT Immunofluorescence 488 
HaCaT cell culture infected with recombinant vaccinia virus expressing MC084S (v319). Reactivity of 489 
high titre human serum HDV0901071 and secondary antibody Alexafluor 488 (Green) goat anti-human 490 
IgG (H+L).  Nuclei are stained with DAPI (Hoechst) and shown in blue. Samples were analysed for 491 
fluorescence emission properties by using confocal scanning laser microscopy Leica TCS SP2 AOBS. 492 
 493 
Figure 7.  German seroprevalence 494 
Distribution of anti-MC084S antibodies in a German population tested by direct binding ELISA (A) 495 
Serological responses to MCV antigen MC084 in a German population (n=289; ages 0-40 years) 496 
expressed as the δODU value of an individual serum sample. The horizontal bar within each group 497 
represents the median absorbance measurement. (B) Percent seropositivities in different age groups 498 
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after cut–off of 0.36 (i) 0-1years (4.5%), (ii) 2-5 years (25%), (iii) 6-10 years (23.4%), 11-20 years 499 
(12.5%), and 21-40 years (13.5%). 500 
 501 
Figure 8.  UK seroprevalence 502 
Distribution of anti-MC084S antibodies in a UK population tested by direct binding ELISA. (A) 503 
Serological responses to MCV antigen MC084S (V123-R230)  in UK population (n=79) expressed as 504 
the δODU value of an individual serum sample in different groups (i) Primary progressive multiple 505 
sclerosis (PPMS; n=9), (ii) Relapsing remitting multiple sclerosis (RRMS; n=33) and (iii) Healthy 506 
humans  (n=37). The horizontal bar within each group represents the median absorbance measurement 507 
(B) Percent positivity in individual groups for MC084S after cut-off of 0.36 (i) PPMS (22%), (ii) RRMS 508 
(11.11%) and (iii) healthy humans (16.21%). 509 
 510 
Supporting Information Figure Legends 511 
 512 
Figure S1. MC084 antigen optimization. 513 
The figure shows the antigenicity of MC084S (aa123-230) as determined by direct binding ELISA using 514 
high titre human serum (HD V0901071). (A) Saturation was achieved at 3μg/ml. (B) A maximum of 80% 515 
inhibition of anti-serum antibodies with MC084S as inhibitor was observed whereas negligible inhibition 516 
was observed with BSA and human IgG.  517 
 518 
Figure S2. Comparison of antigen reactivity. 519 
The N-terminal truncation of MC084 i.e. MC084v5 (33-117), C-terminal truncation of MC084 i.e. 520 
MC084S (123-230), N-terminal truncation of MC133 i.e. MC133S (1-370) and GST tested as uncleaved 521 
fusion proteins on a GST affinity plate to compare antigen affinity and seroreactivities. The relative 522 
absorbance of individual sera was the same against all antigens tested with only minimal differences in 523 
absorbance.In direct antigen comparison there was no significant difference between truncations of 524 
mc084 and mc133, and no serum showed prevalent reactivity against one or another of the antigen 525 
used. A strep tag was used for detection of recombinant antigen in western blots. The tag did not 526 
interfere with ELISA results in a serum study of 149 serum samples (supplementary data). 527 
 528 
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Figure S3. Tissue staining with high and low litre sera 529 
Tissue sections stained with high (1A-D: HD V0901071, HD V0903005) and low titre sera (2A-D: 530 
HDV0900471, HDV0900040) in two magnifications (4x and 10x). High titre sera stained the spinous 531 
layers as well as cellular debris and MC bodies in and around the intraepidermal lobules golden-brown. 532 
The same section stained with low titre sera as determined in MC084S ELISA showed much reduced or 533 
no reactivity in the same tissue areas. 534 
 535 
Table 1. Summary of seroprevalences in German and UK populations 536 
Groups Total sera Cut-off = 
Mean+3*SD 
(0-1yr+outlier) 
0·36 
Positive Sera 
German sera 
0-1 years 66 3 (4·5%) 
1-5 years 52 13 (25%) 
6-10 years 47 11 (23·4%) 
11-20 years 72 9 (12·5%) 
21-40 years 52 7 (13·5%) 
 289 
Seropositivity in healthy subjects 
14·87 % 
Psoriasis 10 2 (20%) 
SLE
*
 3 1 (33·3%) 
Autoimm
†
 12 2 (16·6%) 
UK sera 
Healthy 
Humans 
33 10 (22%) 
PPMS
#
 9 1 (11·1%) 
RRMS
╬
 37 6 (16·2%) 
Total 293 65 (22.1%) 
*
 SLE – Systemic Lupus Erythematosus 537 
†
 Autoimm. – General autoimmune conditions 538 
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#
PPMS – Primary progressive multiple sclerosis 539 
╬
RRMS – Relapsing remitting multiple sclerosis 540 
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